

EACS European AIDS Clinical Society

GUIDELINES Version 7.1 November 2014

English

Table of Contents

Governing Board Members	2
Panel Members	2
Abbreviations	3

Part I

Assessment of HIV-positive Persons at Initial & Subsequent Visits

Part II

ART of HIV-positive Persons	6
Assessing HIV-positive Person's Readiness to Start and Maintain ART	6
Recommendations for Initiation of ART in HIV-positive Persons without Prior ART Exposure	7
Initial Combination Regimen for ART-naive Adult HIV-positive Persons	8
Acute HIV infection	9
Switch Strategies for Virologically Suppressed Persons	10
Virological Failure	11
Treatment of HIV-positive Pregnant Women	12
ART in TB/HIV Co-infection	13
Post-exposure Prophylaxis	14
Adverse Effects of ARVs & Drug Classes	15
Drug-drug Interactions between ARVs and Non-ARVs	17
Drug-drug Interactions between Antidepressants and ARVs	18
Drug-drug Interactions between Antihypertensives and ARVs	19
Drug-drug Interactions between Analgesics and ARVs	21
Drug-drug Interactions between Antimalarial Drugs and ARVs	21
Dose Adjustment of ARVs for Impaired Hepatic Function	23
Dose Adjustment of ARVs for Impaired Renal Function	24
Administration of ARVs in Persons with Swallowing Difficulties	25

Part III

Prevention & Management of Co-morbidities in HIV-positive Persons	27
Drug Dependency and Drug Addiction	28
Cancer: Screening Methods	29
Lifestyle Interventions	30
Prevention of CVD	31
Hypertension Diagnosis, Grading and Management	32
Hypertension Drug Sequencing Management	33
Drug-drug Interactions between Antihypertensives and ARVs	34
Type 2 Diabetes: Diagnosis	35
Type 2 Diabetes: Management	36
Dyslipidaemia	37
Bone Disease: Screening and Diagnosis	38
Vitamin D Deficiency: Diagnosis and Management	39
Approach to Fracture Reduction in HIV-positive Persons	40
Kidney Disease: Diagnosis and Management	41
ARV-associated Nephrotoxicity	42
Indications and Tests for Proximal Renal Tubulopathy (PRT)	43
Dose Adjustment of ARVs for Impaired Renal Function	44
Work-up and Management of HIV-positive Persons with Increased ALT/AST	45
Liver Cirrhosis: Classification and Surveillance	46
Liver Cirrhosis: Management	47
Diagnosis and Management of Hepatorenal Syndrome (HRS)	48
Dose Adjustment of ARVs for Impaired Hepatic Function	49
Lipodystrophy: Prevention and Management	50
Hyperlactataemia and Lactic Acidosis: Diagnosis, Prevention and Management	51

52
53
55
56
57
58
59
60
61
62
63

Part IV

4

Clinical Management and Treatment of HBV and HCV Co-infection in HIV-positive Persons	64
General Recommendations for Persons with Viral Hepatitis/HIV Co-infection	64
Assessment of Treatment Indications for HBV in Persons with HBV/HIV Co-infection	65
Treatment of Chronic HBV in Persons with HBV/HIV Co-infection	66
Diagnostic Procedures for HCV in Persons with HCV/HIV Co-infection	67
Treatment of HCV in Persons with HCV/HIV Co-infection	68
Management of Persons with Chronic HCV/HIV Co-infection	70
HCV Treatment Options in HCV/HIV Co-infected Persons	71
Drug-drug Interactions between DAAs and ARVs	72
Proposed Optimal Duration of Dual HCV Therapy in Persons with Chronic HCV/HIV Co-infection Not Eligible for Triple Therapy Including DAAs against HCV	73
Use of Boceprevir and Telaprevir in Persons with HIV/HCV Co-infection	74
Definition of Treatment Response of PEG-IFN and RBV	75

Part V

Opportunistic Infections	76
Prevention and Treatment of Opportunistic Infections in HIV-positive Persons	76
Diagnosis and Treatment of TB in HIV-positive Persons	82

References

References	to all sections	85

EACS Guidelines are available online at www.eacsociety.org and in the EACS Guidelines App

Imprint Publisher Panel Chairs	European AIDS Clinical Society (EACS) Jens D. Lundgren (Guidelines Coordinator), Jose M Gatell, Hansjakob Furrer, Jürgen Rockstroh
Guidelines Assistant Coordinator	Lene Ryom
	5
Graphic Design	Notice Kommunikation & Design, Zurich
Version, Date	7.1, November 2014
Copyright	EACS, 2014



These Guidelines were developed by the European AIDS Clinical Society (EACS), a not-for-profit organisation, whose mission is to promote excellence in standards of care, research and education in HIV infection and related co-infections, and to actively engage in the formulation of public health policy, with the aim of reducing HIV disease burden across Europe.

Panel Members

Medical Secretariat

The EACS Medical Secretariat is responsible for the coordination and update of the EACS guidelines based on the recommendations from the four EACS panels.

Guidelines Chair and Coordinator: Jens D Lundgren Assistant Coordinator: Lene Ryom

Copenhagen, Denmark Copenhagen, Denmark

Barcelona, Spain

Basel, Switzerland

Brussels, Belgium

Athens, Greece

Paris. France

Modena, Italy

Milan, Italy

Madrid, Spain

London, United Kingdom

Liverpool, United Kingdom Warsaw, Poland

Copenhagen, Denmark

HIV Treatment

Chair: Jose M Gatell Vice-Chair: Anton Pozniak Young scientist: Christian Manzardo Barcelona, Spain Antonella d'Arminio Monforte Jose Arribas Manuel Battegay Nathan Clumeck Nikos Dedes Anna Maria Geretti Anders Horban Christine Katlama Jens D. Lundgren Christina Mussini François Raffi Peter Reiss Hans Jürgen Stellbrink

Co-morbidities

Chair: Jens D Lundgren Vice-Chair: Georg Behrens Young scientist: Lene Ryom Manuel Battegay Mark Bower Paola Cinque Simon Collins Juliet Compston Gilbert Derav Stéphane De Wit Christoph A. Fux Giovanni Guaraldi Patrick Mallon Esteban Martinez Catia Marzolini Socrates Papapoulos Renaud du Pasquier Neil Poulter Peter Reiss Alessandra Vigano Ian Williams Alan Winston

Nantes, France Amsterdam. The Netherlands Hamburg, Germany Copenhagen, Denmark Hannover, Germany Copenhagen, Denmark Basel, Switzerland London, United Kingdom Milan, Italy London, United Kingdom Cambridge, United Kingdom Paris France Brussels, Belgium Aarau, Switzerland Modena, Italy Dublin, Ireland Barcelona, Spain Basel. Switzerland Leiden, The Netherlands Lausanne, Switzerland

London, United Kingdom

London, United Kingdom

London, United Kingdom

Milan Italy

Amsterdam, The Netherlands

Co-infections Chair: Jürgen Rockstroh

Vice-Chair: Massimo Puoti Young scientist: Christoph Boesecke Bonn, Germany Sanjay Bhagani Raffaele Bruno Diego García Maxime Journiac Karine Lacombe Stefan Mauss Lars Peters Vicente Soriano Andri Rauch Cristina Tural Chris Ward

Bonn, Germany Milan, Italy London, United Kingdom Pavia. Italv Sevilla, Spain Paris, France Paris, France Dusseldorf, Germany Copenhagen, Denmark Madrid, Spain Bern, Switzerland Barcelona, Spain Cardiff, Wales

Bern, Switzerland

Barcelona, Spain

Bern, Switzerland Basel, Switzerland

Bordeaux, France

Paris, France

Copenhagen, Denmark

London, United Kingdom

London, United Kingdom

Milan, Italy Cologne, Germany

Opportunistic Infections

Chair: Hansjakob Furrer Vice-Chair: Jose M Miro Young scientist: Valentin Gisler Luigia Elzi Paola Cinque Gerd Fätkenheuer Ole Kirk Amanda Mocroft Philippe Morlat Anton Pozniak Alain Volny-Anne

Governing Board Members

Manuel Battegay (President) Fiona Mulcahy (Vice-President) Anna Maria Geretti (Secretary) Nathan Clumeck (Treasurer) Peter Reiss (Immediate Past President) Jose Arribas Antonella d'Arminio Monforte Cristiana Oprea Cristina Mussini Jose Gatell Christine Katlama Jens D. Lundaren Anton Pozniak Jürgen Rockstroh Mike Youle

Basel, Switzerland Dublin, Ireland Liverpool, United Kingdom Brussels, Belgium Amsterdam, The Netherlands Madrid, Spain Milan, Italy Bucharest, Romania Modena, Italy Barcelona, Spain Paris, France Copenhagen, Denmark London, United Kingdom Bonn, Germany London, United Kingdom



Abbreviations

Antiretroviral drug (ARV) abbreviations

3TC ABC	lamivudine abacavir	MVC NRTI	maraviroc nucleos(t)i
ATV	atazanavir		reverse tra
COBI	cobicistat		inhibitors
d4T	stavudine	NNRTI	non-nucleo
ddl	didanosine		reverse tra
DLV	delavirdine		inhibitors
DRV	darunavir	NVP	nevirapine
DTG	dolutegravir	PI	protease ir
EFV	efavirenz	Pl/r	, protease ir
EVG	elvitegravir		, pharmacol
ENF	enfuvirtide		boosted w
ETV	etravirine	RAL	raltegravir
FI	fusion inhibitor	RPV	rilpivirine
FPV	fosamprenavir	RTV	ritonavir (u
FTC	emtricitabine		booster=/r
IDV	indinavir	SQV	saguinavir
INSTI	integrase strand	TDF	tenofovir
	transfer inhibitor	TPV	tipranavir
LPV	lopinavir	ZDV	zidovudine

	maraviroc
	nucleos(t)ide
	reverse transcriptase
	inhibitors
ТΙ	non-nucleoside
	reverse transcriptase
	inhibitors
	nevirapine
	protease inhibitors
	, protease inhibitors
	pharmacologically
	boosted with ritonavir
	raltegravir
	rilpivirine
	ritonavir (used as
	booster=/r)
	saguinavir
	tenofovir
	tipranavir
	zidovudine

ACE	angiotensin converting	HDL-c	HDL-cholesterol
	enzyme	HIVAN	HIV-associated
ALP	alkaline phosphatase		nephropathy
ALT	alanine aminotransferase	HPV	human papillomavirus
aMDRD	abbreviated modification	HSR	hypersensivity reaction
	of diet in renal disease	IGRA	interferon-gamma release
	formula		assay
ART	antiretroviral therapy	IHD	ischaemic heart disease
AST	aspartate	IM	intramuscular
	aminotransferase	IV	intravenous
BMD	bone mineral density	IVDU	intravenous drug use
BMI	body mass index	LDL-c	LDL-cholesterol
BP	blood pressure	LGV	lymphogranuloma
cART	combination antitroviral		venereum
	treatment	Mg	magnesium
CKD	chronic kidney disease	мšм	men who have sex with
CMV	cytomegalovirus		men
CNS	central nervous system	PO	per oral
COPD	chronic obstructive	PAP	, papanicolaou test
	pulmonary disease	PEG-IFN	pegylated-interferon
CSF	cerebrospinal fluid	PPI	proton pump inhibitor
CVD	cardiovascular disease	PPD	purified protein derivative
CXR	chest X-rav	PSA	prostate specific antigen
DAA	direct acting antiviral drug	PTH	parathyroid hormone
DXA	dual energy X-ray	RBV	ribavirin
	absorptiometry	SC	subcutaneous
ECG	electrocardiogram	SVR	sustained virological
eGFR	estimated glomerular		response
	filtration rate	STI	sexually transmitted
FBC	full blood count		infection
FDC	fixed dose combination	тс	total cholesterol
FRAX	fracture risk assessment	TDM	therapeutic drug
	tool		monitoring
GT	genotype	TG	triglycerides
HAV	hepatitis A virus	UA/C	urine albumin/creatinine
HBV	hepatitis B virus		ratio
HCV	hepatitis C virus	UP/C	urine protein/creatinine
			ratio
		VL	viral load (HIV-RNA)
		WB	western blot
		7	

Other Abbreviations

zinc

Zn

Part I

Assessment of HIV-positive Persons at Initial & Subsequent Visits

	Assessment	At HIV diagnosis	Prior to starting ART	Follow-up frequency	Comment	See page	
HISTORY							
Medical	Complete medical history including	+	+	First visit	On transfer of care repeat assessment		
	• Family history (e.g. premature CVD, diabetes, hypertension, CKD)	+		First visit	Premature CVD: cardiovascular events in a first degree relative (male < 55, female < 65 years)	31-33	
	Concomitant medicines(i)	+	+	Every visit		_	
	Past and current co-morbidities	+	+	Every visit			
	Vaccination history	+		First visit	Measure antibody titres and offer vaccinations where indicated		
Psychosocial	Current lifestyle (alcohol use, smoking, diet, exercise, drug use)	+	+	6-12 months	Adverse lifestyle habits should be addressed more frequently	30	
	Employment	+	+	As indicated	Provide advice and support if needed		
	Social and welfare	+	+	Every visit	Provide counselling if needed		
	Psychological morbidity	+	+				
	Partner and children	+			Test partner and children if at risk		
Sexual and	Sexual history	+		6-12 months	Address issues concerning sexual dysfunction	56-58	
reproductive health	Safe sex	+			Risk of sexual transmission should be addressed where indicated		
	Partner status and disclosure	+			Consider starting ART in serodifferent couples		
	Conception issues	+	+				
HIV DISEASE		1					
Virology	Confirmation of HIV Ab pos	+			More frequent monitoring of HIV-VL at start of ART	7-11	
thology	Plasma HIV-VL Genotypic resistance test	+ +	+ +/-	3-6 months	Perform genotypic resistance test before starting ART if not previously tested or if at risk of		
	and sub-type				super-infection		
	R5 tropism (if available)		+/-	At virological	Screen if considering R5 antagonism in regimen		
Immunology	CD4 absolute count and % (optional: CD8 and %)	+	+	3-6 months	Consider less frequent monitoring for stable per- sons on ART with high CD4 counts ⁽ⁱⁱ⁾	7-11	
	HLA B5701 (if available)	+	+/-		Screen before starting ABC containing ART, if not previously tested		
CO-INFECTIONS	,	1					
STIs	Syphilis serology	+		Annual/ as indicated	Consider more frequent screening if at risk	56	
	STI screen	+		Annual/ as indicated	Screen if at risk		
Viral Hepatitis	HAV serology	+			Screen at risk; vaccinate if non-immune	55-56,6	
	HCV screen	+		Annual/ as	Annual screen if ongoing risk. Measure HCV-RNA if HCV Ab pos or if acute infection suspected.		
	HBV screen	+	+	indicated	Annual screen in susceptible persons; vaccinate if non-immune		
Tuberculosis	CXR	+		Re-screen if	Consider routine CXR in persons, from high TB	82	
	PPD if CD4 count >400	+		exposure	prevalence populations.		
	IGRA in selected high-risk populations (if available)	+			See Diagnosis and Treatment of TB in HIV-positive persons		
Others	Varicella zoster virus serol- ogy	+			Offer vaccination where indicated	55	
	Measles/Rubella serology	+			Offer vaccination where indicated		
	Toxoplasmosis serology	+					
	CMV serology	+					
	Leishmania serology	+/-			Screen according to travel history/origin		
	Tropical screen (e.g. Schis- tosoma serology)	+/-			Screen according to travel history/origin		



	Assessment	At HIV diagnosis	Prior to starting ART	Follow-up frequency	Comment	See page	
CO-MORBIDITIES	3						
Haematology	FBC	+	+	3-12 months			
	Haemoglobinopathies	+			Screen at risk persons	1	
	G6PD	+			Screen at risk persons	1	
Body composition	Body-mass index	+	+	Annual		30	
Cardiovascular disease	Risk assessment (Framingham score ⁽ⁱⁱⁱ⁾)	+	+		Should be performed in all men > 40 years and women > 50 years without CVD	31	
	ECG	+	+/-	Annual	Consider baseline ECG prior to starting ARVs as- sociated with potential conduction problems		
Hypertension	Blood pressure	+	+	Annual		32-33	
Lipids	TC, HDL-c, LDL-c, TG ^(iv)	+	+	Annual	Repeat in fasting state if used for medical interven- tion (i.e. \geq 8h without caloric intake)	37	
Glucose	Serum glucose	+	+	6-12 months	tion (i.e. ≥ 8h without caloric intake) Consider oral glucose tolerance test / HbA1c if fasting glucose levels of 5.7-6.9 mmol/L (100-125 mg/dL)		
Pulmonary	CXR	+/-		As indicated	Consider CXR if prior history of pulmonary disease		
disease	Spirometry			As indicated	Screen for COPD in at risk persons(xii)	1	
Liver disease	Risk assessment ^(v)	+	+	Annual		45-47	
			More frequent monitoring prior to starting and on treatment with hepatotoxic drugs	_			
Renal disease	Risk assessment ^(vi)	+	+	Annual	More frequent monitoring if CKD risk factors	41-42	
	eGFR (aMDRD) ^(vii)	+	+	3-12 months	present and/or prior to starting and on treatment with nephrotoxic drugs ^(ix) Every 6 months if eGFR < 60 mL/min,		
	Urine dipstick analysis ^(viii)	+	+	Annual			
Bone disease	Bone profile: calcium, PO ₄ , ALP	+	+	6-12 months		38, 40	
	Risk assessment ^(x) (FRAX® ^(xi) in persons > 40 years)	+	+	2 years	Consider DXA in specific persons		
Vitamin D	25(OH) vitamin D	+		As indicated	Screen at risk persons	39	
Neurocognitive impairment	Screening questionnaire	+	+	2 years	Screen all persons without highly confounding con- ditions. If abnormal or symptomatic, see algorithm page 63 for further assessment.	63	
Depression	Questionnaire	+	+	1-2 years	Screen at risk persons	59-61	
Cancer	Mammography			1-3 years	Women 50-70 years	29, 4	
	Cervical PAP			1-3 years	Sexually active women		
	Anoscopy and PAP (MSM)			1-3 years	Evidence of benefit not known		
	Ultrasound and alpha- foetoprotein			6 months	Controversial/Persons with cirrhosis and persons with HBV irrespective of fibrosis stage		
	Others				Controversial		

- i Review all concomitant medicines which may potentially interact with ARVs or increase co-morbidities, see Drug-drug Interactions between DAAs and ARVs
- Drug-drug Interactions between Antidepressants and ARVs Drug-drug Interactions between Antihypertensives and ARVs Drug-drug Interactions between Analgesics and ARVs Drug-drug Interactions between Antimalarial Drugs and ARVs
- and www.hiv-druginteractions.org
- If stable on ART with undetectable VL and CD4 cell count > 350/µL, consider less frequent CD4 cell count monitoring every 6-12 months.
 A risk equation developed from HIV populations is available see
- iii A risk equation developed from HIV populations is available, see www.cphiv.dk/tools.aspx. Of note, if an individual receives medication to control dyslipidaemia and/or hypertension, the estimation should be interpreted with caution.
- iv A calculator for LDL-cholesterol in cases where TG is not high can be found at www.cphiv.dk/tools.aspx.
- Risk factors for chronic liver disease include alcohol, viral hepatitis, obesity, diabetes, insulin resistance, hyperlipidaemia and hepatotoxic drugs.
- vi Risk factors for CKD: hypertension, diabetes, CVD, family history, black

African ethnicity, viral hepatitis, low current CD4 count, smoking, older age, concomitant nephrotoxic drugs.

- vii eGFR: use the abbreviated modification of diet in renal disease (aMDRD) formula based on serum creatinine, gender, age and ethnicity; see www.cphiv.dk/tools.aspx. The Cockcroft-Gault (CG) equation may be used as an alternative.
- viii Some experts recommend UA/C (urinary albumin creatinine ratio) or UP/C (urinary protein creatinine ratio) as a screening test for proteinuria in all persons. UA/C predominantly detects glomerular disease. Use in persons with diabetes. UP/C detects total protein secondary to glomerular and tubular disease.
- ix Additional screening is required for persons receiving TDF and perhaps for certain PIs e.g. ATV and LPV/r, see ARV-associated Nephrotoxicity
- X Classic risk factors: older age, female gender, hypogonadism, family history of hip fracture, low BMI (≤ 19 kg/m²), vitamin D deficiency, smoking, physical inactivity, history of low impact fracture, alcohol excess (> 3 units/day), steroid exposure (minimum 5 mg for > 3 months).
- xi WHO fracture risk assessment (FRAX®) tool: www.shef.ac.uk/FRAX
- xii A diagnosis of COPD should be considered in persons over the age of 35 who have a risk factor (current or ex- smoker) and who present with exertional breathlessness, chronic cough, regular sputum production, frequent winter 'bronchitis' or wheeze.

Part II ART of HIV-positive Persons

Assessing HIV-positive Person's Readiness to Start and Maintain ART^(x)

Goal: to help persons start and/or maintain ART					
Successful ART requires a person's readiness to start and adhere to the regimen over time. The trajectory from problem awareness to maintenance on ART can be divided into five stages. Knowing a person's stage, health care providers use appropriate techniques to assist them to start and maintain ART.	Identify the person's stage of readiness using WEMS ⁽ⁱ⁾ techniques, and start discussion with an open question/invitation: "I would like to talk about HIV medicines." <wait> "What do you think about it?" Based on the person's response, identify his/her stage of readiness and</wait>				
	intervene accordingly. ⁽ⁱⁱ⁾				
Stages of readiness to start ART					
Precontemplation: <i>"I don't need it, I feel good."</i> <i>"I don't want to think about it."</i>	Support: Show respect for the person's attitude. / Try to understand the person's health and therapy beliefs. / Establish trust. / Provide concise, individualised information / Schedule next appointment.				
Contemplation: "I am weighing things up and feel torn about what to do about it."	Support: Allow ambivalence. / Support the person in weighing pros and cons. / Assess the person's information needs and support his/her information seeking. / Schedule the next appointment.				
Preparation: "I want to start, I think the drugs will allow me to live a normal life."	Support: Reinforce the person's decision. / Decide with the person which is the most convenient regimen. / Educate the person on adherence, resist- ance and side effects. / Discuss integration into daily life. / Respect the person's self-assessment. Ask: How confident are you that you can take your medicines as we discussed (specify) once you have started? Use VAS 0-10 ⁽ⁱⁱⁱ⁾ Consider skills training: • Medicines-taking training, possibly MEMS • Directly observed therapy with educational support • Use aids: mobile phone alarm, pillboxes • Involve supportive tools/persons where appropriate				
Action:	'Final check': With a treatment plan established, is the person capable of taking ART?				
Maintenance: "I will continue" or "I have difficulties continuing over the long run" Caveat: A person can relapse to an earlier stage, even from "maintenance" to "precontemplation"	Assess: Adherence every 3-6 months ^(iv) Evaluate adherence: For persons with good adherence: show respect for their success. Assess: The person's own perception of ability to adhere to, and continue, treatment. Ask: In the next 3-6 months, how confident are you that you can take your medicines? Use VAS 0-10 ⁽ⁱⁱⁱ⁾ For a person without sufficient adherence: use mirroring techniques ^(v) on problems, ask open questions to identify dysfunctional beliefs. Assess: Stage of readiness and provide stage-based support Assess: Barriers and facilitators ^(vi) Schedule next appointment and repeat support				
Screen for and talk about problems and facilitators	I will not manage I will manage				
Consider systematic assessment of:Consider talking about:• Depression(vii), see page 59-60• Cognitive problems(viii), see page 63• Social support and disclosure• Harmful alcohol(ix) or recreational drug use, see page 28, 30• Therapy-related factors	 0 + 10 iv Suggested adherence questions: "In the past 4 weeks how often have you missed a dose of your HIV medicines: every day, more than once a week, once a week, once every 2 weeks, once a month, never?" / "Have you missed more than one dose in a row?" [2]. v Mirroring: reflecting back on what a person has said or non-verbally demonstrated (e.g. anger or disappointment) WITHOUT introducing new 				
Recognise, discuss and reduce problems wherever possible in a multidisciplinary team approach.	material by asking questions or giving information.vi Adherence to long-term therapies [3].vii Ask: "During the past month have you often been bothered by feeling				
 WEMS: Waiting (> 3 sec), Echoing, Mirroring, Summarising [1] The person presenting in the clinic may be at different stages of readiness: precontemplation, contemplation or preparation. The first step is to assess this stage, and then to support/intervene accordingly. In the case of late presentation (< 350 CD4 cells/µL), the initiation of ART should not be delayed. The person should be closely followed and optimally supported. Schedule the next appointment within a short time, i.e. 1-2 weeks. VAS (= Visual Analogue Scale; range from 0 to 10, i.e. 0= I will not manage, 10= I am sure I will manage). 	 down, depressed or hopeless?" / "During the past month have you often been bothered by little interest or pleasure in doing things?" / "Is this something with which you would like help?" / If answers are positive, then sensitivity is 96%, specificity 89% [4]. viii Ask: "Do you feel having problems to concentrate in your daily life?" / "Do you feel slowed in your thinking?" / "Do you feel having problems with your memory?" / "Did relatives or friends express that they feel you have problems with your memory or difficulty concentrating?" [5]. ix We recommend the AUDIT-Fast tool to determine harmful alcohol use: "How often have you had 6 or more units (if female), or 8 or more (if male), on a single occasion in the last year?" If the answer is weekly or daily, i. e. screening positive, stop here. If the answer is less than that, ask three more questions. When screening for harmful substance use, drop the first quantitative question and replace "drinking" with "recreational substance" [6]. x Algorithm adapted from [7] 				



Recommendations for Initiation of ART in HIV-positive Persons without Prior ART Exposure⁽ⁱ⁾

Recommendations are graded while taking into account both the degree of progression of HIV disease and the presence of, or high risk for, developing various types of (co-morbid) conditions

Present condition/circumstance	Current CE	04 count ^(ii,iii)
	350-500	> 500
Asymptomatic HIV infection	С	С
To reduce transmission of HIV	С	С
Symptomatic HIV disease (CDC B or C conditions) incl. tuberculosis	R	R
Primary HIV infection	С	С
Pregnancy (before third trimester)	R	R
Conditions (likely or possibly) associated with HIV, other than CDC stage B or C disease:	R	R
 HIV-associated kidney disease 	R	R
 HIV-associated neurocognitive impairment 	R	R
 Hodgkin's lymphoma 	R	R
 HPV-associated cancers 	R	R
 Other non-AIDS-defining cancers requiring chemo- and/or radiotherapy 	С	С
Autoimmune disease – otherwise unexplained	С	С
 High risk for CVD (> 20% estimated 10-yr risk) or history of CVD 	С	С
Chronic viral hepatitis:		
HBV requiring anti-HBV treatment	R	R
HBV not requiring anti-HBV treatment	R ^(iv)	С
HCV for which anti-HCV treatment is being considered or given	R ^(v)	С
HCV for which anti-HCV treatment not feasible	R	С

i,ii ART is always recommended in any HIV-positive person with a current CD4 count below 350 cells/µL.

For persons with CD4 counts above this level, the decision to start ART should be individualised and considered, especially if a person is requesting ART and ready to start, has any of the conditions mentioned above and/or for any other personal reasons. Priority should be given to treating persons with CD4 counts below 350 cells/µL and for persons with higher CD4 counts if they suffer from one of the above-mentioned conditions before placing resources into treatment as prevention. Time should always be taken to prepare the person, in order to optimise compliance and adherence.

Genotypic resistance testing is recommended prior to initiation of ART, ideally at the time of HIV diagnosis; otherwise before initiation of ART. If ART needs to be initiated before genotypic testing results are available, it is recommended to include a ritonavir-boosted PI in the first-line regimen. Before starting treatment, the HIV-VL level and CD4 count should be repeated to obtain a baseline to assess subsequent response.

- iii **R** use of ART is recommended
 - **C** use of ART should be considered and actively discussed with the HIV-positive person; under these circumstances, some experts would recommend starting ART whereas others would consider deferral of ART; this clinical equipoise reflects that whereas certain data, such as hypotheses on pathophysiology and chronic immune activation, supports starting ART, this needs to be balanced against the risk of known or undiscovered adverse drug reactions from use of ART, and hence the risk/benefit ratio for use of ART under these circumstances has not yet been well defined.
- iv See figure page 65 for indication of HBV treatment in HBV/HIV co-infected persons
- Initiation of ART is recommended to optimise the outcome of HCV treatment.



Recommended Regimens(*)

A drug from column A should be combined with the drugs listed in column B)
r arag nom oblamm conolid be combined with the arage noted in oblamm B	

Α	В	Remarks
NNRTI	NRTI	
EFV ⁽ⁱ⁾ RPV ⁽ⁱⁱ⁾	ABC/3TC ^(vii) or TDF/FTC	ABC/3TC co-formulated TDF/FTC co-formulated EFV/TDF/FTC co-formulated RPV/TDF/FTC co-formulated
Pl/r		
ATV/r ^(iv) DRV/r ^(iv)	ABC/3TC ^(vii) or TDF/FTC	ATV/r: 300/100 mg qd DRV/r: 800/100 mg qd
INSTI		
EVG + COBI	TDF/FTC	TDF/FTC/EVG/COBI co-formulated ^(ix)
DTG	ABC/3TC or TDF/ FTC	DTG 50 mg qd TDF/FTC co-formulated ABC/3TC/DTG co-formulated
RAL	ABC/3TC or TDF/FTC	RAL: 400 mg bd

Alternative Regimen Components

NNRTI	Remarks
NVP ⁽ⁱⁱⁱ⁾	
PI/r	
LPV/r ^(v)	
NRTI	
TDF/3TC ZDV/3TC	ZDV/3TC co-formulated
CCR5 inhibitor	
MVC ^(vi)	Only if CCR5 tropic HIV ^(viii) Unlicensed in Europe for naive HIV-positive persons
Alternative combinations	
DRV/r + RAL	Only if CD4 counts > 200 cells/µL and HIV-VL < 100,000 copies/mL
LPV/r + 3TC	Only one randomised trial available

- Only drugs currently licensed for initiation of therapy by the EMA are taken into consideration (in alphabetical order)
- ** Generic HIV drugs are becoming more available and can be used as long as they replace the same drug and do not break recommended fixed dose combinations.
- i EFV: not recommended to be initiated in pregnant women or women with no reliable and consistent contraception; continuation is possible if EFV is already started before pregnancy; not active against HIV-2 and HIV-1 group O strains.
- RPV: only if CD4 count > 200 cells/µL and HIV-VL < 100,000 copies/mL; PPI contraindicated, H2 antagonists to be taken 12h before or 4h after RPV.
- iii NVP: Use with extreme caution in women with CD4 counts > 250 cells/ μL and men with CD4 counts > 400 cells/ μL and only if benefits outweigh the risk; not active against HIV-2 and HIV-1 group O strains.
- iv Castle study (LPV/r vs. ATV/r) showed better tolerability of ATV/r; [7]. Coadministration with PPI is contraindicated for treatment-experienced persons. If coadministration is judged unavoidable, close clinical monitoring is recommended and doses of PPI comparable to omeprazole 20 mg should not be exceeded and must be taken approximately 12 hours prior to the ATV/r.

Artemis study (LPV/r vs. DRV/r) showed better efficacy and tolerability of DRV/r [8].

- ACTG 5142 study showed lower virological efficacy of LPV/r vs. EFV. No PI mutations emerged with LPV/r plus 2 NRTI failures. PI mutations were seen with LPV/r + EFV failures. LPV to be used in cases where oral absorption is the only alternative, especially in intensive care [9].
 vi Not licensed in Europe for naive persons.
- viii ABC contra-indicated if HLA B*5701 positive. Even if HLA B*5701 negative.
- tive, counselling on HSR risk still mandatory. ABC should be used with caution in persons with a high CVD risk and/or persons with a VL > than 100,000 copies/mL.
- viii Only if unavailability or intolerance to other recommended NRTIs.
- ix Should not be initiated in persons with eGFR < 70 mL/min. It is recommended that EVG/COBI/TDF/FTC not be initiated in persons with eGFR < 90 mL/min unless this is the preferred treatment.</p>



Acute HIV infection

Definition of Acute primary HIV infection

High-risk exposure within previous 2-8 weeks, and

- Detectable HIV-VL in plasma (p24 Ag and/or HIV-VL > 1000 copies/mL) and/or
- Negative or indeterminate serologic testing (negative or weakly positive ELISA, and WB \leq 1 band) plus HIV-VL
- Recommendation: confirm HIV infection by HIV antibody test (WB) performed 2 weeks later

Treatment

- Treatment should be considered in all persons. See page 7
- If treatment is considered, the HIV-positive person should preferable be recruited into a clinical trial
- Some experts recommend treatment as a tool for prevention of HIV transmission

Resistance testing

- Recommended in all situations as soon as acute HIV infection is diagnosed, even if treatment not initiated
- · In case it cannot be performed, store a plasma sample for testing

Transmission

- Recognise STIs, including syphilis, gonorrhoea, chlamydia (urethritis and LGV), HPV, HBV and HCV, see page $56\,$
- Counsel newly diagnosed person on high risk of transmission and preventive measures (condoms), including notifying and testing partners

Definition of virologically suppressed

Confirmed HIV-VL< 50 copies/mL

Indication

- Switch for toxicity
- Documented toxicity
- Management of potential drug interactions
- Side effects
- Planned pregnancy

Switch for prevention of long-term toxicity

- Prevention of long-term toxicity (pre-emptive switch)
- Ageing and/or co-morbidity with a possible negative impact of drug(s) in current regimen, e.g. on CVD risk, metabolic parameters.

Switch for simplification

Wish to simplify regimen

Actual regimen no longer recommended

Principles

- A PI/r may be switched for simplification, prevention or improvement of metabolic abnormalities or adherence facilitation to unboosted ATV, an NNRTI, RAL or EVG + COBI only if full activity of the 2 NRTIs remaining in the regimen can be guaranteed.
- Simplification of a complex multidrug regimen in antiretroviral-experienced persons with 1) substitution of drugs difficult to administer (ENF) and/ or with poor activity (NRTI in case of multiple NRTI resistance) and/or poor tolerability and 2) addition of new well-tolerable, simpler and active agent(s).
- Bd to qd NRTI or PI/r switch for simplification, prevention of long-term toxicity.
- 4. Intra-class switch if drug-specific related adverse event.
- 5. Review the complete ARV history and available resistance test results.
- Avoid switching to a drug with a low genetic barrier in the presence of a backbone compromised by the possibility of archived class resistance.

Strategies not recommended

- a. Intermittent therapy, sequential or prolonged treatment interruptions
 b. 2-drug combination, i.e. 1 NRTI + 1 NNRTI or 1 NRTI + 1 PI without RTV or 1 NRTI + RAL, or 2 NRTIs
- c. Triple NRTI combinations

Other strategies

PI/r monotherapy with qd DRV/r or bd LPV/r might represent an option in persons with intolerance to NRTIs or for treatment simplification or in illicit drug users with documented frequent interruption of cART. Such a strategy only applies to persons without history of failure on prior PI-based therapy and who have had HIV-VL < 50 copies/mL in at least the past 6 months and who do not have chronic HBV. LPV/r + 3TC or ATV/r + 3TC may be better options.



Virological Failure

Definition	Confirmed HIV-VL > 50 copies/mL 6 months after starting	In case of	General recommendations:		
	therapy (initiation or modification) in persons that remain on ART. Depending on the VL assay, this limit could be higher or lower.	demonstrated resistance mutations	Use at least 2 and preferably 3 active drugs in the new regimen (including active drugs from previously used classes) Any regimen should use at least 1 fully active PI/r (e.g. DRV/r) plus 1 drug from a class not used previously e.g.		
General	Review expected potency of the regimen				
measures	Evaluate adherence, compliance, tolerability, drug-drug interactions, drug-food interactions, psychosocial issues		fusion, integrase or CCR5 antagonist (if tropism test shows R5 virus only), or 1 NNRTI (e.g. ETV), assessed		
	Perform resistance testing on failing therapy (usually routinely available for HIV-VL levels > 350-500 copies/ mL and in specialised laboratories for lower levels of viraemia) and obtain historical resistance testing for archived mutations		by genotypic testing Defer change if < 2 active drugs available, based on resistance data, except in persons with low CD4 count (< 100 cells/µL) or with high risk of clinical deterioration for whom the goal is the preservation of immune function		
	Tropism testing		through partial reduction of HIV-VL (> 1*log ₁₀ reduction) by recycling		
	Consider TDM		If limited options, consider experimental and new drugs favouring clinical trials (but avoid functional monothera)		
	Review antiretroviral history				
	Identify treatment options, active and potentially active		Treatment interruption is not recommended		
	drugs/combinations		Consider continuation of 3TC or FTC in particular		
Management	If HIV-VL > 50 and < 500-1000 copies/mL		situations even if documented resistance mutation		
of virological	Check for adherence		(M184V/I)		
failure (VF)	Check HIV-VL 1 to 2 months later		If many options are available, criteria of preferred choice include: simplicity of the regimen, toxicity risks evaluation,		
	If genotype not possible, consider changing regimen based on past treatment and resistance history		drug-drug interactions, and future salvage therapy		
	If HIV-VL confirmed > 500/1000 copies/mL, change regimen as soon as possible. What to change will depend on the resistance testing results:		·		
	No resistance mutations found: re-check for adherence, perform TDM				
	Resistance mutations found: switch to a suppressive regimen based on drug history; multidisciplinary expert discussion advised				

Goal of new regimen: HIV-VL < 400 copies/mL after 3 months, HIV-VL < 50 copies/mL after 6 months



Treatment of HIV-positive Pregnant Women

Pregnant women should be monitored every month and as close as possible to the predicted delivery date

Criteria for starting ART in pregnant women (see different scenarios)	Same as for non pregnant
Objective of treatment in pregnant women	Full plasma HIV-VL suppression at least by third trimester and specifically at time of delivery
Resistance testing	Same as for non pregnant women, i.e. before starting ART and in case of virological failure
SCENARIO	
1. Women planning to be pregnant while already on ART	 If under EFV, switch to another NNRTI or boosted PI because of risk of neural tube defects
2. Women becoming pregnant while already on ART	 Maintain ART unless under EFV: switch to another agent (NVP or PI/r) if before 8 weeks (because of risk of neural tube defects)
 Women becoming pregnant while treatment naive irrespective of whether they fulfil the criteria (CD4) for initiation of ART 	3. Starting ART at beginning of 2nd trimester is highly recommended
4. Women whose follow-up starts after week 28 of pregnancy	 Start ART immediately and consider adding RAL to obtain rapid HIV-VL decline in case of high HIV-VL
5. Women whose HIV-VL is not undetectable at third trimester	 Perform resistance testing and consider adding RAL to obtain rapid HIV-VL decline
	Same as non pregnant
	NVP not to be initiated but continuation is possible if started before pregnancy
Antiretroviral regimen in pregnancy	EFV should be avoided during first trimester because of increase in neural tube defects*
	Among PI/r, prefer LPV/r, SQV/r or ATV/r
	If RAL, DRV/r: could be continued
Drugs contra-indicated during pregnancy	ddI + d4T, triple NRTI combinations
iv ZDV during labour	Benefit uncertain if HIV-VL < 50 copies/mL
Single dose NVP during labour	Not recommended
Caesarean section	Benefit uncertain if HIV-VL < 50 copies/mL at week 34-36. In this case, consider vaginal delivery only

* According to prospective studies [10-11]



ART in TB/HIV Co-infection

Principles

Persons with TB should be started on standard TB therapy with 2 months Rifampicin/Isoniazid/Pyrazinamide +/- Ethambutol followed by 4 months Rifampicin/Isoniazid (choice of drugs and length of treatment depends on drug susceptibility and site of disease), see Diagnosis and Treatment of TB in HIV-positive persons

All persons with TB/HIV co-infection should start ART irrespective of CD4 count. Treatment supervision and adherence evaluation are very important

Suggested timing of ART initiation in TB/HIV co-infection according to CD4 Count

< 100 cells/ μ L^(*) As soon as TB treatment is tolerated and wherever possible within 2 weeks

> 100 cells/µL^(**) Can be deferred until between 8 and 12 weeks of TB treatment, especially when there are difficulties with drug-drug interactions, adherence and toxicities

Although a RCT showed that early ART (within 2 weeks) did not reduce mortality in TB meningitis, recommendations on ART initiations should be based on the CD4 cell count in HIV-positive persons with TB co-infection.

- * Be aware of IRIS reaction in persons starting ART at low CD4 levels and with early initiation of ART. Corticosteroids should be considered for treatment of symptomatic IRIS, with dosages and duration tailored according to response.
- ** Although the data suggests a cut-off of 50 cells/µL, because of the daily variability in CD4, a cut-off of 100 cells/µL may be more appropriate.

Recommended 1st line ARV combination with anti-TB medicines

TDF/FTC/EFV, ABC/3TC/EFV or TDF/FTC/RAL

Alternatives

- If HIV-VL < 100,000 copies/mL, fixed-dose combination of ABC/3TC/ZDV bd +/- TDF could also represent a short-term alternative until anti-TB treatment has been completed.
- 2. Rifampicin plus double dose LPV/r or with RTV super boosted (400 mg bd) + LPV

Where combinations are not recommended or to be used with caution or because of resistance/intolerance, specialist HIV treatment advice should be sought.

• PI/r + TDF/FTC, using rifabutin instead of Rifampicin

Use with caution

Important Drug-Drug Interactions between ART and Rifampicin / Rifabutin

ARV drug class	Specific ARVs	Drug- drug interactions and recom- mended adjustment of dose of either or both drugs		
NRTIs		Rifampicin: standard dose of all drugs		
		Rifabutin: standard dose of all drugs		
Pl/r	ATV/r, DRV/r, LPV/r or SQV/r	Rifampicin: not recommended		
	Monitor liver enzymes and, whenever possible, perform TDM for PI/r	Rifabutin: dose as 150 mg x 3/week ⁽ⁱ⁾ . PI/r at standard dose		
NNRTIS	EFV	Rifampicin: No dose change required. EFV: standard dose (some recommend 800 mg if not black African); ARV TDM recommended after 2 weeks		
		Rifabutin: 450 mg daily. EFV: standard dose		
	NVP	Neither Rifampicin nor Rifabutin recom- mended		
	RPV	Rifampicin: not recommended		
		Rifabutin: standard dose. RPV dose should be increased (use with caution)		
	ETV	Rifampicin: not recommended		
		Rifabutin: standard dose of both drugs (few data – use with caution)		
INSTI	EVG	Rifampicin: not recommended		
		Rifabutin: 150 mg x 3/week. EVG: stand- ard dose		
	RAL	Rifampicin: standard dose. RAL 800 mg bd and perform TDM for RAL (standard dose may also work)		
		Rifabutin: standard dose of both drugs		

Initial pharmacokinetic studies in healthy volunteers showed that concentrations of Rifabutin and its active metabolite were significantly increased when combined with PI/r. Thus, a reduction of Rifabutin dosage to 150 mg x3/week was recommended to reduce the risk of Rifabutin related toxicity. However, more recent pharmacokinetic data derived from HIV/TB co-infected persons have shown that the coadministration of LPV/r or ATV/r with Rifabutin (150 mg x3/week) resulted in Rifabutin concentrations that were lower than those observed with rifabutin 300 mg x1/day without PI/r suggesting that Rifabutin dosage may be inadequate. Cases of relapses with acquired Rifamycin-resistant TB have been described in co-infected persons treated with rifabutin 150 mg x3/week and LPV/r or ATV/r. The US guidelines for HIV treatment recommend the administration of Rifabutin at 150 mg x1/day with PI/r. Due to the limited safety data with this dose and combination, persons receiving Rifabutin 150 mg x1/day with PI/r should be closely monitored for Rifabutin related toxicities (i.e. uveitis or neutropenia).



Post-exposure Prophylaxis

Post-exposure Prophylaxis (PEP) recommended in case of

Risk	Nature of exposure	Status of source person	
Blood	Subcutaneous or intramuscular penetration with iv or im needle, or intravascular device	HIV-positive or serostatus unknown, but presence of HIV risk factors	
	Percutaneous injury with sharp instrument (lancet), im or sc needle, suture needle Contact > 15 min of mucous membrane or non intact skin	HIV-positive	
Genital secretions	Anal or vaginal sex	HIV-positive or serostatus unknown but presence of HIV risk factors	
	Receptive oral sex with ejaculation	HIV-positive	
Intravenous drug use	Exchange of syringe, needle, preparation material or any other material	HIV-positive	

- · Rapid testing of the source person for HCV and HIV
- (if HIV-status unknown) recommended If source person HIV-positive on ART, order resistance testing if HIV-VL detectable
- · Individualise PEP according to the source's treatment history and previous resistance tests
- PEP to be started ideally < 4 hours after the exposure, and no later than 48 hours
- Duration of PEP: 4 weeks
- Standard PEP regimen: TDF/FTC (alternative: ZDV/3TC); LPV/r tablets 400/100 mg bd
- Full sexual health screen in case of sexual exposure
- · Follow-up:
 - HIV serology + HBV and HCV, pregnancy test (women) within 48 hours of exposure
 - Re-evaluation of PEP indication by HIV expert within 48-72 hours

 - Assess tolerability of PEP regimen
 Transaminases, HCV-PCR and HCV serology at month 1 if source person HCV-positive (observed or suspected)
 - Repeat HIV serology after 2 and 4 months, syphilis serology after 1 month if sexual exposure



Adverse Effects of ARVs & Drug Classes

Bold: Frequent effects Red: Severe effects Black: Neither Frequent nor Severe⁽ⁱ⁾

	Skin	Digestive	Liver	сv	Musculo- skeletal	Genito- urinary	Nervous	Body fat	Metabolic	Other
NRTI							-			
ABC	Rash*	Nausea* Diarrhoea*		IHD						*Systemic hyper- sensitivity syndrome (HLA B*5701 dependent)
ZDV	Nail pigmen- tation	Nausea	Steatosis		Myopathy, Rhabdo- myolysis				Dyslipi- daemia, Hyperlacta- taemia	Anaemia
d4T		Pancreatitis	Steatosis				Peripheral neuropathy	- Lipoatrophy	Dyslipi- daemia, Hyperlacta- taemia	
ddl		-	Steatosis, Liver fibrosis	IHD					Hyperlacta- taemia	
3TC										
FTC										
TDF					↓ BMD, Osteomalacia ↑ Fractures risk	↓ eGFR, Fanconi syndrome				
NNRTI				1						
EFV	Rash		Hepatitis				Dizziness, Sleep disturbanc- es, Depression		Dyslipi- daemia, Gynaeco- mastia	↓ plasma 25(OH) vitamin D, Teratogen- esis
ETV	Rash									
NVP	Rash [*]		Hepatitis*							*Systemic hypersen- sitivity (CD4- and gender- dependent)
RPV	Rash		Hepatitis			↓ eGFR	Depression, Sleep disturbances, headache			
PI										
ATV			Jaundice Cholelithiasis			↓ eGFR, Ne- phrolithiasis			Dyslipi- daemia	
DRV	Rash	-				Nephrolithi- asis			Dyslipi- daemia	
FPV	Rash	-		IHD					Dyslipi- daemia	
IDV	Dry skin, Nail dystrophy	Nausea and	Jaundice	IHD		Nephrolithi- asis		↑ Abdominal fat	Dyslipi- daemia, Diabetes mellitus	
LPV		Diarrhoea ⁽ⁱⁱ⁾		IHD		↓ eGFR			Dyslipi- daemia	
SQV									Dyslipi- daemia	
TPV			Hepatitis				Intracranial haemorrhage		Dyslipi- daemia	



FI								
ENF	Injection nodules							Hypersensi- tivity
ITI		1	1					
RAL		Nausea			Myopathy, Rhabdomy- olysis		Mood changes	
DTG	Rash		Nausea			↓ eGFR ⁽ⁱⁱⁱ⁾	Headache	Systemic hypersen- sitiv- ity syndrome (<1%)
EVG/ COBI		Nausea, Diarrhoea	Hyperbiliru- binemia			↓ eGFR ⁽ⁱⁱⁱ⁾	Headache	
CCR5 in	hibitors							
MVC			Hepatitis	IHD				↑ Infections risk

i "Frequent effects" (events expected in a least 10% of treated HIVpositive persons), in bold

"Severe effects" (events that can put a person's life at risk and represent a medical emergency), in red

Neither frequent nor severe effects, in black

- ii Frequency and severity differs between individual ARVs.
- iii Due to inhibition of renal tubular creatinine secretion without affecting glomerular filtration itself
- Refers to effects seen in relation to hypersensitivity reactions.

Note: the adverse effects included in the table above are not exhaustive, but represent the most important effects with a likely causal relation. Nausea, diarrhoea and rash are frequently observed in persons on ART, and these symptoms are indicated in the table for drugs where clinical experience suggests a possible causal link.



Drug-drug Interactions between ARVs and Non-ARVs⁽ⁱ⁾

nor	n-ARV drugs	ATV/r	DRV/r	LPV/r	EFV	ETV	NVP	RPV	MVC	DTG	EVG/c	RAL	ABC	FTC	3TC	TDF	ZDV
	atorvastatin	↑	↑	1490%	↓43%	↓37%	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
s	fluvastatin	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	Ŷ	\leftrightarrow										
ng	pravastatin	\leftrightarrow	↑81%	\leftrightarrow	↓44%	Ļ	\leftrightarrow										
rd	rosuvastatin	↑213%	↑48%	107%	\leftrightarrow	Ŷ	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	138%	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
ula	simvastatin	1	Î	↑	↓68%	Ļ	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	1	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
asc	amlodipine	↑ ^{III}	1	1 ^Ⅲ	\downarrow	Ļ	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
cardiovascular drugs	diltiazem	1 ⁱⁱⁱ	1	1 ⁱⁱⁱ	↓69%	↓E	Ļ	E	Е	\leftrightarrow	↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
ardi	metoprolol	1, tiii	↑	1, ∎	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
ö	verapamil	1, tiii	↑	1 ⁱⁱⁱ	Ļ	↓E	Ļ	E	E	\leftrightarrow	↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
	warfarin	↑ or ↓	Ļ	Ļ	↑ or ↓	Ŷ	↑ or ↓	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑ or ↓	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
	diazepam	↑	1	↑	Ļ	↑	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
	midazolam (oral)	1	1	↑	\downarrow	Ļ	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	1	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
	triazolam	1	Î	1	\downarrow	Ļ	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	1	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
	citalopram	1, tiii	1	1 ^Ⅲ	\downarrow	Ļ	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
gs	mirtazapine	↑	1	↑ (\downarrow	Ļ	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
CNS drugs	paroxetine	↑↓ ?	↓39%	↑↓ ?	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑↓ ?	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
S	sertraline	Ļ	↓49%	Ļ	↓39%	Ļ	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
S	bupropion	Ļ	Ļ	↓57%	↓55%	\leftrightarrow	↓	\leftrightarrow	\leftrightarrow	\leftrightarrow	^?	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
	pimozide	1 ⁱⁱⁱ	↑	1 ⁱⁱⁱ	↑	Ļ	Ļ	↔ ^{iv}	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
	carbamazepine	↑D	1	↑D	↓27%D36%	D	↓D	D	D	D	D	D	1	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑ ^{ix}
	lamotrigine	↓39% ⁱⁱ	↓ ⁱⁱ	↓50%	\leftrightarrow												
	phenytoin	↓D	↓D	↓D	↓D	D	↓D	D	D	D	D	D	D	\leftrightarrow	\leftrightarrow	\leftrightarrow	Ļ
	clarithromycin	↑ ⁱⁱⁱ		↑ ⁱⁱⁱ	Ļ	↓E	Ļ	E	E	\leftrightarrow	↑E	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	D
ves	fluconazole	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	E86%	E100%	E	\leftrightarrow	\leftrightarrow	^?	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	E74%
ecti	itraconazole	↑E	↑E	↑E	Ļ	↓E	↓61%	E	E	\leftrightarrow	↑E	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
infe	rifabutin	↑	↑E50%	↑	↓38%	D37%	17%	D	*	\leftrightarrow	↑D	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
anti-infectives	rifampicin	D72%	D	D	D26%	D	D58%	D80%	D	D54%×	D	D40%	D	\leftrightarrow	\leftrightarrow	\leftrightarrow	D47%
a	voriconazole	Ļ	Ļ	Ļ	↓E	↑E	↓E	E	Е	\leftrightarrow	↑E	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
	antacids	D	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	D	\leftrightarrow	D	D	D	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
	PPIs	D	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	D	\leftrightarrow	\leftrightarrow	\leftrightarrow	Е	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
	H2 blockers	D	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	D	\leftrightarrow	\leftrightarrow	\leftrightarrow	Е	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
	alfuzosin	1	1	1	\downarrow	Ļ	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	1	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
	beclometasone inhal.	↑? ∨	↓11%	↑? ∨	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑? ∨	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
sn	buprenorphine	<u></u> ↑67%	1 ^{vi}	\leftrightarrow	↓50%	↓25%	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	135%	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
miscellaneous	budesonide inhal.	↑	1	↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
llar	ergot derivatives	1	↑	Ť	↑	↑	Ļ	E	\leftrightarrow	\leftrightarrow	1	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
sce	ethinylestradiol	↓ ^{vii}	Ļ	Ļ	↔ ^{Viii}	\leftrightarrow	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
mis	fluticasone inhal.	Î	↑	, ↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
	methadone	↓ ^{ii, iii}	↓16%	↓53% ⁱⁱⁱ	↓52%	↑6%	↓ ≈ 50%	↓16%	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	↓	\leftrightarrow	\leftrightarrow	\leftrightarrow	E29-43%
	salmeterol inhal.	1 ⁱⁱⁱ	1	1 ⁱⁱⁱ	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
	sildenafil (erec. dys.)	Î	Î	Î	Ļ	↓37%	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	Î	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
	St John's wort	D	D	D	D	D	D	D	D	D	D	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
	varenicline	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow

Comments:

This table summarises the drug-drug interactions between HIV therapy and some commonly prescribed co-medicines as well as the drug-drug interactions of particular clinical relevance. This table is not exhaustive, for additional drug-drug interactions and for more detailed pharmacokinetic interaction data and dosage adjustments, see www.hiv-druginteractions.org (University of Liverpool).

Colour legend

no clinically significant interaction expected.

these drugs should not be coadministered.

potential interaction which may require a dosage adjustment or close monitoring.

potential interaction predicted to be of weak intensity (< 2 fold ↑AUC or < 50% ↓AUC). A dosage adjustment is *a priori* not recommended unless the drug has a narrow therapeutic index.

Note: the symbol (green, amber, red) used to rank the clinical significance of the drug interaction is based on www.hiv-druginteractions.org.

Legend:

potential elevated exposure of non-ARV drug

↓ potential decreased exposure of non-ARV drug

- ↔ no significant effect
- E potential elevated exposure of ARV
- D potential decreased exposure of ARV
- Numbers refer to decreased/increased AUC of non-ARV/ARV drugs as observed in drug interactions studies
- ii no PK changes with unboosted PI
- iii ECG monitoring is recommended
- iv rilpivirine's manufacturer recommends caution when coadministering with another drug susceptible to prolong QT interval
- increase in concentration of active metabolite observed with RTV 100 mg bd alone but without significant effect on adrenal function
- vi concentration of parent drug unchanged but concentration of metabolite increased
- vii increase in ethinylestradiol with unboosted ATV
- viii no effect on ethinylestradiol but \downarrow progestin
- ix potential haematological toxicity
- no dose adjustment for MVC in absence of PI. With PI (except TPV/r; FPV/r), give MVC 150 mg bd



Drug-drug Interactions between Antidepressants and ARVs

antidepre	essants	ATV/r	DRV/r	LPV/r	SQV/r	EFV	ETV	NVP	RPV	MVC	DTG	EVG/c	RAL
SSRI	citalopram	↑ ^a	↑	↑ ^a	∱ a	Ļ	Ļ	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow
	escitalopram	∱ a	↑	∱ ^a	↑ a	Ļ	Ļ	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow
	fluvoxamine	↑	↑	↑	↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow
	fluoxetine	↑	↑	1	↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow
	paroxetine	↑↓ ?	↓39%	↑↓ ?	↑↓ ?	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑↓ ?	\leftrightarrow
	sertraline	Ļ	↓49%	Ļ	Ļ	↓39%	Ļ	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	1	\leftrightarrow
SNRI	duloxetine	¢↓	¢↓	¢↓	¢↓	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow
	venlafaxine	↑	↑	1	↑	Ļ	Ļ	Ļ	\leftrightarrow	D	\leftrightarrow	↑	\leftrightarrow
ТСА	amitriptyline	1	1	1	1 ^b	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	1	\leftrightarrow
	clomipramine	↑	↑ (1	1 ^b	Ļ	Ļ	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	1	\leftrightarrow
	desipramine	↑	↑ (↑5%	1	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	1	\leftrightarrow
	doxepin	↑	↑	↑	1¢	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑ (\leftrightarrow
	imipramine	↑ ^a	↑	↑ ^a	∱a	Ļ	Ļ	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow
	nortriptyline	∱ a	↑	∱ ^a	1 ^{ab}	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow
	trimipramine	↑	↑	1	↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow
TeCA	maprotiline	↑	↑	↑	↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow
	mianserine	↑ (↑ (1	1	Ļ	Ļ	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow
	mirtazapine	Ŷ	↑	Î	↑	Ļ	Ļ	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	1	\leftrightarrow
Others	bupropion	Ļ	Ļ	↓57%	Ļ	↓55%	\leftrightarrow	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	^?	\leftrightarrow
	lamotrigine	↓32%	Ļ	↓50%	Ļ	\leftrightarrow							
	nefazodone	↑	↑	1	1	Ļ	↓E	Ļ	E	E	\leftrightarrow	↑	\leftrightarrow
	St John's wort	D	D	D	D	D	D	D	D	D	Dc	D	\leftrightarrow
	trazodone		↑	↑	1 ^b	Ļ	Ļ	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow		\leftrightarrow

Legend

- ↑ potential elevated exposure of the antidepressant
- ↓ potential decreased exposure of the antidepressant
- $\leftrightarrow \qquad \text{no significant effect}$
- D potential decreased exposure of ARV drug
- E potential elevated exposure of ARV drug
- a ECG monitoring is recommended
- b coadministration contraindicated in the European SPC. However, US prescribing information recommends TDM for antidepressants. The charts reflect the more cautious option. Numbers refer to decreased AUC of the antidepressant as observed in drug-drug interactions studies.
- SSRI selective serotonin reuptake inhibitors
- SNRI serotonin and norepinephrine reuptake inhibitors
- TCA tricyclic antidepressants
- TeCA tetracyclic antidepressants

Colour legend

no clinically significant interaction expected.

- these drugs should not be coadministered.
- potential interaction, which may require a dosage adjustment or close monitoring.

potential interaction predicted to be of weak intensity (< 2 fold ↑AUC or < 50% ↓AUC). A dosage adjustment is *a priori* not recommended.

Comment



Drug-drug Interactions between Antihypertensives and ARVs

antih	ypertensives	ATV/r	DRV/r	FPV/r	IDV/r	LPV/r	SQV/r	EFV	ETV	NVP	RPV	MVC	DTG	EVG/c	RAL	ABC	FTC	3TC	TDF	ZDV
	cilazapril	\leftrightarrow																		
S	enalapril	\leftrightarrow																		
oito	lisinopril	\leftrightarrow																		
ACE inhibitors	perindopril	\leftrightarrow																		
ц.	quinapril	\leftrightarrow																		
AC	ramipril	\leftrightarrow																		
	trandolapril	\leftrightarrow																		
	candesartan	\leftrightarrow																		
sin	irbesartan	↓	Ļ	↓	Ļ	Ļ	\downarrow	↑	↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	↓	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
iens	losartan	Ja	↓a	Ja	↓a	↓a	↓ <mark>a</mark>	↑ ^b	1¢	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	Ja	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
angiotensin antagonists	olmesartan	\leftrightarrow																		
anç	telmisartan	\leftrightarrow																		
	valsartan	\leftrightarrow																		
	atenolol	↔d	\leftrightarrow	\leftrightarrow	\leftrightarrow	⇔d	⇔ ^d	\leftrightarrow												
β blockers	bisoprolol	↑d	1	1	↑	↑d	↑ <mark>d</mark>	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	1	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
Š	carvedilol	↑↓ ^d	↑↓	î↓	¢↓	1↓d	↑↓ ^d	¢↓	¢↓	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	1	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
ā	metoprolol	↑d	1	1	↑	↑d	↑ ^d	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
8	propranolol	↑ ^d	1	1	↑	↑ ^d	↑ ^d	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
s	amlodipine	↑ ^c	↑	1	180%	1	↑ ^C	Ļ	Ļ	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
calcium channel blockers	diltiazem	↑ ^c	↑	1	↑	1	↑ ^C	↓69%	↓E	Ļ	Е	Е	\leftrightarrow	↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
	felodipine	↑ ^c	↑	↑	↑	1	↑ ^C	↓	Ļ	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
elt	lacidipine	↑ ^c	1	1	1	1	↑ ^C	\downarrow	↓	↓	\leftrightarrow	\leftrightarrow	\leftrightarrow	1	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
une	lercanidipine	Î	1	1	1	Î	Î	\downarrow	↓	↓	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
ch	nicardipine	↑ ^c	1	1	1	1	↑ ^C	↓	↓E	↓	Е	Е	\leftrightarrow	1	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
Ę	nifedipine	↑ ^c	1	1	1	1	↑ ^C	\downarrow	↓	↓	\leftrightarrow	\leftrightarrow	\leftrightarrow	1	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
lci	nisoldipine	↑ ^c	1	1	1	1	↑ ^C	\downarrow	↓	↓	\leftrightarrow	\leftrightarrow	\leftrightarrow	1	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
S	verapamil	↑ ^C	1	1	↑	1	1 ↑	\downarrow	↓E	↓	Е	Е	\leftrightarrow	1	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
	amiloride	\leftrightarrow																		
s	bendroflumethiazide	?	?	?	?	?	?	?	?	?	\leftrightarrow	\leftrightarrow	\leftrightarrow	?	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
etic	chlortalidone	\leftrightarrow																		
diuretics	furosemide	\leftrightarrow	Е	\leftrightarrow																
σ	indapamide	Î	1	1	Î	1	↑	\downarrow	↓	↓	\leftrightarrow	\leftrightarrow	\leftrightarrow	1	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
	torasemide	↓	Ļ	Ļ	↓	↓	\downarrow	1	Î	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\downarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
ร	doxazosin	↑	↑	1	↑	1	↑	\downarrow	↓	↓	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
Others	spironolactone	\leftrightarrow																		

Legend

- ↑ potential elevated exposure of the antihypertensive
- potential decreased exposure of the antihypertensive
- \leftrightarrow no significant effect
- D potential decreased exposure of ARV drug
- E potential elevated exposure of ARV drug
- a [parent drug] decreased but [active metabolite] increased
- b [parent drug] increased but [active metabolite] decreased
- c ECG monitoring recommended
- d risk of PR interval prolongation

Numbers refer to decreased AUC of the antihypertensive as observed in drug-drug interactions studies.

Colour legend

no clinically significant interaction expected.

- these drugs should not be coadministered.
- potential interaction, which may require a dosage adjustment or close monitoring.
- potential interaction predicted to be of weak intensity (< 2 fold ↑AUC or < 50% ↓AUC). A dosage adjustment is a priori not recommended.</p>

Note: although some drug interactions are predicted to potentially require a dosage adjustment based on the drug's metabolic pathway, clinical experience with a particular antihypertensive and ARV drug may indicate that dosage adjustments are not an *a priori* requirement.

Comment



Drug-drug Interactions between Analgesics and ARVs

ana	algesics	ATV/r	DRV/r	FPV/r	IDV/r	LPV/r	SQV/r	EFV	ETV	NVP	RPV	MVC	DTG	EVG/c	RAL	ABC	FTC	3TC	TDF	ZDV
	aspirin	\leftrightarrow	j	\leftrightarrow																
ics	celecoxib	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑a	↑ ^a	\leftrightarrow	j	\leftrightarrow								
ges	diclofenac	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	∱ ^a	∱ ^a	\leftrightarrow	∱j	\leftrightarrow								
analgesics	ibuprofen	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	∱ ^a	∱ ^a	\leftrightarrow	∱j	⇔b								
	mefenamic acid	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑ ^a	∱ ^a	\leftrightarrow	∱j	\leftrightarrow								
-opioid	naproxen	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	∱ <mark>a</mark>	∱ <mark>a</mark>	\leftrightarrow	∱j	⇔p								
Ĩ	nimesulide	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑ <mark>a</mark>	∱ <mark>a</mark>	\leftrightarrow	j	\leftrightarrow								
uou	paracetamol	\leftrightarrow																		
	piroxicam	\leftrightarrow	\leftrightarrow	\leftrightarrow	С	\leftrightarrow	\leftrightarrow	∱ <mark>a</mark>	∱ <mark>a</mark>	\leftrightarrow	j	\leftrightarrow								
	alfentanil	↑	↑	↑	↑	↑	↑	\downarrow	↓	↓	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
	buprenorphine	<u></u> ↑67%	↑ ^d	\leftrightarrow	↑	\leftrightarrow	↑	↓50%	↓25%	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	135%	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
s	codeine	∱ ^g	∱g	∱g	<mark>↑</mark> 9	∱g	∱ <mark>9</mark>	∱ <mark>9</mark>	<mark>↑</mark> 9	<mark>↑</mark> 9	\leftrightarrow	\leftrightarrow	\leftrightarrow	∱ ^g	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
analgesics	dihydrocodeine	↓↑	↓↑	J↑	↓↑	J↑	↓↑	J↑	↓	↓	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
lge	fentanyl	↑	↑	1	↑	↑	1	\downarrow	↓	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑ (\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
ana	methadone	↓ <mark>e</mark>	↓16%	↓18%	↓	↓53% ^e	↓19%ef	↓52%	↑6%	↓ ≈ 50%	↓16% ^e	\leftrightarrow	\leftrightarrow	↑7%	\leftrightarrow	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	Е
id	morphine	↓	Ļ	↓	↓	Ļ	\downarrow	↑	\leftrightarrow											
opioid	oxycodone	↑	↑	1	↑	↑	1	\downarrow	↓	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑ (\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
0	pethidine	↓ ^h	↓ ^h	↓ ^h	↓ ^{c,h}	↓ ^h	↓ ^h	↓ ^h	\leftrightarrow	↓ ^h	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
	sufentanil	↑	↑	↑	↑	↑	↑	\downarrow	Ļ	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
	tramadol	∱ ^g	∱g	∱ <mark>9</mark>	∱ ^g	∱ ^g	∱ ^g	↓i	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	∱ ^g	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow

Legend

- ↑ potential elevated exposure of the analgesic
- potential decreased exposure of the analgesic
- ↔ no significant effect
- D potential decreased exposure of ARV drug
- E potential elevated exposure of ARV drug
- a clinical significance unknown. Use the lowest recommended dose particularly in persons with risk factors for cardiovascular disease, those persons at risk of developing gastrointestinal complications, persons with hepatic or renal impairment, and in elderly persons
- b potential additive haematological toxicity
- c manufacturer's recommendation
- d [parent drug] unchanged but [metabolite] increased
- e both drugs can potentially prolong the QT interval; ECG monitoring recommended
- f coadministration contraindicated in the European SPC. However, US prescribing information advises caution. The charts reflect the more cautious option
- g potential decrease of the analgesic effect due to the reduced conversion to the active metabolite
- h [parent drug] decreased and increase [neurotoxic metabolite]
- i [parent drug] decreased but no change [more active metabolite]
- potential risk of nephrotoxicity, which is increased if NSAID is used for a long duration, if the person has a pre-existing renal dysfunction, has a low body weight or receives other drugs that may increase TDF exposure. Concurrent use of NSAIDs with TDF warrants monitoring of renal function. Numbers refer to increased or decreased AUC of the analgesic as observed in drug-drug interactions studies.

Colour legend

no clinically significant interaction expected.

- these drugs should not be coadministered. potential interaction, which may require a dosage adjustment or
- - close monitoring. potential interaction predicted to be of weak intensity (< 2 fold \uparrow AUC or < 50% \downarrow AUC). A dosage adjustment is *a priori* not recommended.

Comment



Drug-drug Interactions between Antimalarial Drugs and ARVs

Effect of ARVs on antimalarial drugs and key metabolite

Arrows indicate effect of antiretrovirals on antimalarial drug/key metabolite	
Allows Indicate check of antifectovirals of antificial and sheet of inetabolite	
Green no clinically significant interaction expected	
Orange potential interaction (consider treatment ahead of travel and therapeutic drug monitoring)	
Red clinically relevant interaction, do not use or use with caution	

Mefloquine (M)		
Key Metabolite Indication	CYP 3A4 Prophylaxis Treatment	Significance
NNRTI (EFV, NVP, ETV)	\downarrow	No
RPV, RAL, MVC, DTG	\rightarrow	No
PI, COBI	↑ M may reduce PI/C (RTV ca 35%)	Potential

Artemisinins (A)	Artemisinins (A)								
Artemisinins and its key metabolite, dihydroartemisinin, are active compounds									
Key Metabolite Indication	CYP 2B6, 3A4, 2C19 Treatment	Significance							
NNRTI (EFV, NVP, ETV)	↓ A & dihydroartemisin; A & metabolites reduce NVP, but not EFV/ETR	do not use or use with caution							
RPV, RAL, MVC, DTG	\rightarrow A may reduce RPV, MVC	Potential							
PI, COBI.	↑ Increase A: monitor toxicity (liver)	Potential							

Lumefantrin (L)		
Key Metabolite Indication	CYP 3A4 Treatment	Significance
NNRTI (EFV, NVP, ETV)	\downarrow	Potential
RPV, RAL, MVC, DTG	\rightarrow	No
PI, COBI	↑ LPV increases L 2-3x	do not use or use with caution

Atovaquone (A), Proguanil	Atovaquone (A), P	roguanil
---------------------------	--------------	-------	----------

Atovaquone increases ZDV levels by 35%
Synergy with atovaquone is related to proguanil, not its active metabolite; therefore presumably no net effect of induction/inhibition

Key Metabolite Indication	CYP 2C19 Prophylaxis Treatment	Significance
NNRTI (EFV, NVP, ETV)	↓ ETV is increased	Potential
RPV, RAL, MVC, DTG	\rightarrow	No
PI, COBI	↓ At & P take with fat meal, consider dose increase	Potential

Doxycycline		
Key Metabolite Indication	N/A Prophylaxis	Significance
NNRTI (EFV, NVP, ETV)	possibly ↓	Potential
RPV, RAL, MVC, DTG	\rightarrow	No
PI, COBI	\rightarrow	No

Chloroquine		
Key Metabolite Indication	CYP 3A4, 2D6 Treatment	Significance
NNRTI (EFV, NVP, ETV)	\rightarrow	No
RPV, RAL, MVC, DTG	\rightarrow	No
PI, COBI	\rightarrow	No

Quinine (Q)		
Key Metabolite Indication	CYP 3A4, 2D6 Treatment	Significance
NNRTI (EFV, NVP, ETV)	↓ Consider dose increase	Potential
RPV, RAL, MVC, DTG	\rightarrow	No
РІ, СОВІ	↑ RTV increases Q 4x: consider dose reduction, monitor toxicity (tinnitus). CAVE: PI & Q prolong QT	Potential

Primaquine		
Key Metabolite Indication	CYP 1A2, 2D6, 3A4 (Prophylaxis) Treatment	Significance
NNRTI (EFV, NVP, ETV)	N/A	Potential
RPV, RAL, MVC, DTG	\rightarrow	No
PI, COBI	N/A	



Dose Adjustment of ARVs for Impaired Hepatic Function

NRTIS	
ABC	Child-Pugh Score 5-6: 200 mg bd (use oral solution)
	Child-Pugh Score > 6: Contraindicated
ddl	Contraindicated
	If used no dosage adjustment
d4T	Contraindicated
	If used no dosage adjustment
FTC	No dosage adjustment
3TC	No dosage adjustment
TDF	No dosage adjustment
TDF/FTC	No dosage adjustment
ZDV	Reduce dose by 50% or double the interval between doses if Child-Pugh > 9
NNRTIS	
DLV	No dosage recommendation; use with caution in persons with hepatic impairment
EFV	No dosage adjustment; use with caution in persons
TDF/FTC/EFV	with hepatic impairment
ETV	Child-Pugh score < 10: no dosage adjustment
NVP	Child-Pugh score > 6: contraindicated

Pls	
ATV	Child-Pugh Score 7–9: 300 mg once daily
	Child-Pugh Score > 9: not recommended
	RTV boosting is not recommended in persons with hepatic impairment (Child-Pugh Score > 7)
DRV	Mild to moderate hepatic impairment: no dosage adjustment
	Severe hepatic impairment: not recommended
FPV	PI-naive persons only:
	Child-Pugh Score 5–9: 700 mg bd
	Child-Pugh Score 10–15: 350 mg bd
	PI-experienced persons:
	Child-Pugh Score 5-6: 700 mg bd + RTV 100 mg qd
	Child-Pugh Score 7–9: 450 mg bd + RTV 100 mg qd
	Child-Pugh Score 10–15: 300 mg bd + RTV 100 mg qd
IDV	Mild to moderate hepatic insufficiency: 600 mg q8h
LPV/r	No dosage recommendation; use with caution in persons with hepatic impairment
NFV	Mild hepatic impairment: no dosage adjustment
	Moderate to severe hepatic impairment: not recommended
RTV	Refer to recommendations for the primary PI
SQV	Mild to moderate hepatic impairment: use with caution
	Severe hepatic impairment: contraindicated
TPV	Child-Pugh score < 7: use with caution
	Child-Pugh score > 6: contraindicated
FI	
ENF	No dosage adjustment
CCR5 Inhibitor	1
MVC	No dosage recommendations. Concentrations will likely be increased in persons with hepatic impairment
INSTI	
RAL	No dosage adjustment

Note: Hepatic dysfunction is a good indication for TDM as clinical experience with these dose adjustments is very limited

Dose Adjustment of ARVs for Impaired Renal function

	eGFR ⁽ⁱ⁾ (mL/min)					Haemodialysis	
		≥ 50	30-49	10-29	< 10	Thernoularysis	
NRTIS							
ABC	300 mg q12h	No dose adjustment required	No dose adjustment required	No dose adjustment required			
ddl ⁽ⁱⁱ⁾	≥ 60 kg	400 mg q24h	200 mg q24h	150 mg q24h	> 60 kg: 1	00 mg/24h	
	< 60 kg	250 mg q24h	125 mg q24h	100 mg q24h	< 60 kg: 7	′5 mg/24h	
d4T	> 60 kg	30 mg q12h	15 mg q12h	15 mg q24h	15 mg q24h	15 mg q24h AD(iv)	
	< 60 kg	40 mg q12h	20 mg q12h	20 mg q24h	20 mg q24h	20 mg q24h AD(iv)	
FTC		200 mg q24h	200 mg q48h	200 mg q72h	200 mg q96h	200 mg q96h	
3TC		300 mg q24h	150 mg q24h	100 mg q24h ⁽ⁱⁱⁱ⁾	50-25 mg q24h ⁽ⁱⁱⁱ⁾	50-25 mg q24h ⁽ⁱⁱⁱ⁾ AD ^(iv)	
TDF ^(vii)		300 mg q24h	300 mg q48h	Not recommended	Not recommended	300 mg q7d AD ^(iv)	
				(300 mg q72-96h, if no alternative)	(300 mg q7d, if no alternative)		
ZDV		300 mg q12h	No dose adjustment required	· · · · ·	100 mg q8h	100 mg q8h	
ABC/3TC							
ZDV/3TC		Use individual drugs					
ABC/3TC/ZDV							
TDF/FTC		q24h	q24h q48h Use individual drugs				
NNRTIS							
EFV		600 mg q24h	No dose adjustment required				
ETV		200 mg q12h		No dose a	djustment required		
NVP		200 mg q12h	No dose adjustment required				

	eGF	R ⁽ⁱ⁾ (mL/min)			Lie en ediciveia
	≥ 50	30-49	10-29	< 10	Haemodialysis
Pls					
ATV/r	300/100 mg q24h	No dose adj	ustment required	(v,vi)	
DRV/r	800/100 mg q24h 600/100 mg q12h	No dose adj	ustment required	(v)	
FPV/r	700/100 mg q12h	No dose adj	ustment required	(V)	
LPV/r	400/100 mg q12h	No dose adj	No dose adjustment required ^(v)		
SQV/r	1000/100 mg q12h	No dose adj	No dose adjustment required ^(v)		
TPV/r	500/200 mg q12h No dose adjustment requ			(v)	
Other ART					
RAL	400 mg q12h	No dose adj	ustment required	(v) (dose AD(iv))	
TDF/FTC/EVG/COBI	Do not initiate if eGFR < 70 mL/min	Discontinue	if eGFR < 50 mL	./min	
MVC: co-administered without CYP3A4 inhibitors ^(viii)	300 mg q12h	No dose adj	ustment required	1	
MVC: co-adminis- tered with CYP3A4 inhibitors ^(viii)	if eGFR < 80 mL/min 150 mg q24h ^(viii) except: 150 mg q12h if co-administered with FPV/r				

- i eGFR according to the abbreviated MDRD (Modification of Diet in Renal Disease) formula. The Cockcroft-Gault (CG) equation may be used as an alternative.
- ii Dose reduction if combined with TDF
- iii 150 mg loading dose
- iv AD: after dialysis
- Limited data available in persons with renal impairment; pharmacokinetic analysis suggests no dose adjustment required
- vi Associated with nephrotoxicity; consider alternative PI if pre-existing CKD
- vii Associated with nephrotoxicity; consider alternative ART if pre-existing CKD
- viii See summary of product characteristics for specific recommendations; use with caution if eGFR < 30 mL/min

Administration of ARVs in Persons with Swallowing Difficulties

Drug	Formulation	Crush tablets	Open capsules	Comment
NRTI				
ABC	tablet (300 mg) solution 20 mg/mL	yes		bitter taste
ddl	capsule (125, 200, 250, 400 mg)	no	no	use powder: contains Ca and Mg antacids, dissolve in \ge 30 mL of water (add apple juice), take on empty stomach
d4T	capsule (20, 30, 40 mg) oral solution 1 mg/mL	no	yes	take on empty stomach
FTC	capsule (200 mg) solution 10 mg/mL	no	yes	dissolve in \ge 30 mL of water, contains Na 460 µmol/mL Bioequivalence: 240 mg solution = 200 mg capsule adjust dosage accordingly
3TC	tablet (150, 300 mg) solution 10 mg/mL	yes		
TDF	tablet (245 mg)	yes		better: dissolve in \geq 1 dL of water/orange or grape juice (bitter taste)
ZDV	capsule (250 mg)	no	no	sticky, bitter taste
	syrup 10 mg/mL			better: use syrup or iv 6 mg/kg per day in glucose 5%
TDF/FTC	tablet (200/245 mg)	yes		better: dissolve in ≥ 1 dL of water/orange or grape juice (bitter taste)
ABC/3TC	tablet (300/600 mg)	no		use solution of individual compounds
ZDV/3TC	tablet (150/300 mg)	yes		disperse in ≥ 15 mL water, alternative: use solution of individual compounds
ABC/3TC/ZDV	tablet (150/300/300 mg)	no		use solution of individual compounds
NNRTI				
EFV	tablet (600 mg)	yes		difficult to dissolve; solution has lower bioavailability; if > 40 kg use 720 mg
	capsule (50, 100, 200 mg)	no	yes	
	solution 30 mg/mL			
ETV	tablet (200 mg)	no		disperse in ≥ 5 mL water
NVP	tablet (200, 400 mg ⁽ⁱ⁾) suspension 10 mg/mL	yes <mark>(i)</mark>		dissolve in water
TDF/FTC/EFV	tablet (200/245/600 mg)	no		
TDF/FTC/RPV	tablet (200/245/25 mg)	no		
PI				
ATV	capsule (150, 200, 300 mg)	no	yes	difficult to open; take with food
DRV	tablet (400, 600 mg) solution 100 mg/mL	yes		take with food
FPV	tablet (700 mg) suspension 50 mg/mL			bitter taste; adults take suspension on empty stomach
IDV	capsule (200, 400 mg)	no	no	
LPV/r	tablet (200/50 mg) solution 80, 20 mg/mL	no		42% alcohol, do not dilute with water (risk of precipitation), rinse with milk (no water); take with food, bitter taste: dilute with chocolate milk
NFV	tablet (250 mg)	yes		difficult to dissolve; better: use powder
RTV	tablet (100 mg) solution 80 mg/mL	no		43% alcohol, do not dilute solution (risk of precipitation), rinse with milk (no water); bitter taste; take with food
SQV	tablet (500 mg)	no		
	capsule (200 mg)	no	yes	
TPV	capsule (250 mg) solution 100 mg/mL	no	no	higher bioavailability of oral solution: no dosing recommendation for adults
Others				
MVC	tablet (150, 300 mg)	yes		
RAL	tablet (400 mg)	yes		bitter taste
TDF/FTC EVG/COBI	tablet (200/245/150/150 mg)	no		



Drug	Formulation	Crush tablets	Open capsules	Comment
Prophylaxis/treatme	nt of opportunistic infections			
Azithromycin	tablet (250 mg) suspension 40 mg/mL	no		
Cotrimoxazole	tablet (400/80 mg, forte 800/160 mg) solution 40/8 mg per mL	yes; forte difficult		dilute solution 3-5 times with water (high osmolality)
Fluconazole	capsule (50-200 mg) suspension 40 mg/mL	no	yes	
Pyrimethamine	tablet (25 mg)	yes		take with food
Valganciclovir	tablet (450 mg)	no	no	difficult to dissolve
Rifampicin	tablet (450, 600 mg)	yes		take on empty stomach
	capsule (150, 300 mg)	no	yes	
	suspension 20 mg/mL			
Rifabutin	capsule (150 mg)	no	yes	dissolve in water
Isoniazid	tablet (100, 150, 300 mg)	yes		take on empty stomach
Pyrazinamide	tablet (500 mg)	yes		
Ethambutol	tablet (100, 400 mg)	yes		difficult to dissolve better: use iv solution
Rifampicin/Isoniazid	tablet (150/100, 150/75 mg)	yes		take on empty stomach
Rifater (Rifampicin, Isoniazid, Pyrazinamide)	tablet (120/50/300 mg)	yes		take on empty stomach
Rimstar (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol)	tablet (150/75/400/275 mg)	yes		take on empty stomach
Ribavirin	capsule (200 mg)	no	yes	disperse in orange juice, take with food

i Extended release effect lost. Note: NVP 400 mg once daily (immediate release) can lead to sub-therapeutic trough levels in individuals with higher body weight (≥ 90 kg) compared to NVP 200 mg twice daily. Therefore, twice-daily NVP administration should be preferred in individuals with higher body weight



Part III Prevention and Management of Co-morbidities in HIV-positive Persons

Co-morbidities include cardiovascular, renal, hepatic, metabolic, neoplastic and bone pathologies, central nervous system disorders and sexual dysfunction. Although HIV and other infections may be involved in their pathogenesis, this section of the EACS guidance focuses on preventive and/or management principles other than use of antivirals and other anti-infectious agents in adult and adolescent HIV-positive persons. These co-morbidities are becoming increasingly important for HIV-positive persons as a consequence of increased life expectancy resulting from effective ART. Several demonstrated and proposed HIV-associated risk factors may contribute to their development, which include residual immunodeficiency, immune activation, inflammation and coagulation, co-infections (e.g. HCV, CMV) that may persist in spite of controlled HIV replication, as well as adverse effects of ART.

Health care professionals involved with the care of HIV-positive persons who are not familiar with the use of ART should consult HIV specialists before introducing or modifying any type of medicines for co-morbidity in an HIV-positive person.

Conversely, many HIV physicians are not specialists in co-morbidities, and should seek expert advice where appropriate in the prevention and management of such conditions. Situations where consultation is generally recommended are indicated in this document.

Preventing or managing these co-morbidities in HIV often involves polypharmacy, which increases the risk of suboptimal adherence and hence may compromise the continued benefit of ART. Additionally, the possibility of drug-drug interactions with ARVs should always be carefully considered prior to introducing any other medicine, see page 17, where the drug interactions are and online documents referred to in the text

www.hiv-druginteractions.org and online documents referred to in the text.

These recommendations are intended to provide the best guide to clinical management, and it is recognised that the level of evidence to support the recommendations may vary substantially. Indeed, there is limited evidence from randomised controlled trials on best management of co-morbidities in HIV. As a result, current management is mainly derived from general medical guidelines. These recommendations therefore represent the collective consensus opinion of a panel of experts in the field of HIV and the respective range of co-morbidities, and no attempt to rate the underlying evidence and strength of the panel's recommendations was undertaken.

Depending on future clinical research findings, these recommendations will be regularly updated as required. The online version at www.eacsociety.org and the EACS Guidelines App contain more detailed information and links to other relevant websites; these will be regularly updated. The current recommendations highlight co-morbidities that are seen frequently in the routine care of HIV-positive persons and those for which specific issues should be considered.

Characteristics of drugs used as opioid substitution therapy $(\mathsf{OST})^{(i)}$

Feature	Methadone	Buprenorphine
Dose required to prevent withdrawal symptoms according to degree of opioid dependency	Linear relationship (from 10-300 mg per day)	Linear relationship for persons with less opioid dependency only – ceiling effect (max daily dose 24 mg)
Interaction with ARVs	Methadone plasma concentrations are reduced if used together with NNRTIs or PIs: Buprenorphine (B) and active metabolite norbuprenorphine (N) plasma concentrations are reduced if combined with NNRTIs and increased if combined with NNRTIs and increased if combined with some PIs • LPV/r: ↓ 50% • LPV/r: ↓ 50% • LPV/r: ↓ 50% • ETV: ↓ vp to 50% (B) and 70% (N) • ATV, IDV: ↓ < 10%	
	CAVE: withdrawal symptoms if combined with ARV drug toxicity if such ARVs are interrupted – reverse	
Risk of overdose	Yes	No if used as a co-formulation with naloxone
Causing QT prolongation on ECG	Yes (dose-response relationship) ⁽ⁱⁱ⁾	No
Risk of obstipation	High	High
Type of administration	Tablet or liquid	Tablet applied sublingual
Risk of further impairment in persons with existing liver impairment	Yes	Yes

ii

See Drug-drug Interactions between Analgesics and ARVs ECG recommended for daily methadone doses exceeding 50 mg; special caution with concomitant use of other drugs known to cause QT prolongation (e.g. certain PIs such as SQV/r as well as albuterol (USAN) or salbutamol (INN), amiodarone, amitriptyline, astemizole, chloroquine, clomipramine and moxifloxacin).



Cancer: Screening Methods⁽ⁱ⁾

Problem	Persons	Procedure	Evidence of benefit	Screening interval	Additional comments
Anal cancer	MSM	Digital rectal exam ± PAP test	Unknown; advocated by some experts	1-3 years	If PAP test abnormal, anoscopy
Breast cancer	Women 50-70 years	Mammography	↓ Breast cancer mortal- ity	1-3 years	
Cervical cancer	Sexually active women	PAP test	↓ Cervical cancer mortality	1-3 years	Target age group should include the 30 to 59- year age range at least. Longer screening interval if prior screen- ing tests repeatedly negative
Colorectal cancer	Persons 50-75 years	Faecal occult blood test	↓ Colorectal cancer mortality	1-3 years	Benefit is marginal
Hepatocellular carcinoma	Persons with cirrhosis & Persons with HBV irrespective of fibrosis stage	Ultrasound and alpha- foetoprotein	Earlier diagnosis allow- ing for improved ability for surgical eradication	Every 6 months	
Prostate cancer	Men > 50 years	Digital rectal exam ± prostate specific antigen (PSA)	Use of PSA is contro- versial	1-3 years	Pros: ↑ early diagnosis Cons: Overtreatment, no ↓ cancer-related mortality

i Screening recommendations derived from the general population.

These screenings should preferably be done as part of national general population-screening programmes. Although non-Hodgkin's lymphoma has a higher incidence in HIV-positive persons than in the general population, it is currently unknown whether it can be screened.

Careful examination of skin should be performed regularly to detect cancers such as Kaposi's sarcoma, basal cell carcinoma and malignant melanoma.



Lifestyle Interventions⁽ⁱ⁾

Smoking cessation	 Brief unambiguous statement about need to stop smoking If person is not contemplating, try to motivate and emphasise positive short-term aspects (more money for better things, better taste for food, better skin, less dyspnoea), and long-term benefits (prevention of COPD, IHD, stroke, lung cancer) If person is contemplating, try to fix stop date, establish reward system Use nicotine substitution (patch, chewing gum, spray), varenicline or bupropion during weaning phase if neces- sary. Note: both varenicline and bupropion may cause central nervous system side effects including suicide; bu- propion may interact with PIs and NNRTIs, see page 17. Consider referring person to specialised stop smoking clinics Anticipate relapses, explain and consider them as part of the weaning process to final nicotine abstinence
Dietary counselling	 Dietary intervention should not interfere with the dietary requirements necessary for appropriate absorption of ART drugs Keep caloric intake balanced with energy expenditure Limit intake of saturated fat, cholesterol and refined carbohydrates Reduce total fat intake to < 30% and dietary cholesterol to < 300 mg/day Emphasise intake of vegetables, fruit and grain products with fibre Cut back on beverages and foods with added sugar. Choose and prepare foods with little or no salt. Aim to eat less than 1,500 mg of sodium per day. Emphasise consumption of fish, poultry (without skin) and lean meat Consider referral to dietician, one-week food and drink diary to discover 'hidden' calories Avoid binge eating ('yo-yo dieting') In persons with HIV-related wasting and dyslipidaemia, address wasting first and consider referral to dietician Persons who are obviously overweight should be motivated to lose weight. Starvation diets are not recommended (immune defence mechanisms potentially decreased). Malnutrition has to be addressed where observed. Normal BMI range: 18.5-24.9; Overweight: 25.0-29.9, Overwe

Obesity: > 30.0 kg/m²


	 The following questions are helpful to determine average alcohol intake How often do you drink alcohol: never, ≤ 1/month, 2-4x/month, 2-3x/week, > 4x/week If you drink alcohol, how much typically at a time: 1-2, 3-4, 5-6, 7-9, > 10 drinks How many times do you have 6 or more alcoholic drinks at one occasion: never, < 1/month, 1x/month, 1x/week, more or less daily. Intake of alcohol should be restricted to no more than one drink per day for women and two drinks per day for men (< 20-40 g/d). In particular, persons with hepatic disease, adherence problems, inadequate CD4 cell increase, tumours, past tuberculosis, diarrhoea and other conditions associated with high alcohol intake should be motivated to decrease or stop alcohol intake.
Exercise promotion	 Promote active lifestyle to prevent and treat obesity, hypertension and diabetes Encourage self-directed moderate level physical activity (take the stairs, cycle or walk to work, cycling, swimming, hiking etc.) •Emphasise regular moderate-intensity exercise rather than vigorous exercise Achieve cardiovascular fitness (e.g. 30 minutes brisk walking > 5 days a week) Maintain muscular strength and joint flexibility

i Based on recommendations by the US Preventive Services Task Force



Prevention of CVD

Principles: The intensity of efforts to prevent CVD depends on the underlying risk of CVD, which can be estimated⁽ⁱ⁾. The preventive efforts are diverse in nature and require involvement of a relevant specialist, in particular if the risk of CVD is high and always in persons with a history of CVD.



- i Use the Framingham equation or whatever system local National Guidance recommends; a risk equation developed from HIV populations is available: see www.cphiv.dk/tools.aspx. This assessment and the associated considerations outlined in this figure should be repeated annually in all persons under care, see page 4-5, to ensure that the various interventions are initiated in a timely way.
- ii Options for ART modification include:
 - (1) Replace PI/r with NNRTI, RAL or another PI/r known to cause less metabolic disturbances, see page 15-17
 - (2) Replace d4T and consider replacing ZDV or ABC with TDF or use an NRTI-sparing regimen.
- iii Of the modifiable risk factors outlined, drug treatment is reserved for certain subgroups where benefits are considered to outweigh potential harm. Of note, there is a combined benefit of various interventions in target groups identified. Per 10 mmHg reduction in systolic blood pressure, per 1 mmol/L (39 mg/dL) reduction in TC and with use of acetylsalicylic

acid, each reduces risk of IHD by 20-25%; the effect is additive. Observational studies suggest that smoking cessation results in about 50% less risk of IHD – and this is additive to other interventions.

- iv See discussion on drug treatment of persons with lower CVD risk at www.nhlbi.nih.gov/guidelines/cholesterol/atp3_rpt.htm
- V Target levels are to be used as guidance and are not definitive expressed as mmol/L with mg/dL in parenthesis. In case LDL cannot be calculated because of high triglyceride levels, the non-HDL-c (TC minus HDL-c) target should be used which is 0.8 mmol/L (30 mg/dL) higher than the corresponding LDL-c target. Target levels for TG are not listed because an independent contribution from TG to CVD risk is uncertain, and hence whether this condition should be treated, see page 37.
- vi Evidence for benefit when used in persons without a history of CVD (including diabetics) is less compelling. BP should be reasonably controlled before aspirin use in such a setting.



Hypertension: Diagnosis, Grading and Management

Other risk factors, asymp- tomatic organ damage or	Blood pressure (mmHg)	Blood Pressure (mmHg)	Blood pressure (mmHg)	Blood Pressure (mmHg)			
disease	High normal SBP 130-139 or DBP 85-89	Grade 1 hypertension SBP 140-159 or DBP 90-99	Grade 2 hypertension SBP 160-179 or DBP 100-109	Grade 3 hypertension SBP ≥ 180 or DBP ≥ 110			
No other risk factors	No BP intervention	 Lifestyle changesⁱ for several months Then add BP drugs targeting < 140/90 	 Lifestyle changesⁱ for several weeks Then add BP drugs targeting < 140/90 	 Lifestyle changes¹ Immediate BP drugs targeting < 140/90 			
1-2 risk factors	 Lifestyle changesⁱ No BP Intervention 	 Lifestyle changesⁱ for several weeks Then add BP drugs targeting < 140/90 	 Lifestyle changesⁱ for several weeks Then add BP drugs targeting < 140/90 	 Lifestyle changesⁱ Immediate BP drugs targeting < 140/90 			
≥ 3 risk factors	 Lifestyle changesⁱ No BP intervention 	 Lifestyle changesⁱ for several weeks Then add BP drugs targeting 140/90 	 Lifestyle changesⁱ BP drugs targeting 140/90 	 Lifestyle changesⁱ Immediate BP drugs targeting < 140/90 			
Organ damage, CKD stage 3 or diabetes	 Lifestyle changesⁱ No BP intervention 	 Lifestyle changesⁱ BP drugs targeting 140/90 	 Lifestyle changesⁱ BP drugs targeting 140/90 	 Lifestyle changesⁱ Immediate BP drugs targeting < 140/90 			
Symptomatic CVD, CKD stage ≥ 4 or diabetes with organ damage/risk factors	 Lifestyle changesⁱ No BP intervention 	 Lifestyle changes BP drugs targeting 140/90 	 Lifestyle changes BP drugs targeting 140/90 	 Lifestyle changes Immediate BP drugs targeting < 140/90 			

BP blood pressure **DBP** diastolic blood pressure:

SBP systolic pressure

Repeated blood pressure measurements should be used for stratification


i Recommended lifestyle interventions, see page 29

Table adapted from [1].



Hypertension: Drug Sequencing Management

Choosing drugs⁽ⁱ⁾ for persons newly diagnosed with hypertension



Abbreviations + details

- A ACE inhibitor (e.g. Perindopril, Lisinopril or Ramipril) or low cost angiotensin receptor blockers (ARB) (e.g. Losartan, Candesartan)
- C Dihydropyridine calcium-channel blocker (e.g. Amlodipine). If not tolerated or if deemed at high risk of heart failure, 'D' drugs can be used instead. Where a C drug is preferred but not tolerated, Verapamil or Diltiazem may be used (note: dose with caution with PIs as these may increase plasma concentrations of these calcium-channel blockers, potentially leading to toxic reactions)
- D Thiazide-type diuretic* e.g. Indapamide or Chlorthalidone
- i Some calcium-channel blockers interact marginally with the pharmacokinetics of ARVs, see Drug-drug Interactions between Antihypertensives and ARVs
- ii Black persons are those of African or Caribbean descent, and not mixed race, Asian or Chinese persons
- Wait 2-6 weeks to assess whether target, see page 31, is achieved; if not, go to next step
- iv Requirement of 4-5 drugs to manage hypertension needs specialist training
- * This excludes thiazides (e.g. HCTZ, Bendroflumethiazide etc.)



Drug-drug Interactions between Antihypertensives and ARVs

antih	ypertensives	ATV/r	DRV/r	FPV/r	IDV/r	LPV/r	SQV/r	EFV	ETV	NVP	RPV	MVC	DTG	EVG/c	RAL	ABC	FTC	3TC	TDF	ZDV
ACE inhibitors	cilazapril	\leftrightarrow																		
	enalapril	\leftrightarrow																		
	lisinopril	\leftrightarrow																		
	perindopril	\leftrightarrow																		
	quinapril	\leftrightarrow																		
AC	ramipril	\leftrightarrow																		
	trandolapril	\leftrightarrow																		
	candesartan	\leftrightarrow																		
sin	irbesartan	Ļ	Ļ	↓	Ļ	Ļ	↓	↑	1	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
ens	losartan	Ja	Ja	Ja	Ja	↓a	Ja	∱ <mark>b</mark>	∱ ^b	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	↓a	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
angiotensin antagonists	olmesartan	\leftrightarrow																		
anç	telmisartan	\leftrightarrow																		
	valsartan	\leftrightarrow																		
	atenolol	↔d	\leftrightarrow	\leftrightarrow	\leftrightarrow	⇔ <mark>d</mark>	↔ ^d	\leftrightarrow												
ers	bisoprolol	↑ ^d	↑	1	↑	1 ^d	↑ ^d	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	1	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
β blockers	carvedilol	↑↓ ^d	¢↓	↑↓	↑↓	↑↓ <mark>d</mark>	1↓ <mark>d</mark>	¢↓	¢↓	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
ā	metoprolol	↑d	↑	1	↑	↑d	↑ ^d	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
8	propanolol	↑ ^d	Î	1	Î	↑ ^d	↑ ^d	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
٤	amlodipine	↑ ^C	↑	1	180%	↑	↑ ^c	↓	Ļ	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
calcium channel blockers	diltiazem	↑ ^C	↑	1	↑	1	↑ ^c	↓69%	↓E	Ļ	E	Е	\leftrightarrow	1	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
ğ	felodipine	↑ ^C	↑	↑	↑	↑	↑ ^C	↓	Ļ	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
elt	lacidipine	↑ ^c	1	1	1	1	↑ ^c	↓	Ļ	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	1	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
nne	lercanidipine	↑	↑	↑	Î	↑	Î	↓	Ļ	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	1	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
ch	nicardipine	↑ ^C	↑	1	↑	↑	↑ ^C	↓	↓E	Ļ	E	Е	\leftrightarrow	↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
Ę	nifedipine	↑ ^C	1	1	1	1	↑ ^c	↓	Ļ	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	1	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
lci	nisoldipine	1¢	1	1	1	↑	↑ ^c	\downarrow	↓	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	1	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
ca	verapamil	↑ ^C	↑	1	↑	1	↑ ^C	↓	↓E	Ļ	E	Е	\leftrightarrow	1	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
	amiloride	\leftrightarrow																		
s	bendroflumethiazide	?	?	?	?	?	?	?	?	?	\leftrightarrow	\leftrightarrow	\leftrightarrow	?	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
etic	chlortalidone	\leftrightarrow																		
diuretics	furosemide	\leftrightarrow	Е	\leftrightarrow																
σ	indapamide	↑	↑	1	1	↑	1	\downarrow	↓	↓	\leftrightarrow	\leftrightarrow	\leftrightarrow	1	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
	torasemide	Ļ	Ļ	↓	Ļ	Ļ	↓	↑	↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
S	doxazosin	↑	↑	↑	↑	↑	↑	↓	Ļ	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
Others	spironolactone	\leftrightarrow																		

Legend

- ↑ potential elevated exposure of the antihypertensive
- potential decreased exposure of the antihypertensive
- \leftrightarrow no significant effect
- D potential decreased exposure of ARV drug
- E potential elevated exposure of ARV drug
- a [parent drug] decreased but [active metabolite] increased
- b [parent drug] increased but [active metabolite] decreased
- c ECG monitoring recommended
- d risk of PR interval prolongation

Numbers refer to decreased AUC of the antihypertensive as observed in drug-drug interactions studies.

Colour legend

no clinically significant interaction expected.

- these drugs should not be coadministered.
- potential interaction which may require a dosage adjustment or close monitoring.
- potential interaction predicted to be of weak intensity (< 2 fold ↑AUC or < 50% ↓AUC). A dosage adjustment is a priori not recommended.</p>

Note: although some drug interactions are predicted to potentially require a dosage adjustment based on the drug's metabolic pathway, clinical experience with a particular antihypertensive and ARV drug may indicate that dosage adjustments are not an *a priori* requirement.

Comment



Type 2 Diabetes: Diagnosis

Diagnostic Criteria⁽ⁱ⁾


	Fasting plasma glucose mmol/L (mg/dL) ⁽ⁱⁱ⁾	Oral glucose tolerance test (OGTT) 2-h value mmol/L (mg/dL) ⁽ⁱⁱⁱ⁾	HbA1c ^(iv) (mmol/mol)
Diabetes	≥ 7.0 (126) OR→	≥ 11.1 (200)	≥ 6.5% (≥ 48)
Impaired glucose tolerance (IGT)	< 7.0 (126) AND→	7.8 – 11.0 (140-199)	Prediabetes
Impaired fasting glucose (IFG)	5.7– 6.9 AND (100-125)	< 7.8 (140)	5.7-6.4% (39-47)

As defined by WHO and [2]

 An abnormal finding should be repeated before confirming the diagnosis
 Recommended in persons with fasting blood glucose of 5.7 - 6.9 mmol/L (100-125 mg/dL) as it may identify persons with overt diabetes

iv Do not use HbA1c in presence of haemoglobinopathies, increased erythrocyte turnover and severe liver or kidney dysfunction. Falsely high values are measured under supplementation with iron, vitamin C and E as well as older age (age > 70: HbA1c +0.4 %). HbA1c values in treated HIV-positive persons, particularly when on ABC, tend to underestimate type 2 diabetes. Both IGT and IFG increase CVD morbidity and mortality, and increase the risk of developing diabetes by 4-6 fold. These persons should be targeted for lifestyle intervention, and their CVD risk factors must be evaluated and treated.

Type 2 Diabetes⁽¹⁾: Management



Treatment goals:

Prevention of hyper-/hypoglycaemia, glucose control (HbA1c < 6.5-7% without hypoglycaemia, fasting plasma glucose 4-6 mmol/L (73-110 mg/dL), prevention of long-term complications

- Normal blood lipids, see page 31, and blood pressure < 130/80 mmHg, see page 32.
- Acetylsalicylic acid (75-150 mg/d) considered in diabetics with elevated underlying CVD risk, see page 31.
- Nephropathy, polyneuropathy and retinopathy screening should be performed as in diabetic persons without HIV
- · Consultation with a specialist in diabetology is recommended
- Type 1 diabetes should be treated according to national guidelines.
 Very limited data for any oral antidiabetic agents in terms of CVD prevention, and no data in HIV-positive persons. Incretins (DDP4 inhibitors [e.g. Saxagliptin, Sitagliptin] and GLP-1 agonists [e.g. Liraglutide & Exenatide] are currently being evaluated in several major morbidity/mortality studies (neutral results to date); no clinically significant drug-drug interaction or adverse effects on CD4 cell counts expected; clinical use of Pioglitazone questioned by its side effects; HbA1c targets up to 7.5% can be considered for older persons with long-standing type 2 diabetes and evidence of CVD.



Dyslipidaemia

Principles: Higher LDL-c levels increase risk of CVD and reduction thereof reduces this risk (see table below for drugs used on this indication); the reverse is probably true for HDL-c but trial data are less compelling. The CVD risk implications from higher than normal TG levels are even less clear, as TG has not consistently been shown to independently predict the risk of CVD. Furthermore, the clinical benefit of treating moderate hypertriglyceridaemia is uncertain; very high TG (> 10 mmol/L or > 900 mg/dL) increase risk of pancreatitis.

Diet (more fish), exercise, maintaining normal body weight, reducing alcohol intake and stopping smoking tends to improve HDL and triglyceride levels. Reducing dietary saturated fat intake improves LDL-levels; if not effective, consider change of ART then consider lipid-lowering medication, see page 31. Statins should be used by all those with established vascular disease and among those with type 2 diabetes or at high risk of CVD, irrespective of lipid levels.

Drugs used to lower LDL-c

DRUG CLASS	DRUG	DOSE	SIDE EFFECTS	Advise on use of statin together with ART		
				use with PI/r	use with NNRTI	
Statin ⁽ⁱ⁾	Atorvastatin ⁽ⁱⁱ⁾	10-80 mg qd	Gastrointestinal symptoms,	Start with low dose ^(v) (max: 40 mg)	Consider higher dose ^(vi)	
	Fluvastatin ⁽ⁱⁱⁱ⁾	20-80 mg qd	headache, insomnia, rhabdomyolysis (rare) and toxic hepatitis	Consider higher dose(vi)	Consider higher dose(vi)	
	Pravastatin ⁽ⁱⁱⁱ⁾	20-80 mg qd		Consider higher dose ^(vi,vii)	Consider higher dose ^(vi)	
	Rosuvastatin ⁽ⁱⁱ⁾	5-40 mg qd		Start with low dose ^(v) (max: 20 mg)	Start with low dose ^(v)	
	Simvastatin ⁽ⁱⁱ⁾	10-40 mg qd		Contraindicated	Consider higher dose(vi)	
Cholesterol uptake ↓ ⁽ⁱ⁾	Ezetimibe ^(iv)	10 mg qd	Gastrointestinal symptoms	No known drug-drug interactions with ART		

A statin is preferred first-line therapy; different statins have variable intrinsic LDL-c lowering ability

- ii, iii, iv Target levels for LDL-c, see page 31. In persons where LDL-c targets are difficult to achieve, consult/refer to specialist
- ii, iii, iv Expected range of reductions of LDL-c: ii 1.5-2.5 mmol/L (60-100 mg/dL), iii 0.8-1.5 mmol/L (35-60 mg/dL), iv 0.2-0.5 mmol/L (10-20 mg/dL)
- v, vi The ARV may v inhibit (statin toxicity, ↓ dose) or vi induce (=less effect of statin, ↑ dose gradually to achieve expected benefit ii, iii) the excretion of the statin
- vii Exception: If used with DRV/r, start with lower dose of Pravastatin



Bone Disease: Screening and Diagnosis

CONDITION	CHARACTERISTICS	RISK FACTORS	DIAGNOSTIC T	ESTS	
 Osteopenia Postmenopausal women and men aged ≥ 50 years with T-score -1 to -2.5 Osteoporosis Postmenopausal women and men aged ≥ 50 years with T-score ≤ -2.5 Premenopausal women and men aged < 50 years with Z-score ≤ -2 and fragility fracture 	 Reduced bone mass Increased prevalence of fractures in people with HIV Asymptomatic until fractures occur Common in HIV Up to 60% prevalence of osteo- penia Up to 10-15% prevalence of osteoporosis Aetiology multifactorial Loss of BMD observed with antiretroviral initiation Greater loss of BMD with initiation of certain ARVs⁽ⁱ⁾ 	Consider classic risk factors ⁽ⁱⁱ⁾ Consider DXA in any person with ≥ 1 of: ⁽ⁱⁱⁱ⁾ 1. Postmenopausal women 2. Men ≥ 50 years 3. History of low impact fracture 4. High risk for falls ^(iv) 5. Clinical hypogonadism (sympto- matic, see Sexual Dysfunction) 6. Oral glucocorticoid use (minimum 5 mg/d prednisone equivalent for > 3 months) Preferably perform DXA in those with above risk factors prior to ART initiation. Assess effect of risk factors on fracture risk by including DXA results in the FRAX® score (www.shef.ac.uk/FRAX) • Only use if > 40 years • May underestimate risk in HIV- positive persons • Consider using HIV as a cause of secondary osteoporosis ^(v)	DXA scan Rule out causes of secondary osteoporosis if BMD abnormal ^(VI) Lateral spine X-rays (lumbar and thoracic) if low spine BMD, osteoporosis on DXA, or significant height loss or kyphosis develops. (DXA-based vertebral fracture as- sessment [VFA] can be used as an alternative to lateral spine X-ray).		
Osteomalacia	 Defective bone mineralisation Increased risk of fractures and bone pain Vitamin D deficiency may cause proximal muscle weakness High prevalence (> 80%) of vita- min D insufficiency in some HIV cohorts 	 Dark skin Dietary deficiency Avoidance of sun exposure Malabsorption Obesity Renal phosphate wasting^(vii) 	Deficiency < 10 < 25		ion nmol/L < 25 < 50 check PTH ement if
Osteonecrosis	 Infarct of epiphyseal plate of long bones resulting in acute bone pain Rare but increased prevalence in HIV 	Risk factors: • Low CD4 cell counts • Glucocorticoid exposure • IVDU	MRI		

- i Greater loss of BMD observed with initiation of regimens containing TDF and some PIs. Additional loss and gains in BMD observed with switch to and away from TDF-containing ARV regimens, respectively. Clinical relevance to fracture risk not determined.
- Classic risk factors: older age, female gender, hypogonadism, family history of hip fracture, low BMI (≤ 19 kg/m2), vitamin D deficiency, smoking, physical inactivity, history of low impact fracture, alcohol excess (> 3 units/day), steroid exposure (minimum prednisone 5 mg/d or equivalent for > 3 months)
- iii If T-score normal, repeat after 3-5 years in groups 1 and 2; no need for re-screening with DXA in groups 3 and 4 unless risk factors change and only rescreen group 5 if steroid use ongoing.
- iv Falls Risk Assessment Tool (FRAT) www.health.vic.gov.au/agedcare/ maintaining/falls/downloads/ph_frat.pdf
- Although use of HIV as a secondary risk factor in FRAX® has not been validated, including HIV as a secondary cause in a risk assessment will help to estimate risk in persons with risk factors for fracture along with low BMD.
- vi Causes of secondary osteoporosis include hyperparathyroidism, hyperthyroidism, malabsorption, hypogonadism/amenorrhoea, diabetes mellitus, and chronic liver disease.
- vii For diagnosis and management of renal phosphate wasting, see Indications and Tests for Proximal Renal Tubulopathy (PRT).

Vitamin D Deficiency: Diagnosis and Management

Vitamin D	Test	Therapy ⁽ⁱ⁾
Deficiency: < 10 ng/mL (< 25 nmol/L) ⁽ⁱⁱ⁾ Insufficiency: < 20 ng/mL (< 50 nmol/L)	25 hydroxy vitamin D (25(OH) vitamin D) If deficient, consider checking par- athyroid hormone (PTH), calcium, phosphate ⁽ⁱⁱⁱ⁾ , alkaline phosphatase	If vitamin D deficient, replacement recommended. Various regimens suggested ^(IV) Consider re-checking 25(OH) vitamin D levels 3 months after replacement. After replacement, maintenance with 800-2000 IU vitamin D daily.
Vitamin D deficiency prevalent in both HIV+ and HIV- populations – may not be directly associated with HIV. Factors associated with lower	Check vitamin D status in persons with history of:low bone mineral density and/or fracturehigh risk for fracture	Replacement and/or supplementation of 25(OH) vitamin D is recommended for persons with vitamin D insufficiency ^(vi) and: • osteoporosis • osteomalacia • increased PTH (once the cause has been identified)
vitamin D: • Dark skin • Dietary deficiency • Avoidance of sun exposure • Malabsorption • Obesity • Chronic kidney disease • Some ARVs ^(V)	Consider assessment of vitamin D status in persons with other factors associated with lower vitamin D levels (see left column)	Consider retesting after 6 months of vitamin D intake

- i Can be provided according to national recommendations/availability of preparations (oral and parenteral formulations). Combine with calcium where there is insufficient dietary calcium intake. Consider that in some countries food is artificially fortified with vitamin D.
- ii Some experts consider a value of ≤ 30 ng/mL as vitamin D deficiency. Low vitamin D has a prevalence of up to 80% in HIV cohorts and was associated with increased risk for osteoporosis, type 2 diabetes, mortality and AIDS events. Consider seasonal differences (in winter approximately 20% lower than in summer).
- iii Consider that hypophosphataemia can be associated with TDF therapy. This phosphate loss through proximal renal tubulopathy may be independent of low vitamin D, see page 42. A combination of low calcium + low phosphate +/- high alkaline phosphatase may indicate osteomalacia and vitamin D deficiency.
- iv Expect that 100 IU vitamin D daily leads to an increase in serum 25(OH) vitamin D of approximately 1 ng/mL. Some experts prefer a loading dose of e.g. 10,000 IU vitamin D daily for 8-10 weeks in persons with vitamin D deficiency. The principal goal is to achieve a serum level > 20 ng/mL (50 nmol/L) and to maintain normal serum PTH levels. Combine with calcium where potential for insufficient dietary calcium intake. The therapeutic aim is to maintain skeletal health; vitamin D supplementation has not been proven to prevent other co-morbidities in HIV-positive persons.
- The role of HIV-therapy or specific drugs remains unclear. Some studies suggest an association of EFV with reductions in 25(OH)D but not 1.25(OH)D. PIs may also affect vitamin D status by inhibiting conversion of 25(OH)D to 1.25(OH)D.
- vi The implications of vitamin D levels that are below the physiological reference range but not markedly reduced and the value of supplementation are incompletely understood



Approach to Fracture Reduction in HIV-positive Persons

Reducing risk of fractures	 Ensure sufficient dietary calcium (1-1.2 g daily) and vitamin D (800-2,000 IU daily) intake⁽ⁱⁱ⁾ Where appropriate, screen for osteoporosis⁽ⁱⁱⁱ⁾ and refer to national/regional guidelines on treatment of osteoporosis If no guidelines available, consider bisphosphonate^(iv) treatment in all osteoporotic postmenopausal women and men > 50 years old (BMD T-score ≤ -2.5) and those with a history of fragility fracture. Consider treatment based on BMD alongside consideration of other risk factors for fracture, especially age. Use bisphosphonate and ensure adequate calcium and vitamin D intake No significant interactions between bisphosphonates and antiretrovirals If antiretroviral naive, consider options for ART that preserve BMD^(v) 	
	 In complicated cases (e.g. young men, premenopausal women, recurrent fracture despite bone protective therapy), refer to osteoporosis specialist If on bisphosphonate treatment, repeat DXA after 2 years and reassess need for continued treatment after 3-5 years 	

- Falls Risk Assessment Tool (FRAT), see www.health.vic.gov.au/agedcare/maintaining/falls/downloads/ph_frat.pdf
- ii See page 39 for diagnosis and management of vitamin D deficiency.
- iii See page 38 for screening and diagnosis of bone disease in HIV.
- iv Bisphosphonate treatment with either of: Alendronate 70 mg once weekly po; Risedronate 35 mg once weekly po; Ibandronate 150 mg oral monthly or 3 mg iv every 3 months; Zoledronic acid 5 mg iv once yearly.
- BMD loss is greatest in the first year after ART initiation, with more BMD loss with ART regimens containing TDF and some PIs. Consider relative risk/benefit of using these agents in persons with high fracture risk.
- vi In persons on effective ART, a switch to TDF can lead to further BMD loss while a switch away from TDF (alongside optimisation of vitamin D status) in one study of older men with low BMD resulted in increased BMD.

Kidney Disease: Diagnosis and Management

Diagnosis of Kidney Disease

		eGFR ⁽ⁱ⁾		
		≥ 60 mL/min	30-59 mL/min	< 30 mL/min
ia(ii)	UP/C ⁽ⁱⁱⁱ⁾ < 50 UP/C ⁽ⁱⁱⁱ⁾ 50-100	 Check risk factors for CKD and nephrotoxic medicines including ART^(iv) Discontinue or adjust drug dosages where 		 Check risk factors for CKD and nephrotoxic medicines including ART^(IV) Discontinue or adjust drug dosages where appropriate^(V) Perform renal ultrasound Urgent referral to nephrologist
Proteinuri	UP/C ⁽ⁱⁱⁱ⁾ > 100			

Management of HIV-associated Kidney Disease(vi)

Prevention of progressive renal disease	Comment
1. ART	Start ART immediately where HIV- associated nephropathy (HIVAN) ^(vii) or HIV immune complex disease strongly suspected. Immunosup- pressive therapy may have a role in immune complex diseases. Renal biopsy to confirm histological diag- nosis recommended
 2. Start ACE inhibitors or angiotensin-Il receptor antago- nists if: a. Hypertension and/or b. Proteinuria 	Monitor eGFR and K ⁺ level closely on starting treatment or increasing dose a. Blood pressure target: < 130/80 mmHg
 3. General measures: a. Avoid nephrotoxic drugs b. Lifestyle measures (smoking, weight, diet) c. Treat dyslipidaemia^(viii) and diabetes^(IX) d. Adjust drug dosages where necessary 	CKD and proteinuria are independ- ent risk factors for CVD

eGFR: use abbreviated MDRD based on serum creatinine, gender, age and ethnicity. The Cockcroft-Gault (CG) equation may be used as an alternative.

If not previously known to have CKD, confirm pathological eGFR within 2 weeks. Use of COBI, DTG and boosted PIs, is associated with an increase in serum creatinine/reduction of eGFR due to inhibition of proximal tubular creatinine transporters without impairing actual glomerular filtration: consider new set point after 1-2 months

- ii Urinalysis: use urine dipstick to screen for haematuria. To screen for proteinuria, use urine dipstick and if ≥ 1+ check urine protein/creatinine (UP/C), or screen with UP/C. Proteinuria defined as persistent if confirmed on ≥ 2 occasions > 2-3 weeks apart. If UP/C not available, use urine albumin/creatinine (UA/C), see note⁽ⁱⁱⁱ⁾
- iii UP/C in spot urine is preferred to UA/C as detects total urinary protein secondary to glomerular and tubular disease. UA/C largely detects glomerular disease and can be used for screening for HIV-associated renal disease where UP/C is not available, but is not appropriate for screening for tubular proteinuria secondary to drug nephrotoxicity (e.g. TDF). If both UP/C and UA/C are measured, UP/C > UA/C suggests tubular proteinuria. Screening values for UA/C are: < 30, 30-70 and > 70. UA/C should be monitored in persons with diabetes. UPC ratio is calculated as urine protein (mg/L) / urine creatinine (mmol/L); may also be expressed as mg/mg. Conversion factor for mg to mmol creatinine is x 0.000884.
- Repeat eGFR and urinalysis as per screening table, see page 5
 See Dose Adjustment of ARVs for Impaired Renal Function
- vi Joint management with a nephrologist
- vii HIVAN suspected if black ethnicity & UP/C > 100 mg/mmol &
- no haematuria
- viii See page 37
- ix See page 35-36

ARV-associated Nephrotoxicity

Renal abnormality*	ARV	Management ^(vi)
 Proximal tubulopathy with any combination of: 1. Proteinuria: urine dipstick ≥ 1, or confirmed increase in UP/C > 30 mg/mmol⁽¹⁾ 2. Progressive decline in eGFR and eGFR < 90 mL/min⁽ⁱⁱ⁾ 3. Phosphaturia⁽ⁱⁱⁱ⁾: confirmed hypophosphataemia secondary to increased urine phosphate leak 	TDF	 Assessment: Tests for proximal renal tubulopathy/renal Fanconi syndrome⁽ⁱⁱⁱ⁾ Consider renal bone disease if hypophosphataemia of renal origin: measure 25(OH) vitamin D, PTH, DEXA Consider stopping TDF if: Progressive decline in eGFR and no other cause Confirmed hypophosphataemia of renal origin and no other cause Osteopenia/osteoporosis in the presence of increased urine phosphate leak
Nephrolithiasis: 1. Crystalluria 2. Haematuria ^(iv) 3. Leucocyturia 4. Loin pain 5. Acute renal insufficiency	IDV ATV (DRV)	Assessment: • Urinalysis for crystalluria/stone analysis • Exclude other cause for nephrolithiasis • Renal tract imaging including CT scan Consider stopping IDV/ATV if: • Confirmed renal stones • Recurrent loin pain +/- haematuria
Interstitial nephritis: 1. Progressive decline in eGFR ⁽ⁱⁱ⁾ 2. Tubular proteinuria ⁽ⁱⁱⁱ⁾ / haematuria 3. Eosinophiluria (if acute)	IDV ATV(V)	Assessment: • Renal ultrasound • Refer nephrologist Consider stopping IDV/ATV if: • Progressive decline in eGFR and no other cause

- * Use of COBI, DTG, RPV, but also PIs, is associated with an increase in serum creatinine/reduction of eGFR due to inhibition of proximal tubular creatinine transporters without impairing actual glomerular filtration: consider new set point after 1-2 months
- i UP/C in spot urine detects total urinary protein including protein of glomerular or tubular origin. The urine dipstick analysis primarily detects albuminuria as a marker of glomerular disease and is inadequate to detect tubular disease.
- ii eGFR, according to the abbreviated MDRD (Modification of Diet in Renal Disease) formula. The Cockcroft-Gault (CG) equation may be used as an alternative.
- iii See Indications and Tests for Proximal Renal Tubulopathy (PRT)
- iv Microscopic haematuria is usually present
- ATV may cause decline in eGFR also without clinical detected nephrolithiasis – but exact pathology and clinical significance remain unclear
- vi Tools to predict risk of kidney disease while using different nephrotoxic ARVs are currently beeing developed

Indications and Tests for Proximal Renal Tubulopathy (PRT)

Indications for proximal renal tubulopathy tests	Proximal renal tubulopathy tests ^(iv) , including	Consider stopping TDF if
 Progressive decline in eGFR⁽ⁱ⁾ & eGFR < 90 mL/min & no other cause and/or Confirmed hypophosphataemia⁽ⁱⁱ⁾ and/or Confirmed increase in UP/C⁽ⁱⁱⁱ⁾ Renal insufficiency even if stable (eGFR < 60 mL/min) Tubular proteinuria^(v) 	 Blood phosphate and urinary phosphate excretion^(vi) Blood glucose and glucosuria Serum bicarbonate and urinary pH^(vii) Blood uric acid level and urinary uric acid excretion^(viii) Serum potassium and urinary potassium excretion 	Confirmed proximal renal tubulo- pathy with no other cause

- i eGFR according to the abbreviated MDRD formula (Modification of Diet in Renal Disease). The Cockcroft-Gault (CG) equation may be used as an alternative.
- Serum phosphate < 0.8 mmol/L or according to local thresholds; consider renal bone disease, particularly if alkaline phosphatase increased from baseline: measure 25(OH) vitamin D, PTH
- iii UP/C in spot urine, detects total urinary protein, including protein of glomerular or tubular origin. The urine dipstick analysis primarily detects albuminuria as a marker of glomerular disease and is inadequate to detect tubular disease
- iv It is uncertain which tests discriminate best for TDF renal toxicity. Proximal tubulopathy is characterised by: proteinuria, hypophosphataemia, hypokalaemia, hypouricaemia, renal acidosis, glucosuria with normal blood glucose level. Renal insufficiency and polyuria may be associated. Most often, only some of these abnormalities are observed
- v Tests for tubular proteinuria include retinol binding protein, α1- or β2 -microglobulinuria, cystatin C, aminoaciduria
- Vi Quantified as fractional excretion of phosphate (FEPhos): (PO₄(urine) / PO₄(serum)) / (Creatinine(urine) / Creatinine(serum)) in a spot urine sample collected in the morning in fasting state. Abnormal > 0.2 (> 0.1 with serum phosphate < 0.8 mmol/L)
- vii S-bicarbonate < 21 mmol/L and urinary pH > 5.5 suggests renal tubular acidosis
- viii Fractional excretion of uric acid (FEUricAcid): (UricAcid(urine) / UricAcid(serum) / (Creatinine(urine) / Creatinine(serum)) in a spot urine sample collected in the morning in fasting state; abnormal > 0.1



Dose Adjustment of ARVs for Impaired Renal function

		eGFR ⁽ⁱ⁾ (mL/min)				
		≥ 50	30-49	10-29	< 10	Haemodialysis
NRTIS						
ABC	300 mg q12h	No dose adjustment required	No dose adjustment required	No dose adjustment required		
ddl ⁽ⁱⁱ⁾	≥ 60 kg	400 mg q24h	200 mg q24h	150 mg q24h	> 60 kg: 1	00 mg/24h
	< 60 kg	250 mg q24h	125 mg q24h	100 mg q24h	< 60 kg: 7	′5 mg/24h
d4T	> 60 kg	30 mg q12h	15 mg q12h	15 mg q24h	15 mg q24h	15 mg q24h AD ^(iv)
	< 60 kg	40 mg q12h	20 mg q12h	20 mg q24h	20 mg q24h	20 mg q24h AD ^(iv)
FTC		200 mg q24h	200 mg q48h	200 mg q72h	200 mg q96h	200 mg q96h
3TC		300 mg q24h	150 mg q24h	100 mg q24h ⁽ⁱⁱⁱ⁾	50-25 mg q24h ⁽ⁱⁱⁱ⁾	50-25 mg q24h ⁽ⁱⁱⁱ⁾ AD ^(iv)
TDF ^(vii)		300 mg q24h	300 mg q48h	Not recommended	Not recommended	300 mg q7d AD ^(iv)
				(300 mg q72-96h, if no alternative)	(300 mg q7d, if no alternative)	
ZDV		300 mg q12h	No dose adjustment required		100 mg q8h	100 mg q8h
ABC/3TC						
ZDV/3TC		_		Use individual drugs		
ZDV/3TC/ABC		_				
TDF/FTC		q24h	q48h Use individual drugs			
NNRTIS						
EFV		600 mg q24h		No dose a	djustment required	
ETV		200 mg q12h	No dose adjustment required			
NVP		200 mg q12h	No dose adjustment required			


	eGFR	Heemedichusia				
	≥ 50	30-49	10-29	< 10	Haemodialysis	
Pls						
ATV/r	300/100 mg q24h	300/100 mg q24h No dose adjustment required ^(v,vi)				
DRV/r	800/100 mg q24h 600/100 mg q12h	No dose adjust	ment required ^(v)			
FPV/r	700/100 mg q12h	No dose adjust	ment required ^(v)			
LPV/r	400/100 mg q12h	No dose adjust	ment required ^(v)			
SQV/r	1000/100 mg q12h	No dose adjust	ment required ^(v)			
TPV/r	500/200 mg q12h	No dose adjustment required ^(v)				
Other ART						
RAL	400 mg q12h No dose adjustment required ^(v) (dose AD ^(iv))					
TDF/FTC/COBI/EVG	Do not initiate if eGFR < 70 mL/min Discontinue if eGFR < 50 mL/min					
MVC: co-administered without CYP3A4 inhibitors ^(viii)	300 mg q12h No dose adjustment required					
MVC: co-adminis- tered with CYP3A4 inhibitors ^(viii)	if eGFR < 80 mL/min 150 mg q24h ^(viii) except: 150 mg q12h if co-administered with FPV/r					

- eGFR according to the abbreviated MDRD (Modification of Diet in Renal Disease) formula. The Cockcroft-Gault (CG) equation may be used as an alternative.
- ii Dose reduction if combined with TDF
- iii 150 mg loading dose
- iv AD: after dialysis
- Limited data available in persons with renal impairment; pharmacokinetic analysis suggests no dose adjustment required
- vi Associated with nephrotoxicity; consider alternative PI if pre-existing CKD vii Associated with nephrotoxicity; consider alternative ART if
- pre-existing CKD
 viii See summary of product characteristics for specific recommendations; use with caution if eGFR < 30 mL/min



Work-up and Management of HIV-positive Persons with Increased ALT/AST

Identify potential cause of increased liver enzymes, using the following steps:



i Nonalcoholic steatohepatitis




Liver Cirrhosis: Classification and Surveillance

Child-Pugh classification of the severity of cirrhosis

	Point*				
	1	2	3		
Total bilirubin, mg/dL (µmol/L)	< 2 (< 34)	2-3 (34-50)	> 3 (> 50)		
Serum albumin, g/L (µmol/L)	> 35 (> 507)	28-35 (406-507)	< 28 (< 406)		
INR	< 1.7	1.71-2.20	> 2.20		
Ascites	None	Mild/Moderate (diuretic respon- sive)	Severe (diuretic refrac- tory)		
Hepatic en- cephalopathy	None	Grade I-II (or suppressed with medicine)	Grade III-IV (or refractory)		

* 5-6 points: Class A 7-9 points: Class B 10-15 points: Class C



Liver Cirrhosis: Management

Management of HIV-positive persons with cirrhosis should be done in collaboration with experts in liver diseases. More general management guidance is described below.

For dosage adjustment of antiretrovirals, see Dose Adjustment of ARVs for Impaired Hepatic Function.

In end-stage liver disease (ESLD), use of EFV may increase risk of CNS symptoms.

ART, if otherwise indicated, also provides net benefit to cirrhotic persons. See Diagnosis and Management of Hepatorenal Syndrome (HRS).

Management of hypervolaemic Management strategy of hepatic hyponatraemia encephalopathy (HE) 1. Fluid restriction: 1000-1500 mL/ **General management** day (consumption of bouillon al-1. Identify and treat precipitating lowed ad libitum) factor (GI haemorrhage, infection, 2. If fluid restriction is ineffective, pre-renal azotaemia, constipation, consider use of oral Tolvaptan sedatives) 2. Short-term (< 72 hours) protein a. To be started in hospital at restriction may be considered if 15 mg/day for 3-5 days, then titrated to 30-60 mg/day until HE is severe normal s-Na; duration of treatment unknown (efficacy/safety Specific therapy Lactulose 30 cm³ orally every 1-2h only established in short-term studies (1 month)) until bowel evacuation, then adjust b. S-Na should be monitored to a dosage resulting in 2-3 formed closely, particularly after bowel movements per day (usually initiation, dose modification or if 15-30 cm³ orally bd) clinical status changes. c. Rapid increases in s-Na Lactulose enemas (300 cm³ in 1L of concentration (> 8 mmol/day) water) in persons who are unable to should be avoided to prevent take it orally. Lactulose can be osmotic demyelisation discontinued once the precipitating syndrome factor has resolved d. Persons may be discharged after s-Na levels are stable and without need to further adjust dose

Management strategy in uncomplicated ascites

Management s	Management strategy in uncomplicated ascites				
General management	 Treat ascites once other complications have been treated Avoid NSAIDs Norfloxacin prophylaxis (400 mg orally, qd) in persons with 1) an ascites protein level of < 1.5 mg/dL, 2) impaired renal function (serum creatinine level > 1.2 mg/dL, BUN > 25 mg/dL), 3) s-Na level < 130mE g/L), or 4) severe liver failure (Child Pugh score > 9 points with s-bilirubin level > 3 mg/dL) 				
Specific management	 Salt restriction: 1-2 g/day. Liberalise if restriction results in poor food intake Large volume paracentesis as initial therapy only in persons with tense ascites Administer intravenous albumin (= 6-8 g per litre ascites removed) 				
Follow-up and goals	 Adjust diuretic dosage every 4-7 days Weigh the person at least weekly and BUN, s-creatinine, and electrolytes measured every 1-2 weeks while adjusting dosage Double dosage of diuretics if: weight loss < 2 kg a week and BUN, creatinine and electrolytes are stable Halve the dosage of diuretics or discontinue if: weight loss ≥ 0.5 kg/day or if there are abnormalities in BUN, creatinine or electrolytes Maximum diuretic dosage: Spironolactone (400 mg qd) and Furosemide (160 mg qd) 				

Nutrition of cirrhotic persons

Caloric requirements

25-30 Kcal/Kg/day of normal body weight

Protein requirements

- Protein restriction is not recommended (see above for exception if HE)
 - fHE)

Analgesia in persons with hepatic failure

- Acetaminophen can be used; caution on daily dose (max 2 g/day).
- NSAIDs generally avoided, predispose persons with cirrhosis to develop GI bleeding. Persons with decompensated cirrhosis are at risk for NSAID-induced renal insufficiency.

 Opiate analgesics are not contraindicated but must be used with caution in persons with pre-existing hepatic encephalopathy.

· Type: rich in branched chain (non-

Some studies support that paren-

teral proteins carry less risk of en-

cephalopathy since not converted

by colonic bacteria into NH₃

aromatic) amino acids

Micronutrients

Mg and Zn

Screening for hepatocellular carcinoma

- Ultrasound (US) every 6 months Alpha-foetoprotein is a suboptimal surveillance tool because of low sensitivity and specificity
- In case of suspicious lesions on US, perform CT scan (+arterial phase) or dynamic contrast-enhanced MRI
- Confirm diagnosis by fine needle aspiration or biopsy should CT scan or MRI be inconclusive.

When to refer for liver transplantation

Best to refer early as disease progresses rapidly

- = MELD⁽ⁱⁱ⁾ score 10-12 (listing at 15)
- Decompensated cirrhosis (at least one of the following complications) • Ascites
- · Hepatic encephalopathy
- Variceal bleeding
- Spontaneous bacterial peritonitis
- Hepatorenal syndrome
- · Hepatopulmonary syndrome
- Hepatocellular carcinoma
- i Alpha-foetoprotein may also be expressed in $\mu g/L$ (cut-off value of 400 is the same)

ii Unit for both S-creatinine and S-bilirubin is mg/dL. MELD score = 10 {0,957 Ln (serum creatinine (mg/dL)) + 0.378 Ln (total bilirubin (mg/dL)) + 1.12 Ln (INR) + 0.643}. See www.mdcalc.com/meldscore-model-for-end-stage-liver-disease-12-and-older/



Diagnosis and Management of Hepatorenal Syndrome (HRS)

Diagnosis	 Consider HRS in a person with cirrhosis and ascites and a creatinine level of > 1.5 mg/dL. It is a diagnosis of exclusion - before making the diagnosis, the following need to be ruled out and treated: Sepsis (person needs to be pancultured) Volume depletion (haemorrhage, diarrhoea, overdiuresis) Vasodilatators Organic renal failure (urine sediment; kidney ultrasound) Diuretics should be discontinued and intravascular volume expanded with iv albumin. If renal dysfunction persists despite above, diagnose HRS 		
Recommended therapy	Liver transplant (priority dependent on MELD score). If person is on transplant list, MELD score should be updated daily and communicated to transplant centre.		
Alternative (bridging therapy)	Vasoconstrictors	Octreotide	100-200 mcg subcutaneously td
			\rightarrow Goal to increase mean arterial pressure by 15 mm HG
		+ Midodrine	5-15 mg orally td
		or Terlipressin ⁽ⁱ⁾	0.5-2.0 mg iv every 4-6 hours
	and iv albumin (both for at least 7 days)		50-100 g iv qd

 Tesamorelin (growth hormone releasing factor) was shown to reduce visceral adipose tissue volume but this effect was lost on discontinuation; the drug is not currently licensed in Europe



Dose Adjustment of ARVs for Impaired Hepatic Function

NRTIS		
ABC	Child-Pugh Score 5-6: 200 mg bd (use oral solution)	
	Child-Pugh Score > 6: Contraindicated	
ddl	Contraindicated	
	If used no dosage adjustment	
d4T	Contraindicated	
	If used no dosage adjustment	
FTC	No dosage adjustment	
3TC	No dosage adjustment	
TDF	No dosage adjustment	
TDF/FTC	No dosage adjustment	
ZDV	Reduce dose by 50% or double the interval between doses if Child-Pugh > 9	
NNRTIS		
DLV	No dosage recommendation; use with caution in persons with hepatic impairment	
EFV	No dosage adjustment; use with caution in persons	
TDF/FTC/EFV	with hepatic impairment	
ETV	Child-Pugh score < 10: no dosage adjustment	
NVP	Child-Pugh score > 6: contraindicated	

Pls		
ATV	Child-Pugh Score 7–9: 300 mg once daily	
	Child-Pugh Score > 9: not recommended	
	RTV boosting is not recommended in persons with hepatic impairment (Child-Pugh Score > 7)	
DRV	Mild to moderate hepatic impairment: no dosage adjustment	
	Severe hepatic impairment: not recommended	
FPV PI-naive persons only:		
	Child-Pugh Score 5–9: 700 mg bd	
	Child-Pugh Score 10–15: 350 mg bd	
	PI-experienced persons:	
	Child-Pugh Score 5-6: 700 mg bd + RTV 100 mg qd	
	Child-Pugh Score 7–9: 450 mg bd + RTV 100 mg qd	
	Child-Pugh Score 10–15: 300 mg bd + RTV 100 mg qd	
IDV	Mild to moderate hepatic insufficiency: 600 mg q8h	
LPV/r	No dosage recommendation; use with caution in persons with hepatic impairment	
NFV	Mild hepatic impairment: no dosage adjustment	
	Moderate to severe hepatic impairment: not recommended	
RTV	Refer to recommendations for the primary PI	
SQV	Mild to moderate hepatic impairment: use with caut	
	Severe hepatic impairment: contraindicated	
TPV	Child-Pugh score < 7: use with caution	
	Child-Pugh score > 6: contraindicated	
FI		
ENF	No dosage adjustment	
CCR5 Inhibitor	1	
MVC	No dosage recommendations. Concentrations will likely be increased in persons with hepatic impairment	
INSTI		
RAL	No dosage adjustment	

Note: Hepatic dysfunction is a good indication for TDM as clinical experience with these dose adjustments is very limited

Lipodystrophy: Prevention and Management

LIPOATROPHY	LIPOHYPERTROPHY
 Prevention Avoid d4T and ZDV or pre-emptively switch away from them Regimens containing ritonavir-boosted PIs lead to more limb fat gain than regimens containing NNRTIs Regimens not containing NRTIs lead to more fat gain than regimens containing NRTIs CCR5 and INSTI have not been associated with lipoatrophy in registrational studies, although not in formal comparative studies 	 Prevention No proven strategy. ATV/r has been associated with more central fat gain than EFV Weight gain expected with effective ART reflecting "return to health" type of response Weight reduction or avoidance of weight gain may decrease visceral adiposity Avoid inhaled Fluticasone (and potentially other inhaled corticosteroids) with RTV-boosted PI as it may cause Cushing syndrome or adrenal insufficiency
 Management Modification of ART Switch d4T or ZDV to ABC or TDF: Only ART modification proven to partially restore subcutaneous fat; increase in total limb fat ~400-500 g/year Risk of toxicity from new drug, see Adverse Effects of ARVs & Drug Classes Switch to regimen not including NRTIs Increase in total limb fat ~400-500 g/year May increase risk of dyslipidaemia Surgical intervention Offered for relief of facial lipoatrophy only 	 Management Diet and exercise may reduce visceral adiposity; Limited data, but possible reduction in visceral adipose tissue and improvement in insulin sensitivity and blood lipids, especially in obesity associated with lipohypertrophy No prospective trials in HIV-positive persons to definitely indicate degree of diet and/or exercise needed to maintain reduction in visceral fat May worsen subcutaneous lipoatrophy Pharmacological interventions to treat lipohypertrophy have not been proven to provide long-term effects and may introduce new complications; Growth hormone Decreases visceral adipose tissue May worsen subcutaneous lipoatrophy and insulin resistance Tesamorelin(i) Metformin Decreases visceral adipose tissue in insulin resistant persons May worsen subcutaneous lipoatrophy

i See Diagnosis and Management of Heptatorenal Syndrome (HRS)

Hyperlactataemia and Lactic Acidosis: Diagnosis, Prevention and Management

Risk factors	Prevention/Diagnosis	Symptoms
 Use of ddl > d4T > ZDV HCV/HBV co-infection Use of ribavirin Liver disease Low CD4 cell count Pregnancy Female sex Obesity 	 Avoid d4T + ddl combination Routine monitoring of serum lactate levels not recommended - does not predict risk of lactic acidosis. Measurement of serum lactate, bicarbonate & arterial blood gases + pH indicated in case of symptoms suggestive of hyperlactataemia Close monitoring for symptoms if > 1 risk factor 	 Hyperlactataemia: unexplained nausea, abdominal pain, hepatomegaly, elevated ALT and/or AST, weight loss Acidaemia: asthenia, dyspnoea, arrhythmias Guillain-Barré-like syndrome

Management

Serum Lactate (mmol/L)	Symptoms	Action
> 5 ⁽ⁱ⁾	Yes/No	 Repeat test under standardised conditions to confirm & obtain arterial pH and bicarbonate⁽ⁱ⁾ If confirmed, exclude other causes Arterial pH ↓ and/or bicarbonate ↓⁽ⁱ⁾: Stop NRTIs Arterial pH and/or bicarbonate normal: Consider switch from high to low-risk NRTI & monitor carefully OR stop NRTIs
2-5	Yes	Exclude other causes; if none found: watchfully follow up OR consider switch from high to low-risk NRTI, OR stop NRTI
2-5	No	Repeat test If confirmed, watchfully follow up
< 2		None

i Lactic acidosis is a rare but life-threatening situation usually associated with symptoms; high risk if serum lactate > 5 and especially > 10 mmol/L.

Management of lactic acidosis (irrespective of serum-lactate level)

Admit the person. Stop NRTIs. Provide iv fluids. Vitamin supplementation can be used (vitamin B complex forte 4 mL bd, riboflavin 20 mg bd, thiamine 100 mg bd; L-carnitine 1000 mg bd), although benefit is unproven.



Travel

General precautions	 Delay travel until clinically stable and treatment established Provide drug prescription and referral letter for emergencies Provide medical certificate for import of perso- nal medicines/syringes Carry antiretrovirals split between suitcase and hand luggage Beware of fake drugs
ART	 Maintain hours of medicines (e.g. 23.00 local time) when switching time zones, shortening the interval to the next dose when flying east
Acknowledge increased susceptibility ⁽ⁱ⁾ of HIV- positive	 1. Observe food hygiene Bacterial enterocolitis g. Salmonella, Shigella, Campylobacter Intestinal parasitosis Cyclospora, Cryptosporidium, Isospora, Microsporidia 2. Prevent insect bites Repellents (DEET ≥ 30%, Permethrin) Malaria Chemoprophylaxis/emergency treatment⁽ⁱⁱ⁾ Yellow fever, see page 55 Leishmaniasis Beware of sand flies (dogs)

Advice on travel restrictions - see www.hivtravel.org

 Higher susceptibility due to HIV-associated GALT destruction, low CD4
 According to malaria risk at travel destination and national guidelines; adherence counselling is particularly important in persons visiting friends and relatives. See Drug-drug Interactions between Antimalarial Drugs and ARVs



Drug-drug Interactions between Antimalarial Drugs and ARVs

Effect of ARVs on antimalarial drugs and key metabolite

Arrows indicate effect of antiretrovirals on antimalarial drug/key metabolite	
Allows Indicate check of antifectovirals of antificial and sheet of inetabolite	
Green no clinically significant interaction expected	
Orange potential interaction (consider treatment ahead of travel and therapeutic drug monitoring)	
Red clinically relevant interaction, do not use or use with caution	

Mefloquine (M)		
Key Metabolite Indication	CYP 3A4 Prophylaxis Treatment	Significance
NNRTI (EFV, NVP, ETV)	\downarrow	No
RPV, RAL, MVC, DTG	\rightarrow	No
PI, COBI	↑ M may reduce PI/COBI (RTV ca 35%)	Potential

Artemisinins (A)		
Artemisinins and its key metabolite, dihydroartemisinin, are active compounds		
Key Metabolite Indication	CYP 2B6, 3A4, 2C19 Treatment	Significance
NNRTI (EFV, NVP, ETV)	↓ A & dihydroartemisinin; A & metabolites reduce NVP, but not EFV/ETR	do not use or use with caution
RPV, RAL, MVC, DTG	\rightarrow A may reduce RPV, MVC	Potential
PI, COBI	↑ Increase A: monitor toxicity (liver)	Potential

Lumefantrin (L)		
Key Metabolite Indication	CYP 3A4 Treatment	Significance
NNRTI (EFV, NVP, ETV)	\downarrow	Potential
RPV, RAL, MVC, DTG	\rightarrow	No
PI, COBI	↑ LPV increases L 2-3x	do not use or use with caution

Atovaquone (A), Proguanil

Atovaquone increases ZDV levels by 35%

•Synergy with atovaquone is related to proguanil, not its active metabolite; therefore presumably no net
 effect of induction/inhibition

Key Metabolite Indication	CYP 2C19 Prophylaxis Treatment	Significance
NNRTI (EFV, NVP, ETV)	↓ ETV is increased	Potential
RPV, RAL, MVC, DTG	\rightarrow	No
РІ, СОВІ	↓ At & P take with fat meal, consider dose increase	Potential

Doxycycline				
Key Metabolite Indication	N/A Prophylaxis	Significance		
NNRTI (EFV, NVP, ETV)	possibly ↓	Potential		
RPV, RAL, MVC, DTG	\rightarrow	No		
PI, COBI	\rightarrow	No		

Chloroquine			
Key Metabolite Indication	CYP 3A4, 2D6 Treatment	Significance	
NNRTI (EFV, NVP, ETV)	\rightarrow	No	
RPV, RAL, MVC, DTG	\rightarrow	No	
PI, COBI	\rightarrow	No	

Quinine (Q)			
Key Metabolite Indication	CYP 3A4, 2D6 Treatment	Significance	
NNRTI (EFV, NVP, ETV)	↓ Consider dose increase	Potential	
RPV, RAL, MVC, DTG	\rightarrow	No	
РІ, СОВІ	↑ RTV increases Q 4x: consider dose reduction, monitor toxicity (tinnitus). CAVE: PI & Q prolong QT	Potential	

Primaquine Key Metabolite Indication	CYP 1A2, 2D6, 3A4 (Prophylaxis) Treatment	Significance		
NNRTI (EFV, NVP, ETV)	N/A	Potential		
RPV, RAL, MVC, DTG	\rightarrow	No		
PI, COBI	N/A			



Vaccination

- Vaccinate according to national guidelines for healthy population Delay polysaccharide vaccination until CD4 \geq 200 cells/µL
- Consider repeating vaccinations performed at CD4 < 200 cells/µL (CD4% < 14) following adequate immune reconstitution
- As vaccine responses may be significantly lower in HIV-positive persons, consider antibody titres to assess their effectiveness
- For attenuated live vaccines⁽ⁱ⁾ (in addition to restrictions for general population):
 - *Varicella, measles, mumps, rubella, yellow fever contraindicated if CD4 < 200 cells/µL (14%) and/or AIDS
 Oral typhoid, oral polio (OPV)

 - contraindicated as inactivated vaccines are available

Infection	Vaccination rationale in HIV+ persons	Comment		
Influenza Virus	Higher rate of pneumonia	Yearly		
Human Papilloma Virus (HPV)	Shared risk with HIV of contracting infection. Higher rate of cervical and anal cancer	If HPV infection is established, efficacy of vaccine is questionable		
infection. HIV accelerates liver disease intradermal va high viraemia. according to n		Vaccinate if seronegative. Consider double dose (40 μ g) and intradermal vaccination in non-responders, in particular with low CD4 and high viraemia. Repeat doses until HBs antibodies \geq 10 IU/L / \geq 100 IU/L according to national guidelines. See page 64		
Hepatitis A Virus (HAV)	According to risk profile (travel, MSM, IVDU, active hepatitis B or C infection)	Vaccinate if seronegative. Check antibody titres in individuals with risk profile See page 64		
Neisseria meningitidis	As general population	Use conjugated vaccine (2 doses) if available, then continue with polysac- charide vaccine		
Streptococcus pneumoniae	Higher rate and severity of invasive disease	Consider conjugated 13-valent vaccine instead of PPV-23 polysaccharide vaccine if available ⁽ⁱⁱ⁾ Consider one single booster with PPV-23 after 5 years ⁽ⁱⁱⁱ⁾		
Varicella Zoster Virus (VZV)	Higher rate and severity of both chicken- pox and zoster	Vaccinate if seronegative For contraindications, see*		
Yellow Fever Virus Mandatory for travel to selected coun- tries (provide exemption letter if no true risk of exposure)		Contraindicated if past or current haematological neoplasia or thymus resection/radiation Relatively contraindicated at age > 60 years For other contraindications, see*		

Administer live vaccines simultaneously or with an interval of 4 weeks 13-valent conjugated vaccine may replace 23-valent polysaccharide vaccine as more immunogenic ii

Repetitive boosting may attenuate immune response iii

Sexual and Reproductive Health of HIV-positive Women and Men

Screening questions about sexual and reproductive health and sexual functioning should be routinely asked in every HIV consultation.

Sexual transmission of HIV

Effective measures to reduce sexual transmission of HIV include:

Measure	Comment
Male condom or female condom use	Effective in treated and untreated HIV-positive persons
Post-exposure prophylaxis (PEP)	 Consider after situations of unprotected anal or vaginal intercourse, if one partner has detectab- le HIV-VL and the other partner is seronegative Start as soon as possible and within 72 hours post sexual exposure
ART for HIV-positive partner	 Considered effective from 6 months of fully suppressive ART if no active STIs Consider in e.g. serodifferent couples⁽ⁱ⁾

See page 7

STI screening and treatment

STI screening should be offered to all sexually active HIV-positive persons at the time of HIV diagnosis, annually thereafter or at any time STI symptoms are reported. Diagnosis procedures should follow local or national guide-lines. More comprehensive advice can be found at www.iusti.org/regions/Europe/euroguidelines.htm

The following STIs should be universally considered in HIV-positive persons and their sexual partner(s):

Reproductive health

Reproductive health issues should be preferentially discussed with both partners, particularly in serodifferent couples. RAL, RPV and NRTIs have been shown to have no interaction with oral contraceptives.

Approaches for serodifferent couples who want to have children

Screening for STIs (and treatment, if required) of both partners is mandatory. For HIV-positive women wishing to conceive: (1) avoid using ddl, d4T or triple NRTI, avoid EFV in first trimester; among PI/r, prefer LPV/r, SQV/r or ATV/r, already started NVP, RAL or DRV/r can be continued, see page 12; (2) consider treating the HIV-positive partner to reduce risk of HIV transmission to the HIV-negative partner

No single method is fully protective against transmission of HIV; the following list represents selected measures with increasing safety for serodifferent couples without active STIs:

- Unprotected intercourse during times of maximum fertility (determined by ovulation monitoring), if the HIV-positive partner has undetectable HIV-VL
- Vaginal syringe injection of seminal fluid during times of maximum fertility, if the male partner is HIV-negative
- Sperm washing, with or without intra-cytoplasmic sperm injection, if the male partner is HIV-positive

Sexual dysfunction

Guidelines for treatment of sexual dysfunction in the general population are available for men but not women. Refer to specialist where appropriate. See Sexual Dysfunction and Treatment of Sexual Dysfunction in HIV-positive Men

	Therapy	Comment
Chlamydia infection	Consider Doxycycline (100 mg bd for 7-10 days) or Ofloxacin (200 mg bd), Erythromycin (500 mg qd for 7 days) or Azithromycin (1 g once). For <i>Lymphogranuloma venereum</i> consider Doxy- cycline (100 mg bd for at least 3 weeks)	 May cause therapy-resistant proctitis in HIV-positive MSM Consider co-infections with <i>Neisseria gonorrhoeae</i>
Gonorrhoea	Therapy recommended according to geographi- cal resistance profiles. Ceftriaxone 500 mg im as a single dose together with Azithromycin 2 g as a single dose po.	 Can cause proctitis, prostatitis and epididymitis In women often asymptomatic Fluroquinolone resistance is extensive
HBV infection HCV infection	See table on HIV/HCV or HIV/HBV co-infections, page 64, 66-79	 Interruption of TDF, 3TC or FTC can lead to HBV reactivation Clusters of acute HCV infection in HIV-positive MSM across Europe
HPV infection	Treatment of genital warts is challenging. Con- sider operative removal by laser surgery, infrared coagulation, cryotherapy etc. Management of both pre-invasive cervical lesions as well as peri- and intra-anal lesions should fol- low local or national guidelines	 Infection is mostly asymptomatic; relapse of genital warts is frequent Cervical PAP smear test recommended in all HIV-positive women Anal HPV screening and PAP smear should be considered in all HIV-positive persons practising anal sex Consider high resolution anoscopy in case of suspicious cytological findings (rectal palpation or external inspection is not sufficient)
HSV2 infection	Primary infection: Acyclovir (400–800 mg po td) or Valacyclovir (500 mg bd) for 5 days	 Treatment of HSV2 alone does not prevent HIV-transmission and only modestly prevents HIV disease progression.
Syphilis	Primary/secondary syphilis: Benzathine Peni- cillin G (2.4 million IU im as single dose). Late latent syphilis and syphilis of unknown duration: Benzathine Penicillin (2.4 mio IU im weekly on days 1, 8 and 15); alternatives such as Doxycycline (100 mg bd), or Erythromycin (2 g/day) for 2 weeks are considered less effective. Neurosyphilis: Penicillin G (6 x 3 - 4 million IU iv for at least 2 weeks)	 Expect atypical serology and clinical courses Consider cerebral spinal fluid (CSF) testing in persons with neurological symptoms (evidence for intrathecally-produced specific antibodies, pleocytosis etc.) Successful therapy clears clinical symptoms and/or decreases VDRL test by at least 2 titre levels Serology cannot distinguish re-infection from re-activation



Sexual Dysfunction

When sexual complaints exist:	What is the exact nature of the problem? In which phase(s) of the sexual response cycle does the problem occur?	ty)				
Identify the causes:	Psychological or sociological problems?	Stigma, body image alteration, depression, fear of infecting an HIV-negative partner?	Refer to clinical psychologist			
	Relevant co-morbidity?	CVD (note: if complete sexual response possible - e.g. with another partner, with masturbation or nocturnal - then no major somatic factors are involved)	Refer to urologist, andrologist, cardiologist			
	Relevant medicines, drugs, lifestyle factors?	Drugs associated with sexual dysfunction: 1) psychotropics (anti- depressants, antiepileptics, antipsychotics, Benzodiazepines), 2) lipid-lowering drugs (Statins, Fibrates), 3) antihypertensives (ACE-inhibitors, betablockers, alfablockers), 4) others (Omepra- zole, Spironolactone, Metoclopramide, Finasteride, Cimetidine); 5) contribution from ARVs is controversial and benefit from switch- ing studies is not proven.	Refer to clinical pharmacologist			
	Signs of hypogonadism in men?	Signs of testosterone insufficiency (reduced sexual arousal and libido; decreased frequency of sexual thoughts and fantasies; decreased or absent nocturnal erections; decreased genital sensi- tivity; loss of vitality; fatigue; loss of muscle mass and muscle strength and decreased body hair)	Refer to endocrinologist			



Treatment of Erectile dysfunction	Treatment of Premature ejaculation
 Primarily oral PDE5-Is (Sildenafil, Tadalafil, Vardenafil). All at least 30 minutes before initiation of sexual activity Use lower dose if on Pl/r Sildenafil (25 mg every 48 hours) 	Consider behavioural interventions and/or psychosexual counselling, SSRIs, tricylclic antidepressants, Clomipramine and topical anaesthetics. • Use lower dose of Clomipramine and other tricyclic antidepressants if on Pl/r
 Tadalafil 5 mg initial dose with maximum dose 10 mg in 72 hours Vardenafil 2.5 mg maximum dose in 72 hours Tadalafil also licensed for use as an everyday ongoing therapy 	 Dapoxetine, a short-acting SSRI, is the only drug approved for on-demand treatment of premature ejaculation in Europe. Treatment must be maintained as recurrence is highly likely following withdrawal of medicine

Depression: Screening and Diagnosis

Significance

- Higher prevalence of depression reported in HIV-positive persons (20-40% versus 7% in general population)
 Significant disability and poorer treatment outcomes associated with depression

Screening and diagnosis

Who?	How to screen	How to diagnose
 Risk population Positive history of depression in family Depressive episode in personal history Older age Adolescence Persons with history of drug addiction, psychiatric, neurologic or severe somatic co-morbidity Use of EFV and other neurotropic - incl. recreational - drugs As part of investigation of neurocognitive impairment if any of the 3 initial screening questions are positive, see page 61 	 Screen every 1-2 years Two main questions: Have you often felt depressed, sad or without hope in the last few months? Have you lost interest in activities that you usually enjoy? Specific symptoms in men: Stressed, burn out, angry outbursts, coping through work or alcohol Rule out organic cause (such as hypothyroidism, hypogonadism, Addison's disease, non-HIV drugs, vit B12 deficiency) 	 Symptoms - evaluate regularly A. At least 2 weeks of depressed mood OR B. Loss of interest OR C. Diminished sense of pleasure PLUS 4 out of 7 of the following: Weight change of ≥ 5% in one month or a persistent change of appetite Insomnia or hypersomnia on most days Changes in speed of thought and movement Fatigue Feelings of guilt and worthlessness Diminished concentration and decisiveness Suicidal ideation or a suicide attempt

Depression: Management

Degree of depression	Number of symptoms (see page 59: A,B or C + 4/7)	Treatment	Consultation with expert
No	< 4	No	
Mild	4	 Problem-focused consultation Consider antidepressant treatment⁽ⁱ⁾ Recommend physical activity 	 Always if treating physician is unfamiliar with use of antidepressants If depression not responding to treatment If person has suicidal ideation In case of complex situations such as drug addiction, anxiety disorders,
Intermediate	5-6	Start antidepressant treatment(i)	personality disorders, dementia, acute severe life events
Severe	> 6	Refer to expert (essential)	-

i See Drug-drug Interactions between Antidepressants and ARVs

If a person is diagnosed with depression switching off EFV to another third ARV drug according to switch rules is recommended



Classification, Doses, Safety and Adverse Effects of Antidepressants

Mechanisms & classification	Start dose	Standard dose	Lethality in overdose	Insomnia and agitation	Sedation	Nausea or GI effects	Sexual dysfunction	Weight gain
	m	g/day						
Selective serotonin-reuptake inhibitors (SSRIs) ⁽ⁱ⁾								
Paroxetine	10-20	20-40	Low	+	- / +	+	++	++
Sertraline	25-50	50-150	Low	+	- / +	+	+	+
Citalopram	10-20	20-40	Low	+	- / +	+	+	+
Escitalopram	5-10	10-20	Low	+	- / +	+	+	+
Mixed or dual-ac	Mixed or dual-action reuptake inhibitors							1
Venlafaxine	37.5-75	75-225	Moderate	++	- / +	+	+	- / +
Mixed-action new	Mixed-action newer agents							
Mirtazapine	30	30-60	Low	- / +	++	- / +	-/+	++

- none

+ moderate ++ severe

i For many persons, SSRI induction may be associated with adverse effects (GI tract, dizziness, anxiety, panic attacks). Commencing at lower doses (i.e. 10, 25 & 10 mg for Paroxetine, Sertraline and Citalopram, respectively) and increasing to the above starting doses after 4 to 7 days if tolerated may reduce such effects.



Drug-drug Interactions between Antidepressants and ARVs

antidepre	essants	ATV/r	DRV/r	LPV/r	SQV/r	EFV	ETV	NVP	RPV	MVC	DTG	EVG/c	RAL
SSRI	citalopram	↑ ^a	↑	↑ ^a	∱ a	Ļ	Ļ	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑ (\leftrightarrow
	escitalopram	∱ a	↑	∱ ^a	↑ a	Ļ	Ļ	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑ (\leftrightarrow
	fluvoxamine	↑	↑	↑	↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow
	fluoxetine	↑	↑	1	↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow
	paroxetine	↑↓ ?	↓39%	↑↓ ?	↑↓ ?	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑↓ ?	\leftrightarrow
	sertraline	Ļ	↓49%	Ļ	Ļ	↓39%	Ļ	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑ (\leftrightarrow
SNRI	duloxetine	¢↓	↑↓	¢↓	¢↓	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow
	venlafaxine	↑	↑	↑	↑	Ļ	Ļ	Ļ	\leftrightarrow	D	\leftrightarrow	↑	\leftrightarrow
ТСА	amitriptyline	1	↑ (1	1 ^b	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	1	\leftrightarrow
	clomipramine	↑	1	1	1 ^b	Ļ	Ļ	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow
	desipramine	↑	1	↑5%	1	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow
	doxepin	↑	↑	↑	1¢	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow
	imipramine	↑ ^a	↑	↑ ^a	∱a	Ļ	Ļ	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow
	nortriptyline	∱ a	↑	∱ ^a	∱ ^{a,b}	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow
	trimipramine	↑	↑	1	↑	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow
TeCA	maprotiline	↑	↑	↑ (↑ (\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow
	mianserine	↑ (1	1	1	Ļ	Ļ	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	1	\leftrightarrow
	mirtazapine	1	↑ (1	1	Ļ	Ļ	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow
Others	bupropion	Ļ	Ļ	↓57%	Ļ	↓55%	\leftrightarrow	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	^?	\leftrightarrow
	lamotrigine	↓32%	Ļ	↓50%	Ļ	\leftrightarrow							
	nefazodone	1	Î	Î	1	Ļ	↓E	Ļ	E	E	\leftrightarrow	↑	\leftrightarrow
	St John's wort	D	D	D	D	D	D	D	D	D	Dc	D	\leftrightarrow
	trazodone	↑	↑	↑	1 ^b	Ļ	Ļ	Ļ	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑	\leftrightarrow

Legend

- ↑ potential elevated exposure of the antidepressant
- ↓ potential decreased exposure of the antidepressant
- $\leftrightarrow \qquad \text{no significant effect}$
- D potential decreased exposure of ARV drug
- E potential elevated exposure of ARV drug
- a ECG monitoring is recommended
- b coadministration contraindicated in the European SPC. However, US prescribing information recommends TDM for antidepressants. The charts reflect the more cautious option. Numbers refer to decreased AUC of the antidepressant as observed in drug-drug interactions studies.
- SSRI selective serotonin reuptake inhibitors
- SNRI serotonin and norepinephrine reuptake inhibitors
- TCA tricyclic antidepressants
- TeCA tetracyclic antidepressants

Colour legend

no clinically significant interaction expected.

these drugs should not be coadministered.

potential interaction which may require a dosage adjustment or close monitoring.


potential interaction predicted to be of weak intensity (< 2 fold \uparrow AUC or < 50% \downarrow AUC). A dosage adjustment is *a priori* not recommended.

Comment

The symbol (red, amber, green) used to rank the clinical significance of the drug interaction is based on www.hiv-druginteractions.org (University of Liverpool). For additional drug-drug interactions and for more detailed pharmacokinetic interaction data and dosage adjustments, refer to the above-mentioned website.



Algorithm for Diagnosis and Management of HIV-Associated Neurocognitive Impairment (NCI) in Persons without Obvious Confounding Conditions



* When administered twice daily. Once-daily administration of these drugs, although common in clinical practice, has not been studied extensively with regard to CNS effects/CSF penetration and may have different CNS activity.



Part IV Clinical Management and Treatment of HBV and HCV Co-infection in HIV-positive Persons

General Recommendations for Persons with Viral Hepatitis/HIV Co-infection

Screening

- All HIV-positive persons should be screened for HCV at time of HIV diagnosis and annually hereafter. Screening should use an anti-HCV antibody test. A positive result should be followed by HCV-RNA and genotype determination. Persons with risk factors (ongoing IVDU, mucosal traumatic sex, ongoing unprotected anal intercourse, recent sexually transmitted infection) with unexplained increase in hepatic transaminases and a negative anti-HCV antibody test should be tested for HCV-RNA for early detection of a recent infection.
- HIV-positive persons should be screened for HAV and HBV. Persons who are anti-HBc positive and HBsAg negative, in particular those with elevated liver transaminases, should be screened for HBV-DNA in addition to HBsAg to rule out occult HBV infection.
- Hepatitis delta antibodies should be screened for in all HBsAg positive persons.
- 4. Persons with liver cirrhosis Child Pugh class A or B and Child Pugh class C awaiting liver transplantation and persons with HBV irrespectively of fibrosis stage should be screened at 6-monthly intervals with hepatic ultrasound (CT in case of nodules– alpha-foetoprotein may also be used, but value controversial) for the occurrence of hepatocellular carcinoma (HCC). Routine screening is also advised for oesophageal varices at the time of diagnosis mainly when there is evidence of portal hypertension and at 3-4-year intervals thereafter if not present initially, see page 46. Regarding HCC screening, see page 47. In the presence of a liver nodule or a liver mass, recall policy of EASL/EORTC guidelines should be followed. Management of HCC should be defined for each case with a multidisciplinary team including transplant surgeon, interventional radiologist and hepatologist. In persons treated with Sorafenib, toxicity of ARVs and Sorafenib should be strictly monitored.

Vaccination see page 55

- 5. Persons lacking anti-HAV IgG antibodies or anti-HBs antibodies should be offered vaccination for the respective virus to prevent infection regardless of their CD4 cell count. The response to the HBV vaccine is influenced by the CD4 cell count and level of HIV-VL. In persons with low CD4 cell count (< 200 cells/µL) and ongoing HIV replication, ART should be initiated first prior to respective vaccination. Because of the lack of data on the impact of immunization in isolated anti-HBc IgG positive persons (HBsAg negative, anti-HBc positive and anti-HBs negative profile), vaccination is not presently recommended in this population. This guideline might be revised when more data is available from current trials. Occult HBV (HBsAg negative and HBV-DNA positive) should be ruled out in all persons with isolated anti-HBc.
- 6. In HIV-positive persons vaccinated for HBV with insufficient response (anti-HBs < 10 IU/L), re-vaccination should be considered. Double-dose (40 µg) at 3-4 time points (months 0, 1, 6 and 12) may help to improve response rates to the HBV vaccine. Persons who fail to seroconvert after HBV vaccination and remain at risk for HBV should have annual serological tests for evidence of HBV infection. TDF based cART has been associated with prevention of HBV infection in these persons.

ART

- 7. HIV-positive persons with HBV and/or HCV co-infection benefit from early ART because liver fibrosis progression is reduced with immune reconstitution and suppression of HIV-VL. Thus, ART initiation with a TDF-based regimen is recommended in all persons with HBV coinfection needing anti-HBV therapy irrespective of CD4 cell count, and in all HBsAg positive persons with less than 500 CD4 cells irrespective of HBV disease status to prevent transition to a more active HBV disease state due to immune suppression.
- In persons with chronic HCV, ART initiation is recommended when CD4 cell counts drop below 500 cells/µL. Stopping ART has been associated with enhanced risk for AIDS and non-AIDS related events; indeed, the risk for non-AIDS events was particularly enhanced for persons with he-

patitis co-infection. Stopping anti-HBV containing ART should be avoided in persons with HIV/HBV co-infection because of the high risk of severe hepatitis flares and decompensation following HBV reactivation hepatitis.

End Stage Liver Disease (ESLD)

- HIV-positive persons require the same measures for the treatment of oesophageal varices, hepatorenal syndrome, hepatic encephalopathy or ascites as HIV-negative persons, see page 46-48 and Diagnosis and Management of Hepatorenal Syndrome (HRS).
- Persons with viral hepatitis/HIV co-infection suffering from ESLD warrant particular attention in the management of liver insufficiency; see Dose Adjustment of ARVs for Impaired Hepatic Function. Nevertheless, it is important to highlight that ART initiation in cirrhotic persons generally improves overall survival and is therefore strongly recommended in these persons when indicated.
- 11. Renal complications are frequent, see page 47 and Diagnosis and Management of Hepatorenal Syndrome (HRS)
- 12. Persons with HCC or a MELD-score > 15*, CD4 cell count > 100 cells/ µL and options for efficacious and durable ART should be evaluated for liver transplantation (OLTX). OLTX outcomes in persons with HIV/HBV co-infection are particularly promising, whereas post-transplant survival in persons with HIV/HCV co-infection has been somewhat lower than in persons with HCV mono-infection mainly due to the complicated course of HCV re-infection after transplantation.
- * MELD calculation, see page 47.

Prevention/Support

- 13. Psychiatric, psychological, social and medical support should be made available to persons with alcohol intake to stop drinking.
- 14. Substitution therapy (opioid replacement therapy) in persons with active drug abuse as a step towards cessation of active drug use should be encouraged. Help provided (e.g. through needle and syringe exchange programme) reduces the risk of re-infection including parenteral viral transmission (harm reduction strategy). See Drug Dependency and Drug Addiction
- 15. Since HBV and HIV, and occasionally HCV, are transmitted sexually, adequate counselling including the use of condoms is advisable. Information on the risk of HCV transmission due to mucosal traumatic sexual practices associated with a high likelihood of blood contact should be provided and risk reduction should be discussed.


Delta Virus

16. In persons with Delta virus co-infection and significant liver fibrosis (≥ F2), long-term (> 18 months) treatment with PEG-IFN might be considered in association with TDF-based ART. Because of its anti-HBV activity, TDF should be added to PEG-IFN in order to reduce HBV-DNA load. Treatment efficacy should be monitored with HBV-DNA and HDV-RNA measurements, when available, and with follow-up of biochemical and liver fibrosis estimates.

Persons with anti-HCV antibodies and detectable HCV-RNA should be offered anti-HCV treatment in order to induce a sustained virologic response for HCV co-infection. Persistent off-treatment HDV-RNA negativity and anti-HBs seroconversion are the ideal goals of antiviral treatment for hepatitis Delta even if they can only be obtained in a minority of persons. Histological remission of liver disease is a less ambitious but more likely to be achieved goal. In persons with Delta virus and ESLD or HCC, liver transplantation from HBsAg negative donor should be strongly considered especially in the absence of active HCV co-infection. Transplant with anti-HBV post-OLTX prophylaxis cures HBV and Delta virus infection.




Assessment of Treatment Indications for HBV in Persons with HBV/HIV Co-infection



Note: In persons with significant liver fibrosis (F2-F4), anti-HBV treatment might be considered even when serum HBV-DNA is below 2000 IU/mL and liver enzymes are not elevated.



Treatment of Chronic HBV in Persons with HBV/HIV Co-infection



- i For management of cirrhotic persons, see page 46-49. Persons with liver cirrhosis and low CD4 cell count require careful surveillance in the first months after starting ART in order not to overlook immune reconstitution syndrome and subsequent liver decompensation due to flares of liver enzymes.
- ii See page 65 for assessment of HBV Rx indication. Some experts strongly believe that any person with HBV infection requiring ART should receive TDF + 3TC or FTC unless history of TDF intolerance, particularly with advanced liver fibrosis (F3/F4). TDF administration should be adapted to eGFR if necessary. In persons with no history of treatment with 3TC and strict contraindication of TDF use, Entecavir can be used in addition to fully suppressive cART without FTC or 3TC.
- iii ART-naive Asian, HBeAg positive, HIV-co-infected persons initiating ART with TDF or TDF+FTC reached unexpectedly high rates of HBe (and even HBs) seroconversion, strengthening the rationale for early ART. In persons with HBV GT A, high ALT and low HBV-DNA, PEG-IFN might be used for a total length of 48 weeks. The addition of an NRTI-based anti-HBV regimen has not been proved to increase PEG-IFN efficacy. Recent data obtained in HBV mono-infected persons suggests that on-treatment quantification of HBsAg in persons with HBeAg-negative chronic HBV treated with PEG-IFN may help identify those likely to be cured by this therapy and optimise treatment strategies. This was also observed for NRTI-based strategies even if the rate of HBs seroconversion in this setting was very low. The optimal treatment duration for nucleos(t)ide analogues with anti-HBV activity has not yet been determined and experts recommend life-long therapy if anti-HBV nucleos(t)ides are given as part of ART. With persons not requiring ART and on treatment with Telbivudine +/- Adefovir, or those on ART where the nucleoside backbone needs changing, anti-HBV therapy may be stopped cautiously in HBeAg positive persons who have achieved HBe-seroconversion for at least six months or after confirmed HBs-seroconversion in those who are HBeAg negative. In persons with liver cirrhosis, stopping of effective anti-HBV treatment is not recommended in order to avoid liver decompensation due to flares of liver enzymes.
- In some cases of TDF intolerance (i.e. renal disease, see page 42), TDF in doses adjusted to renal clearance in combination with effective ART may be advisable (see page, 44). If TDF is strictly contra-indicated, Entecavir + Adefovir may be tried. However, efficacy and renal toxicity need to be closely monitored, because of the proven renal toxicity of Adefovir. In persons with no prior 3TC exposure, Entecavir may be used alone. NRTI substitution should only be performed if feasible and appropriate from the perspective of maintaining HIV suppression. Caution is warranted to switch from a TDF-based regimen to drugs with a lower genetic barrier, e.g. FTC or 3TC, in particular in 3TC-pretreated cirrhotic persons as viral breakthrough due to archived YMDD mutations is likely to happen. This has also been described in individuals with previous 3TC HBV-resistance who have been switched from TDF to Entecavir. The addition of Entecavir to TDF in persons with low persistent HBV-replication has not statistically proved to be efficient and should therefore be avoided. Results of trials are awaited.



Diagnostic Procedures for HCV in Persons with HCV/HIV Co-infection

Diagnosis of HCV

HCV-Ab (turn positive 1-6 months after infection as late seroconversions have been described, may rarely be lost due to immunosuppression) HCV-RNA levels⁽ⁱ⁾ (in particular important for the prediction of response to IFN treatment)

Status of Liver Damage

Staging of fibrosis (e.g. FibroScan, liver biopsy, serum fibrosis markers⁽ⁱⁱ⁾) Hepatic synthetic function (e.g. coagulation, albumin, cholinesterase) Ultrasound every 6 months if cirrhosis (gastroscopy upon diagnosis of cirrhosis and every 1-2 years thereafter), see page 46

Before HCV Treatment

HCV GT and HCV-RNA

Autoantibodies (ANA, LKM1)(iii)

TSH, thyroid autoantibodies (risk of hyperthyroidism under IFN-based therapy)

Monitoring of HCV Treatment

Differential blood count and liver enzymes every 2-4 weeks HCV-RNA at week 4 (to evaluate rapid virological response (RVR) under IFN-based HCV regimens and to ensure compliance), at end-of-treatment and at week 12 and 24 after treatment cessation (to assess SVR).

CD4 cell count and HIV-VL every 12 weeks

TSH every 12 weeks under IFN-based therapy

- i Low HCV-RNA defined as <400,000-600,000 IU/mL when using PEG-IFN+RBV. There is no standard conversion formula for converting the amount of HCV-RNA reported in copies/mL to the amount reported in IU/mL. The conversion factor ranges from about one to five HCV-RNA copies per IU/mL.
- ii Serum fibrosis markers include APRI, FIB-4, Hyaluronic acid, Fibrometer, Fibrotest, Forns, Hepascore and other indices; recently more complex tests such as Fibrometer, Fibrotest and Hepascore have shown to more accurately predict liver fibrosis than simple biochemical tests such as APRI, FIB-4 or Forns.
- iii Persons with positive anti LKM or ANA with homogeneous pattern should be evaluated for concurrent autoimmune hepatitis especially in the presence of ALT elevation during INF-based treatment.



Treatment of HCV in Persons with HCV/HIV Co-infection

Treatment indication

- 1. HCV treatment offers the possibility of eradicating HCV within a defined treatment period which translates into HCV cure. This is potentially advantageous for the subsequent management of the person with HIV, and every person with co-infection should therefore be considered for treatment when the benefits of therapy outweigh the risks. This also needs to be seen in the context of faster liver fibrosis progression in persons with HCV/HIV co-infection and with better HCV-treatment outcome with the use of direct acting antivirals (DAAs) in these persons. Furthermore, achieving SVR has also been associated with an improved survival even in lower fibrosis stages (F2) suggesting benefits of HCV therapy beyond cure of HCV and prevention of further liver disease progression. Similar HCV cure rates in HCV/HIV co-infected persons as in HCV mono-infected persons under DAA therapy have further questioned the separation of HIV co-infected persons as a separate patient group and have claimed treatment indication and regimens to be the same as in HCV mono-infection.
- If chronic HCV is detected early in the course of HIV infection (before ART initiation), treatment for chronic HCV is advised n presence of immediate HCV treatment indication (≥F2). For persons with a CD4 cell count < 500 cells/µL, early ART initiation is recommended to optimise HCV treatment outcome.
- 3. Information on liver fibrosis staging is important for making therapeutic decisions in persons with co-infection. However, a liver biopsy is no longer mandatory for considering treatment of chronic HCV.
- 4. In case of the availability of a liver biopsy or FibroScan[®] demonstrating lack of or minimal liver fibrosis (F0-1), regardless of HCV GT, treatment can be deferred. This may be especially important in countries where no or only limited DAAs have become available so far or where cost reimbursement issues still have not been clarified. In these cases, fibrosis assessment should be carried out periodically to monitor for fibrosis progression (see page 70).

Treatment of chronic HCV in persons with HCV/HIV-co-infection

 With first pilot studies in HCV treatment-naive and treatment experienced persons with HCV/HIV co-infection demonstrating significant higher SVR 12-24 rates with DAA based therapy, IFN-free DAA combinations should be considered standard of care for chronic HCV, in particular in advanced fibrosis.

The combination of Sofosbuvir 400 mg qd and a weight-adapted dose of RBV of 1000 (wt<75 Kg) -1200 (wt>75Kg) mg/day (administered bd) for 12 weeks has become the new gold standard therapy for all HCV GT2 persons promising HCV cure in >90% of persons. Persons with cirrhosis can be treated for an extended duration of 16 weeks. In countries where no Sofosbuvir is available PEG-IFN and RBV combination treatment for 24 weeks (if RVR i.e. negative HCV-RNA at week 4 after starting HCV therapy) or 48 weeks represents an alternative treatment choice for HCV GT2. The standard dose for PEG-IFN 2a is 180 µg once weekly, and for PEG-IFN 2b 1.5 µg/kg body weight once weekly.

6. The approval of further DAA have offered the opportunity of IFN- and RBV-free DAA combination regimens which because of significantly improved tolerability and higher HCV cure rates should be considered as preferred option where available and reimbursable. In particular combination of Sofosbuvir (all GT1-4) and Simeprevir (only

GT1 or 4) or Sofosbuvir and Daclatasvir (all GT1-4) and Simeprevir (only GT1 or 4) or Sofosbuvir and Daclatasvir (all GT1-4) are recommended, see IFN-free HCV Treatment Options.

In case of limited DAA availability or reimbursement issues Sofosbuvir in combination with PEG-IFN and RBV would be the next best treatment option (for GT1, 3-6), see IFN-containing HCV Treatment Options For Fibrosis Stages up to CHILD A. Simeprevir in combination with PEG-INF and RBV can also be an alternative (for GT1 or 4; but with longer treatment duration for IFN), but absence of the Q80K mutation should be demonstrated prior to treatment initiation. Use of older, first generation HCV PIs (Boceprevir and Telaprevir; only

indicated in GT1) are only recommended where other DAAs are not currently available and for some future time.

 Use of HCV PIs is associated with additional toxicities: Boceprevir causes anaemia, Teleprevir skin rash and Simeprevir hyperbilirubinaemia and skin reactions/photosensibility.

- 8. Please keep in mind that the field of DAAs is evolving rapidly with an expected European approval of IFN- and RBV-free fix-dose combination of Sofosbuvir/Ledipasvir in November 2014 as well as IFN-free combination of Paritaprevir/RTV/Ombitasvir, 150mg/100mg/25mg qd and Dasabuvir early 2015 which will add additionally treatment options into the HCV treatment armamentarium. Clearly these IFN-free treatment options together with the ones already available will be preferred treatment choices, and should encourage to no longer use IFN-based HCV therapies.
- Due to drug-drug interactions in particular HIV and HCV PIs careful checking for interactions is urgently recommended prior to starting HCV therapy, see www.hep-druginteractions.org or Drug-drug Interactions Between ARVs and DAAs. During PEG-IFN-RBV therapy, ddl is contraindicated in persons with cirrhosis and should be avoided in persons with less severe liver disease. D4T and ZDV should also be avoided if possible.

Treatment goal

 The primary aim of HCV treatment is SVR defined as undetectable HCV-RNA 12-24 weeks after the end of therapy, evaluated using sensitive molecular tests.

Stopping rules


11. If an early virological response (decline of at least 2*log₁₀ reduction in HCV-RNA at week 12 compared to baseline) is not achieved when treating HCV infection with PEG-IFN and RBV, treatment should be stopped, see page 73. Different stopping rules apply when DAAs are being used in combination with PEG-IFN and RBV and are summarised, see page 74. Futility rules with Simeprevir in combination with PEG-IFN and RBV are that HCV-RNA> 25 IU/mL after 4,12 or 24 weeks of HCV therapy should be discontinued. In case of successful Telaprevir-based HCV therapy at week 4 (HCV-RNA < 1000 IU/mL), Telaprevir should be continued until week 12, see page 74. If HCV-RNA at week 12 is still < 1000 IU/mL, dual therapy with PEG-IFN-RBV should be continued until week 24. If HCV-RNA is undetectable at week 24, dual therapy with PEG-IFN-RBV should be continued for another 24 weeks resulting in total treatment duration of 48 weeks. Futility rules for Boceprevircontaining HCV therapy are that in case of HCV-RNA > 100 IU/mL at week 12 or detectable HCV-RNA at week 24, all HCV therapy needs to be discontinued and interpreted as lack of response and high risk for Boceprevir resistance selection. In PEG-IFN and Sofosbuvir or IFN-free based therapies reasons to stop treatment may be non-adherence or toxicities on an individual basis.

Treatment of Acute HCV

12. Identification of persons with acute HCV is important since treatment in the acute phase leads to higher SVR rates than for treatment of chronic HCV. In persons with acute HCV, HCV-RNA should be measured at initial presentation and 4 weeks later. Treatment should be offered in persons without a decrease of 2*log10 of HCV-RNA at 4 weeks compared with initial HCV-RNA and to persons with persistent serum HCV-RNA 12 weeks after diagnosis of acute HCV. Duration of treatment should be based on RVR regardless of GT. Persons who do not achieve $a \ge 2^* \log_{10}$ decrease in HCV-RNA level at week 12 should discontinue therapy. Unfortunately, results from randomized prospective treatment trials are not available so far to allow a more precise recommendation on treatment duration or the role of RBV in treatment of acute HCV at this point. Also only uncontrolled data in 19 HIV-positive persons receiving 12 weeks of Telaprevir, PEG-IFN and RBV is available as yet. Therefore, considering the high cure rates with PEG-IFN-RBV alone in acute HCV, DAAs are currently not recommended unless there is a lack of virological response (at week 12 < 2*log₁₀ decrease in HCV-RNA), a situation in which treatment intensification with DAAs can be discussed on an individual basis.




Algorithm for Management of Acute HCV in Persons with HCV/HIV Co-infection





Management of Persons with Chronic HCV/HIV Co-infection



* Metavir fibrosis score: F0=no fibrosis; F1= portal fibrosis, no septae; F2= portal fibrosis, few septae, F3=bridging fibrosis, F4=cirrhosis.

** Monitor fibrosis stage annually, preferably with two established methods. Consider Treatment, if rapid progression.



HCV Treatment Options in HCV/HIV Co-infected Persons

IFN-free HCV Treatment Options						
HCV GT	Treatment	Treatment duration				
1&4	SOF + RBV	24 weeks*				
	SOF + SMP	12 weeks**				
	SOF + DCV	12 weeks in non-cirrhotics, 24 weeks in compensated cirrhotics				
2	SOF + RBV	12 weeks***				
3	SOF + RBV	24 weeks				
	SOF + DCV + RBV	24 weeks in compensated cirrhotics and/or treatment-experienced				
5&6	and 6 infection persons	n the absence of clinical data on DAAs in HCV GT 5 nd 6 infection persons should be treated similar to ICV GT 1 and 4 infection				

- **RBV** Ribavirin
- SOF Sofosbuvir
- SMP Simeprevir
- DCV Daclatasvir

Licensed only for persons who are not eligible for IFN-containing therapy

Possible extension up to 24 weeks in treatment-experienced cirrhotics and/or addition of RBV ++

*** Possible extension up to 16 weeks in treatment-naïve cirrhotics or relapsers; up to 24 weeks in treatment-experienced

HCV GT	Treatment	Treatment duration					
1&4	SOF + PEG-IFN/RBV	12 weeks (possible exten- sion up to 24 weeks in cirrhotics)					
	SMP* + PEG-IFN/RBV	24 weeks** (48 weeks in cirrhotics and treatment- experienced)					
	DCV + PEG-IFN/RBV***	24 weeks if RVR, 48 week if non-RVR					
2	PEG-IFN/RBV	IFN-free treatment recom- mended. If SOF not avail- able: PR 24 weeks if RVR, 48 weeks if non-RVR					
3	SOF + PEG-IFN/RBV	12 weeks (possible exten- sion up to 24 weeks in cirrhotics)					
5&6		In the absence of clinical data on DAAs in HCV GT 5 and 6 infection persons should be treated similar to HCV GT and 4 infection					

Ribavirin RBV SOF Sofosbuvir SMP Simeprevir

DCV Daclatasvir

SMP for 12 weeks only
 also in relapsers

*** GT4 only, DCV for 24 weeks only



Drug-drug Interactions between DAAs and ARVs

H	CV drugs	ATV/r	DRV/r	LPV/r	EFV	ETV	NVP	RPV	MVC	DTG	EVG/c	RAL	ABC	FTC	3TC	TDF	ZDV
	Boceprevir	D35%	↓32%D44%	↓45%D34%	↓19%E20%	10%D23%	↓E	Е	Е	\leftrightarrow	↓D	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	↔ ⁱ
s	Daclatasvir	110% ⁱⁱ	1 ⁱⁱⁱ	↑ ⁱⁱⁱ	↓32% ^{iv}	↓ ^{iv}	↓ ^{iv}	\leftrightarrow	\leftrightarrow	\leftrightarrow	↑ ⁱⁱⁱ	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	10%E10%	\leftrightarrow
A	Simeprevir	1	1	Î	↓71%D10%	Ļ	↓	↑6%E12%	\leftrightarrow	\leftrightarrow	1	↓11%E8%	\leftrightarrow	\leftrightarrow	\leftrightarrow	↓14%E18%	\leftrightarrow
	Sofosbuvir	\leftrightarrow	134%	\leftrightarrow	↓6%D4%	\leftrightarrow	\leftrightarrow	1¢9%E6%	\leftrightarrow	\leftrightarrow	\leftrightarrow	↓13%D27%	\leftrightarrow	↓6%	\leftrightarrow	↓6%	\leftrightarrow
	Telaprevir	↓20%E17%	↓35%D40%	↓54%	↓26%D7%	↓16%	↓?	↓5%E	Е	E25%	↑13%D16%	E31%	\leftrightarrow	\leftrightarrow	\leftrightarrow	E30%	↔ ⁱ

Legend

- potential elevated exposure of DAA
- potential decreased exposure of DAA T
- no significant effect \leftrightarrow
- D potential decreased exposure of ARV
- potential elevated exposure of ARV Е Numbers refer to decreased/increased AUC of DAAs and ARVs as observed

in drug interactions studies

- potential haematological toxicity Daclatasvir should be reduced to 30 mg once daily with ATV/r. No ii dose reduction with unboosted ATV
- Daclatasvir should be reduced to 30 mg once daily iii
- iv Daclatasvir should be increased to 90 mg once daily.

Colour legend

no clinically significant interaction expected.

these drugs should not be coadministered.




potential interaction which may require a dosage adjustment or close . monitoring.

Note: the symbol (green, amber, red) used to rank the clinical significance of the drug interaction is based on www.hep-druginteractions.org.



Proposed Optimal Duration of Dual HCV Therapy in Persons with Chronic HCV/HIV Co-infection Not Eligible for Triple Therapy Including DAAs against HCV




i Where no access to DAAs available or high chances of cure even with dual therapy (favourable IL28B GT, low HCV-RNA and no advanced fibrosis)



Use of Boceprevir, Telaprevir, Simeprevir or Sofosbuvir with PEG-IFN + RBV in Persons with HIV/HCV Co-infection

0	4 	12 I		24 	48
PEG-IFN + RBV	Boceprevir (800 mg td)	+ PEG-IFN + RBV			
		\checkmark		↓	
		If \geq 100 IU/mL, stop all therap		stop all therapy	
0	4	12	V-RNA	24	48
0	4	2 		24 	48
Telaprevir (+ PEG-IFN		PEG-IFN + RB	V		
	\checkmark	\checkmark		↓	
	If > 1000 IU/mL, stop			op PEG-IFN/RBV	
		HC	V-RNA		
0	4	12	:	24 	48
Simeprevir	150 mg gd				
+ PEG-IFN		PEG-IFN + RB	V	Only in prior non responders	
	\checkmark				
	If > 25 IU/mL, stop a	all therapy			
			HCV-RNA		
Therany sho					
inclupy sho	ould be stopped if there is	a confirmed increase in HCV-F	RNA by 1*log ₁₀ following a	decline at any stage.	



No stopping rules apply: Fixed duration of 12 weeks regardless of HCV-RNA decline.



Definition of Treatment Response of PEG-IFN and RBV

	Time	HCV-RNA
Rapid Virological Response (RVR)	Week 4 on treatment	Undetectable (< 50 IU/mL)
Early Virological Response (EVR)	Week 12 on treatment	Undetectable (< 50 IU/mL)
Delayed Virological Response (DVR)	Week 12 on treatment	> 2*log ₁₀ decrease from baseline but not undetectable
Null Response (NR)	Week 12 on treatment	< 2*log ₁₀ decrease from baseline
Partial Non-Response (PR)	Week 12 and week 24 on treatment	> 2*log ₁₀ decrease at week 12 but detectable at week 12 and 24
Sustained Virological Response (SVR)	24 weeks post treatment	Undetectable (< 50 IU/mL)
Breakthrough	Any time during treatment	Reappearance of HCV-RNA at any time during treatment after virological response
Relapse (RR)	End of treatment and week 24 post treatment	Undetectable HCV-RNA at end of therapy, detectable by week 24 post treatment

Adapted from [3] See www.easl.eu/assets/application/files/4a7bd873f9cccbf_file.pdf



Part V Opportunistic Infections

Prevention and Treatment of Opportunistic Infections in HIV-positive Persons

Primary Prophylaxis			
Disease	Drug	Dose	Comments
Pneumocystis jirovecii (PcP) & Toxoplasma gondii			Indication: CD4 < 200 cells/µL, CD4 percentage < 14%, or oral thrush Stop: if CD4 > 200 cells/µL over 3 months or CD4 100-200 cells/µL and HIV- VL undetectable for 3 months
Positive or Negative Serology for Toxoplasmosis	TMP-SMX	1 double-strength tablet (ds) (800/160 mg) 3 x /week po or 1 single-strength tablet (ss) (400/80 mg)/day po or 1 ds tablet/day po	
Negative Serology for Toxoplasmosis	Pentamidine	300 mg in 6 mL Aqua 1 x Inhalation/month	
Negative Serology for Toxoplasmosis	Dapsone	1 x 100 mg/day po	Check for G6PD-deficiency
Positive or Negative Serology for Toxoplasmosis	Atovaquone suspension	1 x 1500 mg/day po (with food)	
Positive Serology for Toxoplasmosis	Dapsone	200 mg 1x/week po	Check for G6PD-deficiency
	+ Pyrimethamine	75 mg 1x/week po	
	+ Folinic Acid	25 mg 1x/week po	
Positive Serology for toxoplasmosis	Atovaquone suspension	1 x1500 mg/day po (with food)	
	+ Pyrimethamine + Folinic acid	75 mg/week po 25 mg/week po	
Non-Tuberculous Mycobacteria (M. avium complex, M. genavense, M. kansa	sii)		Indication: CD4 < 50 cells/µL Stop: if CD4 > 100 cells/µL over 3 months
Regimens listed are alternatives	Azithromycin	1 x 1200-1250 mg/week po	
	or Clarithromycin	2 x 500 mg/day po	
	or Rifabutin	300 mg/day po	Check for interactions with ARVs

Disease	Drug	Dose	Comments
Pneumocystis jirovecii (PcP)			Stop: if CD4 > 200 cells/µL over 3 months
Negative or Positive Serology for Toxoplasmosis	TMP-SMX	1 ds tablet 800/160 mg 3x/week po or 1 ds tablet 400/80 mg 1x/ day po or 1 ds tablet 1x/day po	
Negative Serology for Toxoplasmosis	Pentamidine	300 mg in 6 mL Aqua 1 x Inhalation/month	
Negative Serology for Toxoplasmosis	Dapsone	1 x 100 mg/day po	Check for G6PD-deficiency
Negative or Positive Serology for Toxoplasmosis	Atovaquone suspension	1 x 1500 mg/day po (with food)	
Positive Serology for Toxoplasmosis	Dapsone + Pyrimethamine + Folinic Acid	1 x 200 mg/week po 75 mg/week po 25 mg/week po	Check for G6PD-deficiency
Positive Serology for Toxoplasmosis	Atovaquone suspension + Pyrimethamine + Folinic Acid	1 x 1500 mg/day po (with food) 75 mg/week po 25 mg/week po	



Secondary Prophylaxis, Maintenance [·]	Therapy		
Disease	Drug	Dose	Comments
<i>Toxoplasma gondii</i> Encephalitis			Stop: if CD4 > 200 cells/µL over 6 months
Regimens listed are alternatives	Sulfadiazine + Pyrimethamine + Folinic Acid	2-3 g/day po (in 2-4 doses) 1 x 25-50 mg/day po 1 x 10 mg/day po	
	or Clindamycin + Pyrimethamine + Folinic Acid	3 x 600 mg//day po 1 x 25-50 mg//day po 1 x 10 mg//day po	Additional PCP prophylaxis is necessary
	or Atovaquone suspension + Pyrimethamine	2 x 750-1500 mg/day po (with food) 1 x 25-50 mg/day po	
	+ Folinic Acid	1 x 10 mg/day po	
	or Atovaquone suspension	2 x 750-1500 mg/day po (with food)	
	or TMP-SMX	2 x 800/160mg/day po	
Cryptococcal Meningitis			At least 12 months. Consider stopping, if CD4 >100 cells/µL for at least 3 months
	Fluconazole	1 x 200 mg/day po	
Cytomegalovirus (CMV) Retinitis			Stop: if CD4 > 200 cells/µL over 3 months
Regimens listed are alternatives	Valganciclovir	1 x 900 mg/day po (with food)	
	or Ganciclovir	5 x 5 mg/kg/week iv	
	or Foscarnet	5 x 100 mg/kg/week iv	
	or Cidofovir + NaCl + Probenecid	5 mg/kg every 2 weeks iv	Cidofovir may not be available in all European countries
Mycobacterium avium (MAC) Infection			Stop: if CD4 > 100 cells/µL over 6 months and after MAC treatment at least 12 months
Regimens listed are alternatives	Clarithromycin + Ethambutol	2 x 500 mg/day po 1 x 15 mg/kg/day po	
	or Azithromycin + Ethambutol	1 x 500 mg/day po 1 x 15 mg/kg/day po	
Leishmaniasis			Consider stopping: if CD4>200-350 cells/µL over 3 months, no relapse for at least 6 months and negative PCR in blood or negative urinary antigen
	Liposomal Amphotericin B	4 mg/kg every 2-4 weeks iv	
	or Lipidcomplex Amphotericin	B 3 mg/kg every 3 weeks iv	

Secondary Prophylaxis, Maintenance Therapy					
Disease	Drug	Dose	Comments		
Alternative Therapies	Pentavalent Antimonium Salts (Glucantine®)	20 mg/kg every 4 weeks iv/im			
	or Miltefosine	1 x 100 mg/day po			
	or Pentamidine	300 mg every 3 to 4 weeks iv			

Pneumocystis jirovecii Pneumonia (PcP)				
Preferred Therapy	TMP-SMX	3 x 5 mg/kg/day TMP iv/po + 3 x 25 mg/kg/day SMX iv/po	21 days, then secondary prophylaxis until CD4 cell counts > 200 cells/µL for > 3 months	
	+ Prednisone if PaO2 <10 kPa or <70 mmHg or alveolar/arterial O ₂ gradient > 35 mmHg. Start Prednisone 15-30 min before TMP/SMX	2 x 40 mg/day po 5 days 1 x 40 mg/day po 5 days 1 x 20 mg/day po 10 days	Benefit of corticosteroids if started before 72 hours	
Alternative Therapy for Moderate to Severe	Primaquine	1 x 30 mg (base)/day po		
PcP	+ Clindamycin or	1 x 600-900 mg iv/po		
	Pentamidine or	1 x 4 mg/kg/day iv (infused over 60 min.)	Check for G6PD deficiency	
	CaspofunginFor each regimen+ Prednisone, if $PaO_2 < 10 \text{ kPa}$ or <70 mmHg, or alveolar/arte-	70 mg/1st day followed by 50 mg/day iv	Can be added to the therapy in severe cases	
Alternative Therapy for <i>Mild to Moderate</i>	Primaquine + Clindamycin	1 x 30 mg (base)/day po 1 x 600-900 mg/day po	Check for G6PD deficiency	
	or	1 x 000-900 mg/day po		
	Atovaquone suspension	2 x 750 mg/day po (with food)		
	or Dapsone + Trimethoprim	1 x 100 mg/day po 3 x 5 mg/kg/day po	Check for G6PD deficiency In case of rash: reduce dose of TMP (50%), antihistamines	
<i>Toxoplasma gondii</i> Encephalitis				
Preferred Therapy	Pyrimethamine	Day 1: 200 mg po, then • If ≥ 60 kg; 1 x 75 mg/day po • If < 60 kg: 1 x 50 mg/day po	6 weeks, then secondary prophylaxis until CD4 cell counts > 200 cells/µL for > 6 months	
	+ Sulfadiazine	 If ≥ 60 kg: 2x 3000 mg/day po/iv If < 60 kg: 2 x 2000 mg/day po/iv 		
	+ Folinic Acid	1 x 10 mg/day po		

Disease	Drug	Dose	Comments
Treatment of Opportunistic Infections			
Alternative Therapy	Pyrimethamine	Day 1: 200 mg/day po, then • If ≥ 60 kg: 1 x 75 mg/day po • If < 60 kg: 1 x 50 mg/day po	Additional PcP prophylaxis is necessary
	+ Clindamycin	4 x 600-900 mg/day po/iv	
	+ Folinic Acid	1x 10 mg/day po	
	or		
	TMP-SMX	2 x 5 mg TMP/kg/day po/iv 2 x 25 mg SMX/kg/day po	
	or		
	Pyrimethamine	Day 1: 200 mg po, then If ≥ 60 kg; 1 x 75 mg/day po If < 60 kg: 1 x 50 mg/day po	
	+ Atovaquone	2 x 1500 mg/day po (with food)	
	+ Folinic Acid	1 x 10 mg/day po	
	or		_
	Sulfadiazine	 If ≥ 60 kg: 4 x 1500 mg/day po/iv If < 60 kg: 4 x 1000 mg/day po/iv 	
	+ Atovaquone	2 x 1500 mg/day po (with food)	
	or Pyrimethamine	Day 1: 200 mg po, then • If ≥ 60 kg; 1 x 75 mg/day po • If < 60 kg: 1 x 50 mg/day po	
	+ Azithromycin	1 x 900-1200 mg/day po	
	+ Folinic Acid	1 x 10 mg/day po	
Cryptococcal Meningitis		0 11 11 1	
Induction Therapy	Liposomal Amphotericin B + Flucytosine	3 mg/kg/day iv 4 x 25 mg/kg/day po	 14 days Then perform LP: if CSF culture sterile → switch to oral regimen. Liposomal Amphotericin B is accompanied by significantly fewer adverse effects. Opening pressure should always be measured when an LP is performed. Repeated LPs or CSF shunting are essential to effectively manage increased intracranial pressure which is associated with better survival. Flucytosine dosage must be adapted to renal function. Treat for at least 14 days, then perform LP: if CSF culture sterile → switch to oral consolidation therapy. Defer start of ART for at least 4 weeks.
	or Amphotericin B Deoxycholate + Flucytosine	0,7 mg/kg/day iv 4 x 25mg/kg/day po	
Consolidation Therapy	Fluconazole	1 x 400 mg/day po (loading dose 1 x 800 mg 1st day)	8 Weeks, then secondary prophy- laxis. Repeated LP until opening pressure < 20 cm H ₂ O or 50% of initial value
Candidiasis		I	
Oropharyngeal	Fluconazole	1x 150-200 mg/day po	Once or until improvement (5-7 days)
	or Itraconazole	1-2 x 100-200 mg/day po (oral solution fasting)	7-14 days. Be aware of interactions with ARVs, see Drug-drug Interactions Between ARVs and Non-ARVs
	or Amphotericin B	3-6 lozenges at 10 mg/day or oral suspension 1-2g/day (in 2-4 doses)	7-14 days

Disease	Drug	Dose	Comments
Freatment of Opportunistic Infections			
Esophagitis	Fluconazole	1 x 400 mg/day po	3 days
		or 400 mg loading dose, then 200 mg/day po	10-14 days. Be aware of interactions with ARV's, see Drug-drug Interactions Between ARVs and Non-ARVs
	or Itraconazole	1-2 x 200 mg/day po (oral solution fasting)	10-14 days
Severe cases/azole resistance	Caspofungin	1 x 70 mg 1st day, then 50mg/ day iv	14 days
Herpes simplex virus (HSV) Infections			
nitial Genital / Mucocutaneous HSV	Valacyclovir	2 x 1000 mg/day po	7-10 days or until lesions healed
	or Famciclovir	2 x 500 mg/day po	7-10 days or until lesions healed
	or Acyclovir	3 x 400 mg/day po	7-10 days or until lesions healed
Recurrent Genital / Mucocutaneous HSV (> 6 episodes/year)	Valacyclovir	2 x 500 mg/day po	Chronic suppressive therapy. Alterna- tively start early treatment of recur- rences as above.
Severe Mucocutaneous Lesions	Acyclovir	3 x 5 mg/kg/day iv	After lesions begin to regress switch to oral treatment or until lesions healed
Encephalitis	Acyclovir	3 x 10 mg/kg/day iv	14-21 days
Acyclovir resistant Mucocutaneous HSV nfection	Foscarnet	80-120 mg/kg/day iv in 2-3 divided doses	Until clinical response
	or Cidofovir + Probenecid + Hydration	1 x 5 mg/kg/week iv	Cidofovir may not be available in all European countries
Varicella zoster virus (VZV) Infections			
Primary Varicella Infection (Chickenpox)	Valaciclovir	3 x 1000 mg/day po	5-7 days
Herpes Zoster (Shingles):	Valaciclovir	3 x 1000 mg/day po	10 days
Not Disseminated	or Famciclovir	3 x 500 mg/day po	10 days
	or Acyclovir	3 x 5 mg/kg/day iv	10 days
Herpes Zoster: Disseminated	Acyclovir	3 x 10 mg/kg/day iv	10-14 days
Cytomegalovirus (CMV) Infections			
Retinitis, Immediate Sight-threatening Le- sions	Ganciclovir	2 x 5 mg/kg/day iv	3 weeks, then secondary prophylaxis
	or Foscarnet	2 x 90 mg/day iv	3 weeks, then secondary prophylaxis
Retinitis, Small Peripheral Retinal Lesions	Valganciclovir	2 x 900 mg/day po (with food)	
	or Foscarnet	2 x 90 mg/kg/day iv	
	or Cidofovir + Probenecid + Hydration	1 x 5mg/kg/week iv	Cidofovir may not be available in all European countries
Esophagitis/Colitis	Ganciclovir	2 x 5 mg/kg/day iv	
	or Foscarnet	2 x 90 mg/kg/day iv	
	or Valganciclovir	2 x 900 mg/day po (with food)	In milder disease if oral treatment toler- ated



Treatment of Opportunistic Infect	ions			
Encephalitis/Myelitis	Ganciclovir	2 x 5 mg/kg/day iv		
	or Foscarnet	2 x 90 mg/kg/day iv	 Consider combination of Ganciclovir an Foscarnet in severe cases 	
Disease	Drug	Dose	Comments	
Bacillary angiomatosis (Bartonella I		Duse	Comments	
Bacillary angiornatosis (Bartonella I		2 × 100 mg/day ag		
	Doxycycline	2 x 100 mg/day po	Until improvement (until 2 months)	
	or Clarithromycin	2 x 500 mg/day po	Until improvement (until 2 months)	
Mycobacterium avium-intracellulare	e complex (MAC)			
	Clarithromycin	2 x 500 mg/day po	12 months, then secondary prophylaxis	
	+ Ethambutol	1 x 15 mg/kg/day po		
	Ev. + Rifabutin	1 x 300 mg/day po	Consider Rifabutin if resistance to Macrolides or Ethambutol is suspected, severe immunodeficiency (CD4 < 50 cells/µL), high bacterial load (> 2 L of CFU/mL of blood), no cART	
	Ev. + Levofloxacin	1 x 500 mg/day po	4th drug to consider for disseminated disease	
	Ev. + Amikacin	1 x 10-15 mg/kg/day iv	4th drug to consider for disseminated disease	
	or			
	Azithromycin + Ethambutol	1 x 500 mg/day po 1 x 15 mg/kg/day po	Consider additional drugs as above	
Mycobacterium kansasii	· Ethanibator	r x to highlighday po		
Wycobacterium kansasii	Bifampioin	1 x 600 mg/day ag (ar Difabutia	15 19 months	
	Rifampicin	1 x 600 mg/day po (or Rifabutin 300mg/day po)	15-18 months	
	+ Isoniazid	1 x 300 mg/day po		
	+ Ethambutol	1 x 20 mg/kg/day po		
	or			
	Rifampicin	1 x 600 mg/day po (or Rifabutin 300 mg/day po)	15-18 months	
	+ Clarithromycin	2 x 500 mg po		
	+ Ethambuthol	1 x 15-20 mg/day po		
Leishmaniasis				
Preferred treatment	Liposomal Amphotericin B	1 x 2-4 mg/kg/day iv for 10 consecutive days	Then secondary prophylaxis	
	or Liposomal Amphotericin B	1 x 4 mg/kg/day iv on day 1-5, 10, 17, 24, 31 and 38		
Alternative therapy	Lipidcomplex Amphotericin B	1 x 3 mg/kg/day iv	10 days	
	or Amphotericin B Deoxycholate	1 x 0.5-1 mg/kg/day iv (total dose 1.5-2 g)	Amphotericin B Deoxylate may not be available in all European countries	
	or Pentavalent antimonium salt (Glucantine®)	1 x 20 mg/kg/day iv or im	4 weeks	
	or Miltefosine	1 x 100 mg/kg/day po	4 weeks	



Diagnosis and Treatment of TB in HIV-positive Persons

Treatment of TB in HIV-positive persons

For standard treatment of TB in HIV-positive persons, including appropriate choice of ARVs, see below table and ART in TB/HIV Co-infection

Disease	Drug	Dose	Comments
Susceptible Mycobacterium tubercu	ulosis		
Initial Phase	Rifampicin + Isoniazid + Pyrizinamide + Ethambutol	Weight based	Initial phase (Rifampicin+Isoniazid+Pyri- zinamide+Ethambutol) for 2 months, then Continuation phase (Rifampicin+Isoniazid) according to TB type
Alternative	Rifabutin + Isoniazid + Pyrizinamide + Ethambutol	Weight based	Initial phase (Rifabutin+Isoniazid+ Pyrizinamide+Ethambutol) for 2 months, then Continuation phase (Rifabutin + Isoniazid) according to TB type
Continuation phase	Rifampicin/Rifabutin + Isoniazid according to TB type		 Total duration of therapy: 1. Pulmonary, drug susceptible TB: 6 months 2. Pulmonary TB & positive culture at 8 weeks of TB treatment: 9 months 3. Extrapulmonary TB with CNS involvement or disseminated TB: 9-12 months 4. Extrapulmonary TB with bone/joint involvement : 9 months 5. Extrapulmonary TB in other sites: 6-9 months



Diagnosis of Multi-drug Resistant TB (MDRTB) / Extended-Drug Resistant TB (XDRTB)

MDRTB/XDRTB should be suspected in case of:

- Previous TB treatment
- Contact with MDR/XDR TB index case
- · Birth, travel or work in an area endemic for MDRTB
- · History of poor adherence
- No clinical improvement on standard therapy and/or sputum smear positive after 2 months of TB therapy or culture positive at 3 months
- Homelessness/hostel living and in some countries recent/current incarceration
- In areas with very high MDRTB/XDRTB prevalence

MDRTB: Resistance to Isoniazid and Rifampicin.

XDRTB: Resistance to Isoniazid and Rifampicin and Quinolones and at last one at the following injectable drugs: Kanamycin, Capreomycin or Amikacin

Rapid Detection

Gene Xpert or similar technology has the advantage of rapid detection of drug resistance. Drug susceptibility testing is important in optimizing treatment.

Some countries/regions have neither of the above and have to use an empirical approach.

Treatment of Resistant TB

INH-resistant TB

• RIF or RFB + EMB + PZA for 7 months

Each dose of MDR/XDR TB regimen should be given as DOT throughout the whole treatment.

Treatment regimens should consist of at least four active drugs based on:

- Susceptibility testing for Isoniazid, Rifampicin, Rifabutin, Floroquinolones, injectable agents and other drugs if available
- Treatment history
- · Local surveillance data
- · Drug not been part of regimens used in the area

More than four drugs should be started if the susceptibility pattern is unknown or the effectiveness of one or more agents is questionable.

Drug Choices

Regimens often contain five to seven drugs

Include drugs from groups 1-5 (see below) in hierarchical order based on potency

- 1. Use any of the first-line oral agents (group 1) that are likely to be effective
- 2. Use an effective aminoglycoside or polypeptide by injection (group 2)
- 3. Use a fluoroquinolone (group 3)
- 4. Use the remaining group 4 drugs to complete a regimen of at least four effective drugs
- 5. For regimens with fewer than four effective drugs, consider adding two group 5 drugs

The regimen should be reassessed and modified if needed once drug sensitivity results become available.

Group 1: First-line oral agents	 Pyrazinamide (Z) Ethambutol (E) Rifabutin (RFB)
Group 2: Injectable agents	 Kanamycin (Km) Amikacin (Am) Capreomycin (CM) Streptomycin (S)
Group 3: Fluoroquinolones	 Levofloxacin (LFX) Moxifloxacin (MFX) Ofloxacin (OFX) Gatifloxacin (G)
Group 4: Oral bacteriostatic second- line agents	 Para-aminosalicylic acid (PAS) Cycloserine (CS) Terizidone (TRD) Ethionamide (ETO) Protionamide (PTO)
Group 5: Agents with unclear role in treatment of drug resistant-TB	 Clofazimine (CFZ) Linezolid (LZD) /Tedizolid (TZD) Amoxicillin/Clavulanate (Amx/CLV) Thioacetazone (THZ) Imipenem/Cilastatin (IPM/CLN) High-dose Isoniazid (high-dose H-16–20 mg/kg/day) Clarithromycin (CLR) Consider, Bedaquiline, Delamanid and new anti-TB agents for MDR/XDR TB

Duration of MDR/XDR Treatment

8 months of intensive phase using 5 or more drugs, followed by 12 months of 3 drugs depending on response. E.g. 8 months of Z, Km, OFX, PTO and CS, followed by 12 months of OFX, PTO and CS.

Drug interactions with ART and MDR/XDR regimens

Unless RBT is being used, use normal doses but with caution as few data available on potential drug interactions, see ART in TB/HIV Co-infection



Latent Tuberculosis

Indication: TST > 5 mm or positive IGRA or close contacts to open tuberculosis

•	
Regimen	Comments
Isoniazid (INH) 5 mg/kg/day (max. 300 mg) po + Pyridoxin (Vit B6) 25 mg/day po	6-9 months
Fyndoxiii (Vit B0) 25 mg/day po	
Rifampicin 600 mg/day po or Rifabutin po (dose according to current cART)	4 months, check interactions with cART
Rifampicin 600 mg/day po or Rifabutin po (dose according to current cART) + Isoniazid (INH) 5 mg/kg/day (max 300 mg) po + Pyridoxin (Vit B6) 25 mg/day po	3 months, check interactions with cART
Rifampicin 600mg 2x/week po + INH 900 mg 2x/week po + Pyridoxin (Vit B6) 300mg 1x/week po	3 months, check interactions with cART

References

Green colour refers to specific references used in each section Black colour refers to general references used in each section

Part I Assessment of HIV-positive Persons at Initial & Subsequent Visits

Please see references for Part III

Part II ARV Treatment of HIV-positive Persons

- 1 Langewitz W et al. Spontaneous talking time at start of consultation in outpatient clinic: cohort study. BMJ 2002;325: 682-683.
- 2 Glass TR et al. Antiviral Therapy 13(1):77-85. 2008.
- 3 WHO 2003 p.95-107.
- 4 Arroll B et al. BMJ 327:1144-1146. 2003.
- 5 Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS. 2010 Jun 1;24(9):1243-50.
- 6 The Fast Alcohol Screening Test, Alcohol and Alcoholism (2002) 37 (1): 61-66.7. Castle, Lancet 2008;372:646-55.
- J. Fehr, D. Nicca, W. Langewitz, D. Haerry, M.Battegay, revision 2013
 Artemis, AIDS 2008, Vol 22 No 12: 1389 1397.
- 9 ACTG 5142 study, N Engl J Med 2008;358:2095-106.
- 10 Brogly S. Pediatrics Inf Dis journal 2010.
- 11 French Perinatal Cohort, 20th CROI2013, Atlanta, abstract 81.

Part III Prevention and Management of Co-morbidities in HIV-positive Persons

- 1 EHS 2013 Guidelines, J.Hypertens; 2013:7:1281-1357
- 2 International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. 2005.
- 3 Simioni S, Cavassini M, Annoni JM, Rimbault AA, Bourquin I, Schiffer V, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010 Jun 1;24(9):1243-50.
- 4 Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007 Oct 30;69(18):1789-99.

Peters B, Post F, Wierzbicki AS et al. Screening for chronic comorbid disease in people with HIV: the need for a strategic approach. HIV Med. 2013 Jan;14 Suppl 1:1-11.

El-Sadr WM, Lundgren JD, Neaton JD et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006,355:2283-2296.

Silverberg MJ, Chao C, Leyden WA et al. HIV infection and the risk of cancers with and without a known infectious cause. AIDS. 2009 Nov 13;23(17):2337-45.

Clifford GM, Polesel J, Rickenbach M et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005 Mar 16;97(6):425-32.

De Wit S, Sabin CA, Weber R et al. Incidence and risk factors for new onset diabetes mellitus in HIV infected patients: the D:A:D study. Diabetes care 2008 Jun;31(6):1224-9.

Tien PC, Schneider MF, Cox C et al. Association of HIV infection with incident diabetes mellitus: impact of using hemoglobin A1C as a criterion for diabetes. J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):334-40.

Freiberg MS, Chang CC, Kuller LH et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013 Apr 22;173(8):614-22.

Worm SW, Sabin S, Weber R et al. Risk of Myocardial Infarction in Patients

with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug classes: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. J Infect Dis. 2010 Feb 1;201(3):318-30.

Triant VA, Lee H, Hadigan C et al. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007,92:2506-2512.

Islam FM, Wu J, Jansson et al. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med. 2012 Sep;13(8):453-68.

Grunfeld C, Delaney JA, Wanke C et al. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurement from the FRAM study. AIDS. 2009 Sep 10;23(14):1841-9

Friis-Moeller N, Thibébaut R, Reiss P et al. for the D:A:D study group. Predicting the risk of cardiovascular disease in HIV-infected patients: the Data Collection on Adverse Effects of Anti-HIV Drugs Study. Eur J Cardiovasc Prev Rehabil. 2010 Oct;17(5):491-501

Rothman MS, Bessesen MT. HIV infection and osteoporosis: pathophysiology, diagnosis and treatment options. Curr Osteoporos Rep. 2012 Dec;10(4):270-7.

Ryom L, Mocroft A, Kirk O et al. on behalf of the D:A:D study group. Association Between Antiretroviral Exposure and Renal Impairment Among HIV-positive Persons with Normal Baseline Renal Function: the D:A:D study. J Infect Dis. 2013 May;207(9):1359-1369.

Alsauskas ZC, Medapalli RK, Ross MJ. Expert opinion on pharmacotherapy of kidney disease in HIV-infected patients. Expert Opin Pharmacother 2011,12:691-704.

Mocroft A, Kirk O, Reiss P et al. for the EuroSIDA Study Group. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010 Jul 17;24(11):1667-78.

Bonjoch A, Bayes B, Riba J, et al. Validation of estimated renal function measurements compared with the isotopic glomerular filtration rate in an HIV-infected cohort. Antiviral Res 2010,88:347-354.

Chang HR, Pella PM. Atazanavir urolithiasis. N Engl J Med 2006,355:2158-2159.

Gaspar G, Monereo A, Garcia-Reyne A et al. Fanconi syndrome and acute renal failure in a patient treated with tenofovir: a call for caution. AIDS 2004,18:351-352.

Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005,40:1559-1585.

Benhamou Y, Di Martino V, Bochet M et al. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001,34:283-287.

Kovari H, Ledergerber B, Peter U et al. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin Infect Dis 2009,49:626-635.

Weber R, Sabin CA, Friis-Moeller N et al. Liver related deaths in persons infected with the human immunodeficiency virus: The D:A:D study. Arch Intern Med 2006 Aug 14-28;166(15):1632-1641.

Qurishi N, Kreutzberg C, Lüchters G et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003 Nov 22;362(9397):1708-13.



Part IV Clinical Management and Treatment of Chronic HBV and HCV Co-infection in HIV-positive Persons

- 1 Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference. AIDS 2011 Feb 20;25(4):399-409.
- 2 Ingiliz P, Rockstroh JK. HIV-HCV co-infection facing HCV protease inhibitor licensing: implications for clinicians. Liver Int 2012 Sep;32(8): 1194-9.
- 3 EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011 Aug;55(2):245-64.

Thomson EC, Nastouli E, Main J, et al. Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV. AIDS. 2009;23:89-93.

Lacombe K, Rockstroh J. HIV and viral hepatitis coinfections: advances and challenges. Gut 2012;61(Suppl 1):i47-i58.

Qurishi N, Kreuzberg C, Lüchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet. 2003;362:1708-13.

Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV infected patients. N Engl J Med 2004;351:438–50.

Núñez M, Miralles C, Berdún MA, et al. PRESCO Study Group. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses. 2007;23:972-82.

Rodriguez-Torres M, Slim J, Bhatti L, et al. Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial. HIV Clin Trials 2012;13:142–52.

Sulkowski MS, Sherman KE, Dieterich DT, et al. Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIV: A Randomized Trial. Ann Intern Med. 2013;159:86-96.

Sulkowski M, Pol S, Mallolas J et al. P05411 study investigators. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis. 2013;13:597-605.

Cotte L, Braun J, Lascoux-Combe C, et al. ANRS HC26 Study Group. High Early Virological Response with Telaprevir-Pegylated-Interferon-Ribavirin in Treatment-experienced Hepatitis C Virus Genotype 1/HIV Co-infected Patients: ANRS HC26 TelapreVIH Study. 20th Conference on Retroviruses and Opportunistic Infections, March 3-6, 2013;abstract 36.

Poizot-Martin I, Bellissant E, Piroth L, et al. ANRS-HC27 BOCEPREVIH Study Group. ANRS-HC27 BocepreVIH Interim Analysis: High Early Virologic Response with Boceprevir + Pegylated Interferon + Ribivirin in Hepatitis C Virus/HIV Co-infected Patients with Previous Failure to Pegylated Interferon + Ribivirin. 20th Conference on Retroviruses and Opportunistic Infections, March 3-6, 2013

Berenguer J, Alvarez-Pellicer J, et al. GESIDA 3603/5607 Study Group. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2009 Aug;50(2):407-13.

Berenguer J, Rodríguez E, Miralles P, et al. GESIDA HIV/HCV Cohort Study Group. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus. Clin Infect Dis. 2012 Sep;55(5):728-36. Hézode C, Fontaine H, Dorival C, et al. CUPIC Study Group. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) -NCT01514890. J Hepatol. 2013 May 10. doi:pii: S0168-8278(13)00290-0. 10.1016/j.jhep.2013.04.035. [Epub ahead of print]

Miro JM, Montejo M, Castells L, et al. Spanish OLT in HIV-Infected Patients Working Group investigators. Outcome of HCV/HIV-coinfected liver transplant recipients: a prospective and multicenter cohort study. Am J Transplant. 2012;12:1866-76.

Terrault NA, Roland ME, Schiano T, et al. Solid Organ Transplantation in HIV: Multi-Site Study Investigators. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl. 2012;18:716-26.

Sonneveld MJ, Rijckborst V, Boucher CA, et al. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology. 2010;52:1251-1257.

Neukam K, Camacho A, Caruz A, et al. Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load. J Hepatol. 2012;56:788-794.

Part V Opportunistic Infections

DHHS: Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. July 2013. www.aidsinfo.nih.gov

